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A B S T R A C T
Background
Pharmacological therapy for chronic obstructive pulmonary disease (COPD) is aimed at relieving symptoms, improving quality of life
and preventing or treating exacerbations.
Treatment tends to begin with one inhaler, and additional therapies are introduced as necessary. For persistent or worsening symptoms,
long-acting inhaled therapies taken once or twice daily are preferred over short-acting inhalers. Several Cochrane reviews have looked
at the risks and benefits of specific long-acting inhaled therapies compared with placebo or other treatments. However for patients and
clinicians, it is important to understand the merits of these treatments relative to each other, and whether a particular class of inhaled
therapies is more beneficial than the others.
Objectives
To assess the efficacy of treatment options for patients whose chronic obstructive pulmonary disease cannot be controlled by short-
acting therapies alone. The review will not look at combination therapies usually considered later in the course of the disease.
As part of this network meta-analysis, we will address the following issues.
1. How does long-term efficacy compare between different pharmacological treatments for COPD?
2. Are there limitations in the current evidence base that may compromise the conclusions drawn by this network meta-analysis? If so,
what are the implications for future research?
Search methods
We identified randomised controlled trials (RCTs) in existing Cochrane reviews by searching the Cochrane Database of Systematic
Reviews (CDSR). In addition, we ran a comprehensive citation search on the Cochrane Airways Group Register of trials (CAGR) and
checked manufacturer websites and reference lists of other reviews. The most recent searches were conducted in September 2013.
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Selection criteria
We included parallel-group RCTs of at least 6 months’ duration recruiting people with COPD. Studies were included if they compared
any of the following treatments versus any other: long-acting beta2-agonists (LABAs; formoterol, indacaterol, salmeterol); long-acting
muscarinic antagonists (LAMAs; aclidinium, glycopyrronium, tiotropium); inhaled corticosteroids (ICSs; budesonide, fluticasone,
mometasone); combination long-acting beta2-agonist (LABA) and inhaled corticosteroid (LABA/ICS) (formoterol/budesonide, for-
moterol/mometasone, salmeterol/fluticasone); and placebo.
Data collection and analysis
We conducted a network meta-analysis using Markov chain Monte Carlo methods for two efficacy outcomes: St George’s Respiratory
Questionnaire (SGRQ) total score and trough forced expiratory volume in one second (FEV1). Wemodelled the relative effectiveness of
any two treatments as a function of each treatment relative to the reference treatment (placebo). We assumed that treatment effects were
similar within treatment classes (LAMA, LABA, ICS, LABA/ICS). We present estimates of class effects, variability between treatments
within each class and individual treatment effects compared with every other.
To justify the analyses, we assessed the trials for clinical and methodological transitivity across comparisons. We tested the robustness
of our analyses by performing sensitivity analyses for lack of blinding and by considering six- and 12-month data separately.
Main results
We identified 71 RCTs randomly assigning 73,062 people with COPD to 184 treatment arms of interest. Trials were similar with
regards to methodology, inclusion and exclusion criteria and key baseline characteristics. Participants were more often male, aged in
their mid sixties, with FEV1 predicted normal between 40% and 50% and with substantial smoking histories (40+ pack-years). The
risk of bias was generally low, although missing information made it hard to judge risk of selection bias and selective outcome reporting.
Fixed effects were used for SGRQ analyses, and random effects for Trough FEV1 analyses, based on model fit statistics and deviance
information criteria (DIC).
SGRQ
SGRQ data were available in 42 studies (n = 54,613). At six months, 39 pairwise comparisons were made between 18 treatments in 25
studies (n = 27,024). Combination LABA/ICS was the highest ranked intervention, with a mean improvement over placebo of -3.89
units at six months (95% credible interval (CrI) -4.70 to -2.97) and -3.60 at 12 months (95% CrI -4.63 to -2.34). LAMAs and LABAs
were ranked second and third at six months, with mean differences of -2.63 (95% CrI -3.53 to -1.97) and -2.29 (95% CrI -3.18 to -
1.53), respectively. Inhaled corticosteroids were ranked fourth (MD -2.00, 95% CrI -3.06 to -0.87). Class differences between LABA,
LAMA and ICS were less prominent at 12 months. Indacaterol and aclidinium were ranked somewhat higher than other members of
their classes, and formoterol 12 mcg, budesonide 400 mcg and formoterol/mometasone combination were ranked lower within their
classes. There was considerable overlap in credible intervals and rankings for both classes and individual treatments.
Trough FEV1
Trough FEV1 data were available in 46 studies (n = 47,409). At six months, 41 pairwise comparisons were made between 20 treatments
in 31 studies (n = 29,271). As for SGRQ, combination LABA/ICS was the highest ranked class, with a mean improvement over placebo
of 133.3 mL at six months (95% CrI 100.6 to 164.0) and slightly less at 12 months (mean difference (MD) 100, 95% CrI 55.5 to
140.1). LAMAs (MD 103.5, 95% CrI 81.8 to 124.9) and LABAs (MD 99.4, 95% CrI 72.0 to 127.8) showed roughly equivalent
results at six months, and ICSs were the fourth ranked class (MD 65.4, 95% CrI 33.1 to 96.9). As with SGRQ, initial differences
between classes were not so prominent at 12 months. Indacaterol and salmeterol/fluticasone were ranked slightly better than others in
their class, and formoterol 12, aclidinium, budesonide and formoterol/budesonide combination were ranked lower within their classes.
All credible intervals for individual rankings were wide.
Authors’ conclusions
This network meta-analysis compares four different classes of long-acting inhalers for people with COPD who need more than short-
acting bronchodilators. Quality of life and lung function were improved most on combination inhalers (LABA and ICS) and least on
ICS alone at 6 and at 12 months. Overall LAMA and LABA inhalers had similar effects, particularly at 12 months. The network has
demonstrated the benefit of ICS when added to LABA for these outcomes in participants who largely had an FEV1 that was less than
50% predicted, but the additional expense of combination inhalers and any potential for increased adverse events (which has been
established by other reviews) require consideration. Our findings are in keeping with current National Institute for Health and Care
Excellence (NICE) guidelines.
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P L A I N L A N G U A G E S U M M A R Y
Which long-acting inhaled drugs, used alone or in combination, are the most effective for people with COPD?
Why is this question important?
Inhaled drugs for COPD have been shown to relieve symptoms, improve quality of life and prevent or treat flare-ups. Treatment with
these inhaled drugs tends to begin with one inhaler, and additional therapies are introduced as necessary. For persistent or worsening
symptoms, long-acting inhaled drugs taken once or twice daily are preferred over short-acting ones. Several Cochrane reviews have
looked at the risks and benefits of specific long-acting inhaled therapies compared with placebo or other treatments. However for
patients and clinicians, it is important to understand the benefits of these treatments relative to each other, and whether a particular
type of inhaled therapy is more beneficial than the others.
How did we answer the question?
We looked for studies in existing Cochrane reviews and performed detailed electronic searches up to September 2013. Studies were
included if they lasted at least six months and compared any of the following treatments versus any other for people with COPD: long-
acting beta2-agonists (LABAs-formoterol, indacaterol, salmeterol); long-acting muscarinic antagonists (LAMAs-aclidinium, glycopy-
rronium, tiotropium); inhaled corticosteroids (ICSs-budesonide, fluticasone, mometasone); combination long-acting beta2-agonist and
inhaled corticosteroid (LABA/ICS-formoterol/budesonide, formoterol/mometasone, salmeterol/fluticasone); and placebo.
We conducted a network meta-analysis to assess the benefits of each type of treatment (e.g. long-acting beta2-agonists) relative to the
others for quality of life and lung function. We also looked at how much individual treatments varied (e.g. How different were the
three inhaled steroids from one other?) and whether particular treatments were more effective than others. We assessed the data for six
months and 12 months separately and reported six months as the primary findings.
What did we find?
We found 71 relevant studies, but not all measured the outcomes we were interested in. Forty-two studies were included in the quality
of life analyses (measured on St George’s Respiratory Questionnaire), and 46 were included in the lung function analyses.
Evidence from good quality and similar trials supported LABA/ICS combinations as the most likely treatment strategy to bring the
greatest improvement to quality of life and lung function. Combination therapy gave an average benefit of 3.9 units over placebo at
six months. LAMAs and LABAs were ranked second and third at six months (-2.63 and -2.29 units, respectively), especially when
unreliable trials were not included, but a large degree of overlap in the estimates was noted.
Combination LABA/ICS was the highest ranked class for trough forced expiratory volume in one second (FEV1), with mean improve-
ment over placebo of 133 mL at six months (95% credible Interval (CrI) 101 to 164). As was the case for SGRQ, LAMAs (mean
difference (MD) 104, 95% CrI 82 to 125) were ranked just ahead of LABAs (MD 99, 95% CrI 72 to 128) at six months, and ICSs
were the lowest ranked class (MD 65, 95% CrI 33 to 97).
For both outcomes, the effects of LABA and ICS used alone appeared to increase when used together for six months, but initial
differences between the treatment classes were less obvious after a year of treatment.
Conclusion
Quality of life and lung function were improved most on combination inhalers (LABA and ICS) and least on ICS alone at 6 and 12
months. Overall LAMA and LABA inhalers had similar effects, particularly at 12 months. The network has demonstrated the benefit
of ICS when added to LABA for these outcomes in participants who largely had an FEV1 that was less than 50% predicted, but the
additional expense of combination inhalers and any potential for increased adverse events (which has been shown by other reviews)
require consideration. Our findings are in keeping with current National Institute for Health and Care Excellence (NICE) guidelines.
3Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
B A C K G R O U N D
Description of the condition
Chronic obstructive pulmonary disease (COPD) is a respiratory
disease characterised by chronic and progressive breathlessness,
cough, sputum production and airflow obstruction, all of which
lead to restricted activity and poor quality of life (GOLD). The
World Health Organization (WHO) has estimated that COPD is
the fourth or fifth most common single cause of death worldwide,
and the treatment andmanagement costs present a significant bur-
den to public health. In the UK, the annual cost of COPD to the
National Health Service (NHS) is estimated to be £1.3 million
per 100,000 people (NICE 2011). Furthermore, because of slow
onset and under-recognition of the disease, it is heavily under-di-
agnosed (GOLD). COPD comprises a combination of bronchitis
and emphysema and involves chronic inflammation and structural
changes in the lung. Cigarette smoking is the most important risk
factor; however, air pollution and occupational dust and chemicals
can also increase the risk of developing the disease. COPD is a
progressive disease that leads to decreased lung function over time,
even with the best available care. Currently no cure for COPD
is known, although it is both preventable and treatable. Manage-
ment of the disease is multifaceted and includes interventions for
smoking cessation (van der Meer 2001), pharmacological treat-
ments (GOLD), education (Effing 2007) and pulmonary reha-
bilitation (Lacasse 2006; Puhan 2011). Pharmacological therapy
is aimed at relieving symptoms, improving exercise tolerance and
quality of life, slowing decline and even improving lung function
and preventing and treating exacerbations. COPD exacerbations
impair patients’ quality of life (GOLD), and a large part of the
economic burden of COPD is attributed to the cost of manag-
ing exacerbations, particularly those resulting in use of acute care
services or hospitalisation (Hutchinson 2010). In the UK, one
in eight emergency admissions to hospital is for COPD, and it
is one of the most costly conditions treated by the NHS (NICE
2011). Appropriate pharmacological management of the disease
is therefore important, particularly for reducing and preventing
exacerbations.
Description of the interventions
Pharmacological management of COPD tends to begin with
one treatment, and additional therapies are introduced as neces-
sary to control symptoms and reduce the frequency and sever-
ity of exacerbations (GOLD). The first step is often a short-act-
ing bronchodilator for control of breathlessness when needed: ei-
ther a short-acting beta2-agonist (SABA; e.g. salbutamol) or the
short-acting muscarinic antagonist (SAMA) ipratropium. Both
bronchodilators have a duration of action of four to six hours
(Beeh 2010), and they improve lung function and breathlessness
(Appleton2006; Sestini 2009). For persistent orworseningbreath-
lessness associated with lung function decline, long-acting bron-
chodilators may be introduced (GOLD). These comprise long-
acting beta2-agonists, such as salmeterol or formoterol (LABAs;
durationof action12hours) and indacaterol (duration of action 24
hours), and long-acting anticholinergic agents, such as tiotropium
(duration of action 24 hours) and more recently aclidinium bro-
mide and glycopyrronium bromide. Regular treatment with long-
acting bronchodilators is preferred over treatment with regular
short-acting bronchodilators on the basis of efficacy and adverse
effects (Beeh 2010; GOLD). An alternative when bronchodilators
are not available or affordable is theophylline, an oral phospho-
diesterase (PDE) inhibitor. However, theophylline is less effective
and is less well tolerated than inhaled long-acting bronchodilators.
For patients with severe or very severe COPD (forced expiratory
volume in one second (FEV1) < 50% predicted) with repeated
exacerbations, GOLD recommends the addition of inhaled cor-
ticosteroids (ICSs) to bronchodilator treatment. ICSs are anti-in-
flammatory drugs that are licensed as combination inhalers with
LABAs. The most common combinations of ICS and LABA in
combination inhalers are fluticasone and salmeterol, and budes-
onide and formoterol. The most severely ill group of patients with
advanced COPDmay also benefit from treatment with the PDE4
inhibitor roflumilast, which may reduce the risk of exacerbations
(GOLD), alongside other beta2-agonists or anticholinergic agents
and ICS, but these combinations are not considered in this review.
How the interventions might work
Long-acting beta2-agonists
Inhaled long-acting beta2-agonists (LABAs) activate beta2-recep-
tors in the smooth muscle of the airway, leading to a cascade of
reactions that result in bronchodilation. Commonly used LABAs
include salmeterol, formoterol and indacaterol. The duration of
action for salmeterol and formoterol is approximately 12 hours;
therefore they are usually taken twice daily. Indacaterol has a du-
ration of action of 24 hours and therefore can be taken once daily.
As with long-acting muscarinic antagonists (LAMAs), LABAs are
commonly used to control symptoms and reduce exacerbations in
stable COPD (Moen 2010; Rodrigo 2008). Possible side effects
of LABAs include cardiac effects such as arrhythmia and palpita-
tions, muscle tremors, headache and dry mouth (Berger 2008).
Inhaled corticosteroids
Inhaled corticosteroids (ICSs) are anti-inflammatory drugs. ICSs
are licensed as combination inhalers with LABA. The most com-
mon combinations of ICS and LABA in combination inhalers are
fluticasone and salmeterol, and budesonide and formoterol. Com-
bination inhalers have similar effects to LABA alone, reducing ex-
acerbation rates and improving patients’ quality of life. However,
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some have argued that the difference is small (Rodrigo 2009), and
ICS therapy, alone or in combination with beta2-agonists, is asso-
ciated with increased risk of pneumonia and osteoporotic fracture
(GOLD; Loke 2011; Singh 2010).
Long-acting muscarinic antagonists
Long-acting muscarinic antagonists (LAMAs) are anticholinergic
agents that block the action of the neurotransmitter acetylcholine.
The LAMA tiotropium has gained widespread acceptance as once-
daily maintenance therapy in stable COPD for its effects on symp-
toms and exacerbations (Barr 2005; GOLD). Two newer LAMAs
that can be taken once daily-aclidinium bromide and glycopyrro-
nium bromide-have recently been licensed for the maintenance
treatment of people with COPD. Anticholinergic adverse effects
that may occur include dry mouth, constipation and tachycardia
(Tashkin 2008).
Why it is important to do this review
Several systematic reviews have looked at the risks and benefits
of specific inhaled therapies compared with placebo or other in-
haled therapies. However for patients or for clinicians facing pa-
tients, the question is often this: Which of the long-acting ther-
apy options is the most beneficial treatment option for patients
no longer obtaining symptom relief from short-acting therapies,
but for whom PDE4 inhibitors or other additional therapies are
not yet necessary? Two recent network meta-analyses have focused
primarily on safety outcomes (Decramer 2013; Dong 2013).
O B J E C T I V E S
To assess the efficacy of treatment options for patients whose
chronic obstructive pulmonary disease cannot be controlled by
short-acting therapies alone. The review will not look at combina-
tion therapies usually considered later in the course of the disease.
As part of this networkmeta-analysis, wewill address the following
issues:
1. How does long-term efficacy compare between different
pharmacological treatments for COPD?
2. Are there limitations in the current evidence base that may
compromise the conclusions drawn by this network meta-
analysis? If so, what are the implications for future research?
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised control trials (RCTs) with a parallel-
group design of at least 24 weeks’ duration. Cross-over trials were
not included, as the pharmaceutical treatments under study can
have long-acting effects.
Types of participants
We included RCTs that recruited participants with a clinical di-
agnosis of COPD, such as ATS/ERS 2004. We looked for the fol-
lowing inclusion criteria.
1. Forced expiratory volume in one second (FEV1)/forced
vital capacity (FVC) ratio < 0.7, which confirms the presence of
persistent airflow limitation.
2. One or more of the following key indicators.
i) Progressive and/or persistent dyspnoea.
ii) Chronic cough.
iii) Chronic sputum production.
iv) History of exposure to risk factors (tobacco smoke,
smoke from home cooking and heating fuels, occupational dusts
and chemicals).
Types of interventions
We included studies that compared any of the following therapies
versus any other.
1. LABA (formoterol, salmeterol, indacaterol).
2. LAMA (tiotropium, aclidinium bromide, glycopyrronium
bromide).
3. ICS (budesonide, fluticasone, mometasone).
4. LABA/ICS combination (formoterol/budesonide,
formoterol/mometasone, salmeterol/fluticasone).
5. Placebo.
Treatment classes and individual treatments were compared versus
every other using a class-model network meta-analysis. The list
of included treatments comprised commonly used agents within
each class.
Participants were allowed other concomitant COPD medications
as prescribed by their healthcare practitioner, provided these med-
ications were not part of the trial treatment under study.
Types of outcome measures
For studies of six months’ duration, we used end of study as time
of analysis for all outcomes. For longer studies, we extracted data
reported at six-month and 12-month intervals when available.
Two measures of efficacy were chosen as outcomes because pre-
vious network meta-analyses have primarily assessed safety out-
comes (mortality, Dong 2013; exacerbations and adverse events,
Decramer 2013).
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Primary outcomes
1. Quality of life (measured as change from baseline assessed
with St George’s Respiratory Questionnaire (SGRQ)).
2. Trough FEV1 (change in mL from baseline).
Cost-effectiveness
We did not carry out a formal cost-effectiveness analysis, but we
sought to identify economic evaluations that have compared the
included interventions to supplement the main systematic review
of effects. These are summarised in a short commentary in the
discussion.
Search methods for identification of studies
Electronic searches
To avoid duplication of effort, we first identified RCTs for in-
clusion by searching for relevant Cochrane systematic reviews.
Cochrane systematic reviews use extensive search strategies that in-
clude several databases, manufacturers’ websites and handsearch-
ing of conference abstracts. We searched the Cochrane Database
of Systematic Reviews (CDSR) in The Cochrane Library (2013,
Issue 7) to look for all Cochrane systematic reviews on COPD,
using the search strategy provided in Appendix 1, and from those,
we handpicked the reviews that included relevant comparisons.
From these reviews, we identified individual RCTs that met our
inclusion criteria.
In addition, we ran a search on the Cochrane Airways Group Reg-
ister (CAGR) of trials (see Appendix 2 for details of the Register)
to find studies that may have beenmissed in the review search (e.g.
because of discrepancies in inclusion criteria between individual
reviews and this network, as a result of review searches more than
12 months out of date or when no reviews existed for a particular
comparison). The searchwas done according to guidance provided
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011) and in consultation with an information special-
ist (see Appendix 3 for the search strategy). No date or language
restrictions were applied. We searched NHS Economic Evalua-
tion Database (EED) and Health Economic Evaluations Database
(HEED) for economic evaluations using the strategy provided in
Appendix 1, adapted as appropriate.
Data collection and analysis
Selection of studies
One review author assessed for inclusion all potentially eligible
reviews retrieved through the search and assessed all potentially
eligible RCTs within these reviews (KMK). The CAGR database
searchwas sifted by the same review author, and uncertainties were
resolved by discussion with a second review author (CJC).
Data extraction and management
For the following characteristics, one review author extracted in-
formation for all included RCTs from their published reports
(KMK) if they were already included in a Cochrane review.
1. Individual trial study characteristics (design, duration,
location, participant inclusion/exclusion criteria, funding).
2. Trial arms of interest (drug, dose, inhaler type, allowed co-
medications).
3. Individual trial population details: mean baseline lung
function, pack-years, age and % male.
4. Individual trial outcome data.
Information from studies identified in other reviews was subse-
quently cross-checked (data in each of the existing reviews were
extracted and verified by at least two review authors). Inconsisten-
cies and uncertainties were resolved by consultation with a second
review author (CJC).
Assessing transitivity (similarity of participants,
interventions and trial methodology)
The sets of trials for each treatment must be similar in their
distribution of effect modifiers to permit conclusions based on
a network meta-analysis combining direct and indirect evidence
(Cipriani 2013). We constructed summary tables organised by
class pair-wise comparisons (e.g. LABA vs ICS, LAMA vs placebo)
to assess clinical and methodological similarities of the trials and
their populations.
Assessment of risk of bias in included studies
Although existing reviews were used to identify RCTs, data and
methodological quality were dealt with at an individual trial level.
One review author extracted information related to risk of bias
for all trials and subsequently cross-checked judgements from ex-
isting reviews, standardising ratings across them for consistency.
Judgements were made for the following domains in each study in
accordance with recommendations provided in Chapter 8 of the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2012).
1. Random sequence generation (selection bias).
2. Allocation concealment (selection bias).
3. Blinding (performance bias and detection bias).
4. Incomplete outcome data (attrition bias).
5. Selective reporting.
We did not exclude trials on the basis of risk of bias but conducted
sensitivity analyses to explore the effects of including unblinded
study comparisons.
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Measures of treatment effect
Direct pairwise meta-analysis
We analysed data for the two continuous outcomes as fixed-effect
mean differences (MDs) with 95% confidence intervals (CIs) and
a fixed-effect model. The fixed-effect model assumes that each
study is estimating exactly the same intervention effect, and the
random-effects model assumes that estimated intervention effects
are not all the same but follow a normal distribution across studies.
Data were extracted and analysed as change from baseline in all
studies, and this was extracted from text or tables or was calculated
from figures when necessary. Associated variance for change per
arm was not always available (or could not be derived from the
presented information), and in these cases we used available data
from other trials to estimate a population variance. For SGRQ
and trough FEV1, we calculated the mean of available standard
deviations (SDs) for change scores, which was weighted by sample
size.
Network meta-analysis
We conducted a network meta-analysis (NMA) to estimate the
effect for each class and for each individual intervention using
Markov chain Monte Carlo methods implemented in WinBUGS
1.4.3. Analyses were based on a class model, which assumes that
effects of individual treatments within a class are exchangeable and
are distributed around a class mean (Cooper 2009). Correlations
in multiarm trials were accounted for in the model, which was
adapted from Dias 2013. Non-informative normal priors were
used for class effects, and Uniform (0,5) and (0,100) prior dis-
tributions were used for between-trials and between-classes het-
erogeneity SDs for SGRQ and FEV1, respectively. Three chains
with different initial values were run simultaneously to assess con-
vergence using Brooks-Gelman-Rubin diagnostic plots. The first
20,000 (fixed-effect models) or 40,000 iterations (random-effects
models) were discarded, and 50,000 further iterations were run,
on which all estimates are based. We decided whether to use a
fixed-effect or a random-effects approach on the basis of model
fit statistics and deviance information criteria (DIC) (Dias 2013;
Spiegelhalter 2002), as well as the amount of heterogeneity present
in the pair-wise meta-analyses. The model with lower values on
the DIC was preferred, with differences of three or more units
considered meaningful. If two models had similar DIC, the sim-
plest model (i.e. fixed-effect) was preferred.
Unit of analysis issues
No unit of analysis issues were noted, as we did not analyse any
dichotomous data.
Dealing with missing data
When data or study characteristics were not reported in the pri-
mary publication, we searched clinical trial reports, trial registries
and drug company websites to look for additional data. When
possible, we used data from intention-to-treat (ITT) analyses from
all randomly assigned participants.
Assessment of heterogeneity
In the presence of statistical heterogeneity (I2 > 30%) in the direct
pair-wise meta-analysis, we analysed data using a random-effects
model and investigated possible sources. They could be of a clini-
cal and methodological nature (i.e. differences between individual
studies) in study design (inclusion/exclusion criteria, study du-
ration), participants’ baseline characteristics (disease severity, co-
morbidities, age, gender), risk of bias (open vs blinded studies) or
study sponsorship. The extent of heterogeneity observed informed
our decision of whether to use fixed-effect or random-effects mod-
els for the network meta-analysis.
For the network meta-analysis, we assessed the extent to which
direct evidence and indirect evidence were consistent both quali-
tatively and statistically (Dias 2013a; Lu 2006). Consistency refers
to the agreement between direct and one or more indirect sources
of evidence in a “closed loop” of trials (i.e. a path by which three or
more trials are connected, starting and ending with the same node)
(Lu 2006). We assessed consistency by comparing model fit from
a consistency and ’independent mean effects’ model and by in-
formally comparing output from the NMA versus estimates from
the pair-wise meta-analyses. We used this global test to determine
the presence of inconsistency and to locate areas in the network
at which large inconsistencies were present. The output from the
network meta-analysis was informally compared with estimates
from the pair-wise meta-analyses to check for broad agreement.
When evidence of inconsistency was found, we further investi-
gated potential sources of inconsistency using the node-split ap-
proach (Dias 2010), as this was most appropriate given the struc-
ture of the networks. In cases in which substantial inconsistency
was identified, we explored factors, including participant and de-
sign characteristics, that might contribute to inconsistency, and we
restricted our analysis to a subset of trials for which the evidence
might be more comparable.
Assessment of reporting biases
We tried tominimise reporting bias fromnon-publication of stud-
ies or selective outcome reporting by using a broad search strat-
egy, and by checking references of included studies and relevant
systematic reviews. For each outcome, we commented on the pro-
portion of studies contributing data to the analysis.
Data synthesis
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Using a class-model network meta-analysis, we modelled the rela-
tive effectiveness of any two classes as a function of each class rela-
tive to a reference treatment (placebo).We prespecified five unique
classes of interventions (or nodes) in the network: LABA (salme-
terol, formoterol and indacaterol), LAMA (tiotropium, aclidinium
bromide and glycopyrronium bromide), ICS (fluticasone, budes-
onide and mometasone), LABA/ICS (salmeterol/fluticasone, for-
moterol/budesonide and formoterol/mometasone) and placebo.
We estimated the probability that each class ranks at one of the
five possible positions (e.g. the best, second best, third best). We
obtained estimates of each overall class effect, as well as of the ef-
fects of each treatment within the class compared with every other.
Estimates for within-class variability in treatment effects, as well
as for between-class variability in treatment effects, are presented,
as are ranking probabilities, in tables and figures as appropriate.
Subgroup analysis and investigation of heterogeneity
We planned to perform subgroup analyses based on baseline dis-
ease severity and dose, provided that treatments could be com-
pared indirectly with other trial comparisons through one or more
common comparators (i.e. the networks remained ’connected’).
However, differences in individual doses were built into the net-
work structure, and baseline disease severity was assessed across
nodes as part of the transitivity assessment.
For the network meta-analysis, available data were insufficient to
include baseline severity as a co-variate as a way of exploring sub-
group effects. We extracted key severity criteria for each trial in-
dividually, and we summarised the data across pair-wise compar-
isons to investigate potential differences.
Sensitivity analysis
We assessed the robustness of our analyses by performing sensi-
tivity analyses, excluding studies from the overall analysis of high
risk of bias due to lack of blinding (participants and personnel
and/or outcome assessors), and by considering separately studies
of different duration.
R E S U L T S
Description of studies
Basic study characteristics, includingduration, interventiondetails
and population characteristics, are summarised in Table 1, and full
details of each included study can be found in Characteristics of
included studies.
Results of the search
Results of the search are presented in Figure 1, broken down by the
search for Cochrane reviews on the left and the electronic database
search on the right.
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Figure 1. Study flow diagram.aAll 58 studies identified in the review search were also identified in the
electronic database search.Abbreviations: CDSR = Cochrane Database of Systematic Reviews.
Fourteen relevant Cochrane reviews were identified (Chong 2012;
Geake 2012; Karner 2011; Karner 2011a; Karner 2012; Karner
2012a; Kew 2013; Kew 2014; Nannini 2012; Nannini 2013;
Nannini 2013a; Spencer 2011;Welsh 2013; Yang 2012a), includ-
ing a total of 124 studies. Sixty-six studies were excluded because
of differences in the reviews’ inclusion criteria, most commonly,
’duration less than six months’ (n = 49), and ’cross-over design’ (n
= 16). The remaining 58 studies were included in the review.
Searching the CAGR of trials returned 2034 references, and 58
additional references were identified by searching reference lists
and drug company websites. We excluded 1449 references after
sifting titles and abstracts, and we reviewed full texts after studifi-
cation for the remaining 643. Four hundred eighty-six references
met all inclusion criteria, most of which related to the 58 studies
identified from the review search. The remaining references were
collated into 13 additional studies that met the inclusion criteria.
The most common reasons for excluding citations after viewing
full texts were ’invalid comparison for this review’ (n = 78), ’du-
ration less than six months’ (n = 46) and ’cross-over design’ (n =
29).
9Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Included studies
Seventy-one studies met the inclusion criteria, randomly assigning
73,062 people with a diagnosis of COPD to 184 treatment arms of
interest (including placebo). The number of participants included
in the trials ranged from18 (DalNegro 2003) to 7384 (Vogelmeier
2011 [POET]); the mean number per arm of a trial was 397.
Table 1 lists all 71 studies that met the inclusion criteria, along
with their total duration, treatment arms relevant to the network
and summary characteristics for each study population. Table 2
and Table 3 present pooled characteristics for each class and for
individual nodes within them for studies contributing data to the
SGRQ and trough FEV1 data sets, respectively.
Design and duration
All of the studies were parallel-group, randomised controlled trials,
and most were conducted at multiple centres in several countries.
A vast majority were double-blind; five included one open-label
treatment (see sensitivity analyses), a subset were double-blind and
double-dummy and blinding was unclear in four others.
All studies had a randomly assigned treatment period of at least
24 weeks. Similar numbers of six-month and 12-month studies
were identified (n = 30 and n = 29, respectively), but six-month
data were available in a number of the longer trials. Twelve stud-
ies lasted between two and four years (Burge 2000 [ISOLDE];
Calverley 2007 [TORCH]; Cooper 2010; Lapperre 2009; Pauwels
1999; Renkema 1996; Schermer 2009; SCO40041; Shaker
2009; Tashkin 2008a [UPLIFT]; Vestbo 1999; Wedzicha 2008
[INSPIRE]). For these studies, we used data measured and re-
ported for six and 12 months in the NMA, rather than endpoint.
Data entered in the six-month analysis were reported between 24
and 32 weeks, and data included in the 12-month networks were
measured between 44 and 56 weeks in the individual studies.
Participant inclusion and exclusion criteria
The trials were relatively consistent in their key inclusion and ex-
clusion criteria. All studies required a clinical diagnosis of COPD,
and most specified that this was in accordance with recent guide-
lines (usually ATS/ERS 2004 or GOLD). The cutoff for forced
expiratory volume in one second (FEV1) expressed as the percent-
age predicted normal value ranged from 50% to 80%. Additional
inclusion criteria that were common across trials were these: smok-
ers or ex-smokers with a smoking history of at least 10 pack-years,
40 years of age or older and FEV1/FVC ratio less than 70%.
Exclusion criteria that were common across most trials were these:
history of asthma or other respiratory disease, any significant dis-
ease other than COPD and the need for supplemental oxygen.
Patients who had a COPD exacerbation or upper respiratory tract
infection in the run up to screening (usually within four to six
weeks) were usually excluded. Trials often listed additional exclu-
sion criteria specific to the drugs under study, such as sensitivities
to active ingredients, or medical conditions that might be affected
by known adverse effects.
Baseline characteristics of participants in the trials
Baseline characteristics are presented for all included studies in
Table 1, and for the subsets of studies contributing data to the
SGRQ and FEV1 analyses in Table 2 and Table 3, respectively.
In the SGRQ data set, the overall mean age per class was very
similar, ranging from 62.9 to 64.5 years. In the FEV1 data set,
the overall mean age for each comparison was also very similar,
ranging from 63.3 to 64.3. Both data sets consistently included
more men than women, and the means of trial percentages were
similar between and within comparisons (SGRQ range 69.5% to
82.5%, FEV1 range 67.1% to 73.2%). As might be expected from
variation in inclusion criteria, greater variability was noted in the
summary statistics for percentage predicted FEV1, with the LABA
versus LAMA comparison having somewhat higher scores in both
data sets than the other classes (both means around 55% com-
pared with 39% to 47% in the other comparisons). Overall, most
population means for percentage predicted FEV1 were less than
50% predicted. Mean pack-years were between 40 and 50 for all
comparisons in both data sets. In general, the data indicated a
fairly consistent moderate to severe population across both out-
come data sets and across direct between-class comparisons, which
satisfied the transitivity assumption.
Characteristics of the interventions
Table 4 shows the distribution of treatment arms across all 71 in-
cluded studies, organised by the five prespecified treatment classes.
The text below summarises information about all 71 included
studies. Table 2 and Table 3 show the number of studies making
each class comparison represented in the SGRQ or FEV1 analyses,
respectively.
Lists of allowed co-medications varied between studies, but par-
ticipants were always allowed a short-acting beta-agonist reliever
inhaler and short-term treatment for exacerbations during the ran-
domised period (course of oral corticosteroids or antibiotics).
1. Long-acting beta2-agonists (LABAs)
Thirty-seven LABA treatment arms were identified across 30 stud-
ies (n = 15,266). Twelve studies included a formoterol arm with
treatment given at 12 mcg twice daily, and Rossi 2002 also ran-
domly assigned participants to a higher dose of twice-daily 24mcg.
Formoterol was most commonly given via a dry powder inhaler
but sometimes via a metered-dose inhaler (to retain blinding in
the newer multiarm mometasone studies). Salmeterol was given
at 50 mcg twice daily in 17 studies (n = 9019), primarily via the
Diskus device. Indacaterol, a once-daily preparation, was given
as 150 mcg in three studies (Bateman 2013 [SHINE]; Donohue
2010 [INHANCE]; Kornmann 2011) and as 300 mcg in three
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studies (Dahl 2010; Donohue 2010 [INHANCE]; To 2011), one
of which also used a higher dose of 600 mcg. Donohue 2010
[INHANCE] was conducted in two stages, and the data derived
are for the four randomly assigned groups from stage 2.
2. Long-acting muscarinic antagonists (LAMAs)
Thirty-four LAMA treatment armswere included across 28 studies
(n = 21,805).Most studies used tiotropium18mcg daily, delivered
most often via theHandiHaler. Six studies included two arms that
met criteria for inclusion in the LAMA category: Bateman 2010b
used two tiotropium doses (5 and 10 mcg daily via Respimat),
ATTAIN2011 andGelb 2012 used two aclidiniumdoses (200 and
400 mcg daily) and Bateman 2013 [SHINE], GLOW2 2012 and
SPARK 2013 included both glycopyrronium 50 mcg and open-
label tiotropium. Two additional glycopyrronium studies used 50
mcg via the Breezhaler, and two other aclidinium studies used
the lower of the two doses via the Genuair device. Two other
tiotropium studies used the Respimat device to deliver 5 mcg daily
(Abrahams 2013 and Bateman 2010a).
3. Inhaled corticosteroids (ICSs)
Twenty-seven studies included an ICS arm (n = 6788), with two
including two doses of the same drug that were relevant to the
review (Calverley 2008; FLTA3025). Twelve studies (n = 3491)
reported a fluticasone arm: two studies used 250 mcg twice daily,
and the rest 500 mcg, delivered most often via the Diskus device.
Twelve studies with around half as many people used budesonide
(n = 1900): two at the higher dose of 800 mcg twice daily, and the
rest at 400 mcg, with both doses delivered via dry powder inhalers.
Mometasone was used in four studies (n = 1397) and was given as
400 mcg twice daily or 800 mcg once daily.
4. Long-acting beta2-agonist/inhaled corticosteroid
combinations (LABA/ICS)
Thirty LABA/ICS treatment arms were identified in 25 studies
(n = 9727). Three studies used two budesonide doses (160 mcg
and 320 mcg; Rennard 2009; Sharafkhaneh 2012; Tashkin 2008
[SHINE]), and seven additional studies used only the higher dose
(total N = 3221). Two identically designed studies included two
formoterol/mometasone doses each, 200 and 400 mcg (n = 888).
Sixteen studies had a salmeterol/fluticasone arm (n = 5618), six
at the lower ICS dose of 50/250 mcg and 11 at the higher dose
of 50/500 mcg. All LABA/ICS inhalers were prescribed for twice-
daily use and drugs were delivered by dry powder or pressurised
metered-dose inhalers.
5. Placebo
Most studies included a placebo control arm (n = 55), which con-
sisted of a total of 19,476 people. Inhalers varied across studies
depending on the device used to deliver the study drugs. Once-
daily and twice-daily placebos were combined in the same node
as the reference treatment to increase the number of comparisons
that could be made.
Transitivity (similarity of participants, interventions
and trial methodology)
1. Inclusion and exclusion criteria, as described above, did
not vary systematically across classes; although variation in the
allowed co-medications and in the maximum allowed percentage
predicted FEV1 was noted, these did not translate to systematic
differences in the characteristics of the recruited population.
2. Baseline characteristics were varied between individual
trials, but summary baseline characteristics were comparable
across pair-wise comparisons between classes for both outcome
data sets (see above and Table 2; Table 3). Mean percentage
predicted FEV1 was somewhat higher in the LABA versus
LAMA comparisons conducted in two studies (55% vs 39% to
47% in the other comparisons).
3. Intervention characteristics introduced some potential
sources of systematic variation between trials, notably as a result
of the devices used and the dosing schedule. However, as all
nodes showed variation in the delivery device used and in once-
daily and twice-daily regimens, we did not consider these factors
to violate assumptions needed for indirect comparisons. The
placebo-controlled trials used matching inhalers to control for
bias at a trial level, and variation within classes was similar, so we
considered a combined placebo class valid as the reference
treatment (regardless of device or dosing regimen).
4. Methodology was similar across trials, and no issues with
the comparability of trial duration arose, as we included only
data relevant to the time points specified. Funding sources varied
across classes, depending on the drug manufacturers, but this
variability did not translate into systematic differences in the way
that trials were conducted, nor in the populations recruited (i.e.
similar inclusion criteria, baseline characteristics and study
designs). Average sample size per class was higher in the LAMA
trials (659 and 633 for SGRQ and FEV1, respectively) than in
the four other classes (range 189 to 471 across both outcome
data sets), but variation within the classes was comparable.
Outcomes and analysis structure
For both outcomes, the overall fit of the network meta-analy-
sis class model was compared with the fit of a class model with-
out the consistency assumption (broadly equivalent to a pair-wise
meta-analysis with random class effects), using the total residual
deviance. Statistical inconsistency was not significant on SGRQ
at 12 months nor on the FEV1 analyses (six and 12 months).
However some evidence of inconsistency was noted in the net-
work for SGRQ at six months. This was investigated further us-
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ing the node-split approach (Dias 2010), which found some evi-
dence of inconsistency (P value 0.01, although multiple compar-
isons were made) in the direct evidence comparing indacaterol
150 mcg and tiotropium 18 mcg. We investigated the possible
clinical explanation for this inconsistency and found that stud-
ies directly comparing these two treatments delivered tiotropium
open-label, which affected comparability with other tiotropium
studies, and increased risk of bias (see sensitivity analyses). The
dose was misclassified in one study comparing salmeterol versus
salmeterol/fluticasone combination (salmeterol/fluticasone as 50/
500 bid instead of 50/250). Because the study did not appear in
the main six-month results nor change the class comparisons, we
did not rerun the analyses.
St George’s Respiratory Questionnaire (SGRQ)
The SGRQ is a well-validated and widely used measure of health
status in patients with chronic airflow limitation; the total score
ranges from zero (perfect health) to 100 (most severe status) and
includes the three components of symptoms, activity and impacts.
In the main network of effects at six months, 18 of 25 possible
treatments were represented across 72 treatment arms in 25 studies
(n = 27,024). The fixed-effect model was preferred, as statistical
heterogeneity was not significant. We extracted and analysed data
as change frombaseline per arm and estimated population variance
on the basis of data from studies reporting variance for change
per arm (see Measures of treatment effect). The mean of SDs,
weighted by sample size, was imputed as 14 when variance for
change could not be obtained.
The 12-month analysis contained slightly fewer data and had a
broadly similar structure (containing data for 19 treatment com-
parisons in 24 studies). The fixed-effect model was preferred,
as with the six-month analysis, but Calverley 2003 [TRISTAN]
showed some lack of fit. Data from four studies were removed
from the six-month network in the blinding sensitivity anal-
ysis (Bateman 2013 [SHINE]; Donohue 2010 [INHANCE];
GLOW2 2012; SPARK 2013), and data from two studies were
removed from the 12-month network (GLOW2 2012; SPARK
2013).
The network structure for SGRQ at six months is shown in Figure
2.
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Figure 2. Network structures for both outcomes at six months.
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Trough forced expiratory volume in one second (FEV1)
In the main network of effects at six months, 20 of 25 possible
treatments were represented across 82 treatment arms in 31 studies
(n = 29,271). A random-effects model was preferred, as the fixed-
effect model has very poor fit. Data for eight studies were available
only as treatment contrasts, and the rest were entered as change
frombaseline per arm, alongwith the associated variance. For trials
reporting treatment contrasts, we included co-variance, which was
calculated as the variance of the mean in the control arm (placebo
for all trials). For the rest of the trials, missing variance for change
from baseline was imputed as 283 (mL) from themean of available
SDs weighted by sample size.
One very small trial was excluded from the six-month analysis
(SLMF4010, n = 34) because of the unusually high dropout from
already very small groups (sevenof 17droppedout in both groups).
The study showed very poor fit, even in random-effects models,
because the results contradicted all other trials.
The 12-month analysis contained fewer data (19 treatments com-
pared in 21 studies) but again had a structure broadly similar to
the main six-month analysis. As with the six-month analysis, the
random-effects model was preferred, as the fixed-effect model had
very poor fit. Data from the same four studies were removed from
the six-month and 12-month networks, as for the SGRQ sensitiv-
ity analyses (see Table 5).
The network structure for trough FEV1 at six months is shown in
Figure 2.
Sensitivity analyses
Five studies included a randomly assigned group that received
tiotropium as an open-label treatment (Bateman 2013 [SHINE];
Donohue 2010 [INHANCE]; GLOW2 2012; SPARK 2013;
Vogelmeier 2008). As this introduced the potential for perfor-
mance and assessment bias, we removed these arms from the af-
fected networks in a risk of bias sensitivity analysis, as detailed in
Table 5. Blinding led to unclear or high risk of bias in four ad-
ditional studies, mainly as the result of insufficient reporting, but
none of the studies reported data that could be included in the
networks (Fang 2008; Mahmud 2007; Ohar 2013; To 2011).
As stated in the protocol, we analysed separately data collected at
six months and at 12 months.
Excluded studies
Sixty-six studies were excluded from the 14 relevant Cochrane
reviews, and five others that came up in the electronic database
search are recorded in Characteristics of excluded studies. We did
not record every reference excluded after the full-text sift (n = 157),
as review of the full paper revealed that most trials were apparently
of less than six months’ duration, or they compared treatments
that were not within the scope of the study.
Risk of bias in included studies
Methodological quality of the included studies was generally good.
Across all six domains, around 60% of judgements were ’low risk’,
and 13% were ’high’ risk. It is unlikely that the evidence presented
in this review is affected by biases associated with unacceptable
sequence generation, and most trials were double-blinded. The
most common reasons for probable bias were attrition and se-
lective reporting in the individual trials. A degree of uncertainly
regarding the risk of bias associated with allocation concealment
and blinding of outcome assessors was due mostly to insufficient
reporting. Risk of bias judgements for all of the included studies
are summarised in Figure 3
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
15Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Allocation
Random sequence generation
All studies were randomised trials, and none were given high risk
ratings for either of the selection bias domains. Most were funded
by drug manufacturers with whom the authors had had previous
contact to confirm methods of sequence generation. As such, all
studies were considered to be at low risk of bias for this domain,
with the exception of six studies for which only a conference ab-
stract was available (rated unclear). Of these, none appeared in the
SGRQ data set, and only two contributed FEV1 data.
Allocation concealment
A third of studies described methods of allocation concealment
(interactive voice response system or sealed envelopes) and were
rated as having low risk of bias (n = 24). The remaining studies
did not explicitly describe their methods and were rated as unclear.
This information is likely to be conservative given the high pro-
portion of industry-funded trials, which generally have rigorous
controls for selection bias.
Blinding
Blinding of participants and personnel
A largemajority of trials stated that theywere double-blind, which,
unless otherwise stated, was understood to pertain to at least par-
ticipants and personnel. For this reason, more than 85% of the tri-
als were rated at low risk for performance bias. Seven trials (10%)
were given a high risk of bias rating, which was due mostly to the
fact that one arm of the trial was delivered open-label. In these
instances, treatment comparisons that did not involve the open-
label armwere not affected, and sensitivity analyses removing these
arms assessed the effects of removing these high-risk comparisons
from the networks.
Blinding of outcome assessors
A third of trials gave enough detail to warrant a low risk of bias
rating, which was usually obtained from the clinicaltrials.gov reg-
istration. Most trials did not describe how outcomes were assessed
in sufficient detail to rule out bias associated with unblinded out-
come assessors and hence were rated as unclear. As with allocation
concealment, an unclear rating for studies not explicitly describing
outcome assessor blinding is likely to be conservative. Five studies
were rated as high risk for the same reasons outlined for the par-
ticipant and personnel domain.
Incomplete outcome data
Around half the trials were judged to be at low risk of bias be-
cause the level of dropout was acceptable and balanced between
groups, or because sufficient efforts were made to impute missing
data. Twenty-two trials were given a high risk rating, indicating
a significant risk that unbalanced or especially high attrition may
have compromised the validity of the results, and 13 were rated as
unclear. However, several of the high risk ratings were given to the
longer trials (two years or longer), in which a significant propor-
tion of participants had dropped out by the end of the trial. By
including data at the six-month and 12-month time points rather
than at endpoint in these unusual trials, the risk from attrition
may be reduced, as higher percentages of the randomly assigned
populations were generally included in the earlier analyses.
Selective reporting
Most trials could be linked to a prospectively registered protocol
for cross-checking of reported outcomes (on clinicaltrials.gov or
manufacturers’ websites). Most reported the named outcomes well
in published reports, and a subset had additionally posted results
summaries on clinicaltrials.gov, warranting a low risk rating (n =
43). A third were judged to be at high risk of bias, usually because
outcomes stated in the protocol or important study methods were
missing from published reports, regardless of whether this directly
affected our analyses. Some trials were rated at high risk of bias be-
cause SGRQ or FEV1 data were reported but not in an acceptable
format to be combined in meta-analysis. Although some early tri-
als did not use the SGRQ or used a different FEV1 measurement
for legitimate reasons, this fact and selective outcome reporting
resulted in omission of a significant proportion of relevant trials
from the SGRQ and FEV1 analyses. Eight were rated as unclear,
usually because a protocol could not be located to confirm that all
planned outcomes had been reported.
Effects of interventions
For each outcome, we presented six-month data for themain anal-
yses, along with the number of treatments included, the number
of pair-wise comparisons made and estimates of model fit and het-
erogeneity. Results are presented first as class effects and second
for individual treatments. As the class analysis assumes that treat-
ments within the same class are exchangeable and are distributed
around a class mean, we have also outlined the effects of fitting
the class model on individual treatment effects.
Results from the 12-month networks for each outcome are also
presented (shown graphically alongside the six-month class results
in Figure 4 and Figure 5), and sensitivity analyses for risk of bias
(open-label delivery) are presented for the six-month class analyses.
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Figure 4. St George’s Respiratory Questionnaire (SGRQ) change from baseline-six-month and 12-month
class results.
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Figure 5. Trough forced expiratory volume in one second (FEV1) change from baseline-six-month and 12-
month class results.
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St George’s Respiratory Questionnaire
Across six months and 12 months, 42 studies with 118 individual
treatment nodes were included in the networks (n = 54,613).
Main analysis-six months
Eighteen treatments were compared over a total of 72 treatment
arms in 25 studies (n = 27,024). Thirty-nine pair-wise compar-
isons were made, and the fixed-effect model was preferred because
statistical heterogeneity was not significant (DIC random = 214.9,
fixed = 214.5).
Class effects
Table 6 shows each class effect relative to placebo (i.e. the combined
treatment benefit over placebo), expressed as change frombaseline.
The classes are also ranked (mean and median) and are presented
with estimates of the probability that each is the best class. Figure
4 displays class effects against the reference treatment (placebo),
shown by the vertical dashed line on the right-hand side of the
graph.
Combination LABA/ICS was the highest ranked treatment, with
a mean improvement over placebo of 3.89 units (95% credible
interval (CrI) -4.70 to -2.97). LAMAs and LABAs were ranked
second and third, with mean differences of -2.63 (95% CrI -3.53
to -1.97) and -2.29 (95% CrI -3.18 to -1.53), respectively, but
a large degree of overlap was noted between their credible inter-
vals. Inhaled corticosteroids were the fourth ranked class but still
showed a mean two-unit benefit over placebo at six months (95%
CrI -3.06 to -0.87). Figure 6 shows graphs of the probabilities that
each class ranks in any one of the five possible positions. The me-
dian within-class variance was 0.44 units (95% CrI 0.03 to 1.09).
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Figure 6. St George’s Respiratory Questionnaire (SGRQ) probability ranking diagrams-six months and 12
months.
Individual treatment effects
Effects relative to placebo are presented separately for each treat-
ment in Table 7, along with ranks and estimates with and without
the class model for comparison. The credible intervals for each
treatment were wide and largely overlapping (for both ranks and
mean differences from placebo).
Individual treatment effects of particular note within a class were
associated with indacaterol and aclidinium for LABA and LAMA,
respectively. Effects for both doses of each of these drugs were
dampened by the class model in the six-month SGRQ network
(indacaterol by 0.72 and 0.92 for 300 mcg and 150 mcg, respec-
tively, and aclidinium by 1.13 and 1.78 for 200 mcg and 400
mcg, respectively). Treatments of note for which estimates were
inflated by fitting the class model were formoterol 12 mcg (by
0.64), budesonide 400 mcg (by 0.79) and formoterol/mometa-
sone combination 2/400 mcg (by 0.66).
Additional analyses
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12 months
Nineteen treatments were compared in 24 studies, but a dose
comparison of aclidinium made in Gelb 2012 was disconnected
from the rest of the network. These treatments can be used in class
analysis, as they “borrow” the class effect. The fixed-effect model
was preferred.
In the class analysis (Appendix 4 and Figure 4), LABA/ICS com-
binations remained the highest ranked at 12 months, with only a
slightly smallermean effect over placebo than at six months (-3.60,
95% CrI -4.63 to -2.34). Compared with the six-month analysis,
LABA, LAMA and ICS showedmore similar benefits over placebo
at 12 months, ranging between -2.34 and -2.55, with similar cred-
ible intervals. Within-class variance was slightly larger than in the
six-month analysis (median 0.53, 95% CrI 0.04 to 1.27).
Individual treatment effects for the 12-month analysis are pre-
sented in Appendix 5.
Sensitivity analysis-blinding
Table 6 shows how the six-month effects were affected by removal
of data at high risk of bias for blinding (see ’Effect vs placebo sensi-
tivity analysis’). The difference between point estimates of LAMA
over LABA was larger with less overlap in the credible intervals,
and within-class variance was smaller than in the main analysis
(median 0.35, 95% CrI 0.02 to 0.98). Inconsistency associated
with Donohue 2010 [INHANCE] was resolved by removing the
open-label tiotropium arm, but unexplained poor fit of three fur-
ther trials remained (Kornmann 2011; Rennard 2009; Tashkin
2012). As all open-label arms removed were given tiotropium, it is
possible that the expected treatment benefit over placebo in these
studies was reduced by lack of blinding for these comparisons,
which dampened the overall treatment effect within the LAMA
class.
Trough FEV1
Across six months and 12 months, 46 studies with 120 individual
treatment nodes were included in the networks (n = 47,409).
Main analysis-six months
Twenty treatments were compared over a total of 82 treatment
arms in 31 studies (n = 29,271). Forty-one pair-wise comparisons
weremade. The random-effects model was preferred (DIC = 691),
as the fixed-effect model has very poor fit (DIC = 719.1).
Class effects
Table 8 shows each class effect relative to placebo. As for SGRQ,
the classes are also ranked (mean and median) and are presented
with estimates of the probability that each is the best. Figure 6
displays trough FEV1 class effects (mL) compared with placebo.
Results at six months showed a similar pattern to the SGRQ anal-
ysis. Combination LABA/ICS was the highest ranked treatment,
with a mean improvement over placebo of 133.3 mL (95% CrI
100.6 to 164.0) after six months. As was the case for quality of
life, LAMAs and LABAs were ranked second and third, with mean
differences of 103.5 (95% CrI 81.8 to 124.9) and 99.4 (95% CrI
72.0 to 127.8), respectively, but again a large degree of overlap was
noted between the credible intervals. Inhaled corticosteroids were
the fourth ranked class but still showed a mean 65.4 mL bene-
fit over placebo at six months (95% CrI 33.1 to 96.9). The me-
dian within-class variance was 9.04 mL (95% CrI 0.41 to 34.85).
Figure 7 shows graphs of the probabilities that each class ranks in
any one of the five possible positions.
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Figure 7. Forced expiratory volume in one second (FEV1) probability ranking diagrams-six months and 12
months.
Individual treatment effects
Effects relative to placebo are presented separately for each treat-
ment in Table 9, along with ranks and estimates with and without
the class model for comparison.
The class model affected individual treatment effects to a lesser
extent in the FEV1 network than in the SGRQ one, because less
intra class variation was present. Several treatment effects that were
higher than the class mean were dampened by the class model,
including indacaterol 300 (by 34.6 mL) and salmeterol-fluticas-
one 50/250 mcg combination therapy (by 33.3 mL). Effects for
formoterol 12 mcg and both formoterol/budesonide combination
doses were less favourable within their classes and were inflated by
the class model (by 41.0 mL, and 50.3 and 54.5 mL, respectively).
Although aclidinium was particularly effective in the SGRQ anal-
ysis, the relative effects for both lower doses on trough FEV1 ap-
peared less favourable than other members of the LAMA class
(MD 59.3 and 74.8 mL without the class model compared with
the overall class mean of 103.5). Within the ICS class, the two
budesonide doses showed less benefit over placebo than the two
fluticasone doses. However, credible intervals for the individual
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treatment groups were wide and overlapping.
Additional analyses
12 months
Nineteen treatments were compared in 22 studies. As with the 12-
month SGRQ analysis, the dose comparison of aclidinium made
in Gelb 2012 was disconnected from the rest of the network. The
random-effects model was preferred (DIC = 485.4), as the fixed-
effect model had very poor fit (DIC = 557.4).
In the class analysis (Appendix 6 and Figure 6), LABA/ICS re-
mained the highest ranked treatment strategy, although the effect
over placebo was lower than at six months (100 mL, 95%CrI 55.5
to 140.1). As with SGRQ, the benefit of LAMA over LABA was
much less clear at 12 months, and their credible intervals showed
a large degree of overlap with each other and with the LABA/ICS
class. Within-class variance was larger than in the six-month anal-
ysis (median 18.02, 95% CrI 1.22 to 47.80).
Individual treatment effects for the 12-month analysis are pre-
sented in Appendix 7.
Sensitivity analysis-blinding
Table 8 shows how the six-month effects were influenced by re-
moval of data at high risk of bias for blinding. Within-class vari-
ance was similar to that in the main analysis (median 10.49, 95%
CrI 0.54 to 37.66). The effects were very similar with and with-
out the open-label data, unlike in the SGRQ analysis. This may
reflect the nature of the two measurements, with SGRQ perhaps
more susceptible to performance or detection bias than measures
of lung function.
D I S C U S S I O N
Summary of main results
Evidence from good quality and similar trials supports LABA/ICS
combination therapy as the highest ranking treatment strategy to
improve quality of life and to benefit lung function in the included
trials (mostly with participants whose FEV1 was less than 50%
predicted). Combination therapy gave an average benefit of 3.9
units over placebo at sixmonths (95%CrI -4.70 to -2.97). LAMAs
(MD -2.63, 95% CrI -3.53 to -1.97) were ranked second and
LABAs ranked third at six months (MD -2.29, 95% CrI -3.18 to -
1.53), especially when trials at high risk of bias were not included,
but the difference between these classes was small, and a large
degree of overlap was noted in their estimates.
Combination LABA/ICS was the highest ranked class for trough
FEV1, with a mean improvement over placebo of 133.3 mL at six
months (95% CrI 100.6 to 164.0). As was the case for SGRQ,
LAMAs ranked second (MD 103.5, 95% CrI 81.8 to 124.9) and
LABAs ranked third (MD 99.4, 95% CrI 72.0 to 127.8) at six
months; ICSs were the fourth ranking class (MD 65.4 mL, 95%
CrI 33.1 to 96.9).
For both outcomes, the effects of LABA and ICS monotherapies
appeared to be additive at six months, but initial differences be-
tween treatment classes were less prominent after a year of treat-
ment.
Overall completeness and applicability of
evidence
The SGRQ analyses showed that combination LABA/ICS treat-
ment had a mean difference over placebo in line with the mini-
mal clinically important difference (MCID) of four units, and the
point estimates and 95% confidence intervals of the other classes
were lower than four units. However, it is not appropriate to imply
that LABA/ICS provides a meaningful quality of life benefit while
the other classes do not. A previous review demonstrated that a
treatment that has a mean difference and 95% CI of lower than
four units on the SGRQ can nevertheless lead to a significantly
higher number of patients who reach a four-unit change on the
SGRQ in the treatment group than in the placebo group (Karner
2012a). For FEV1, with the exception of ICS monotherapy, treat-
ment differences ranged from 99 to 133 mL, which is in keeping
with the threshold of clinical significance suggested by Cazzola
2008 (100 to 140 mL).
National guidelines recommend the treatments included in this
review (LABA, LAMA or LABA/ICS) over regular short-acting
medications for patients with exacerbations or persistent breath-
lessness (NICE 2011), otherwise referred to as those with moder-
ate (stage II) or severe (stage III) COPD (GOLD). NICE 2011
recommends the addition of ICS in people who also have less than
50% predicted FEV1. By collating information about participants
included in each of the included trials and assessing for transitiv-
ity, we were able to be clear about the types of patients to whom
the conclusions of this review are likely to apply. Although some
individual trials within the network included participants who ex-
ceeded or fell short of the criteria described in the guidelines, sum-
mary statistics suggest that participant groups in the trials fell into
the moderate and severe categories, and most participants had an
FEV1 of less than 50% predicted. As a result, the evidence is not
applicable to those with mild symptoms. Similarly, because of the
common exclusion criteria in the trials related to co-morbidities,
and asthma in particular, these findings may not be relevant to
some groups of patients. Finally, because the decision was made
not to include some newer treatments and combination therapies
in the network, class results may not be applicable to emerging
treatments.
To supplement the efficacy findings, we sought to identify evi-
dence of cost-effectiveness. As LABA/ICS was the most effective
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treatment for both outcomes and is likely to be the most costly
treatment strategy in many settings, we sought to identify studies
evaluating its cost-effectiveness against other treatment options,
andwhether this varied across patients with varying levels of symp-
toms. Three recent studies based on reanalysis of clinical trials were
found, all of which concluded that LABA/ICS is a cost-effective
treatment strategy for moderate to severe COPD (Chuck 2008;
Earnshaw 2007; Fattore 2005). Evidence suggests that the reduc-
tion in healthcare resource use associated with LABA/ICS com-
pared with placebo or with the single components outweighs the
additional cost of combination inhalers. One study (Chuck 2008)
showed that this benefit was more prominent in patients with se-
vere disease ($39,000 per quality-adjusted life-year (QALY)) than
in those with moderate and severe disease combined ($47,500 per
QALY).
Karner 2012a raised concerns about the safety of tiotropium when
delivered via the Respimat inhaler, arising from indirect compar-
isons between trials using Respimat and Handihaler devices. Pub-
lished evidence from a very large trial that randomly assigned par-
ticipants to tiotropium via Respimat or Handihaler does not show
a higher risk of mortality when the Respimat inhaler was used
(Wise 2013).
Quality of the evidence
We assessed the methodological quality of all included studies and
concluded that risk of bias was generally low across the five do-
mains. Uncertainties associated with allocation concealment and
outcome reporting could have been resolved in part by contact-
ing trial authors, but because most of the included studies were
already included in other Cochrane reviews, it is unlikely that this
would have substantially increased our confidence in the results,
especially because a vast majority of trials were sponsored by man-
ufacturers with whom we have confirmed the adequacy of meth-
ods in the past. The sensitivity analysis removing comparisons at
high risk of performance or detection bias further increased our
confidence in the findings.
The transitivity assumption was upheld across both outcome data
sets. The trials were similar in their conduct, and when discrep-
ancies were noted (especially with allowed co-medications and in-
haler devices), these did not appear to differ systematically between
nodes or classes. Because of the nature of indirect comparisons,
the similarity in baseline characteristics and methodology justified
analysing the trials in a network and increased the applicability
of the results. Participants randomly assigned to the LABA/ICS
arms had somewhat more impaired lung function than those as-
signed to the other classes, but this did not translate into any real
differences when transitivity across pairwise comparisons between
classes was assessed. The presence of several large multi-arm trials
allowed us to combine the indirect evidence obtained via common
comparators with a good quantity of head-to-head data within
and across classes, and this increased the reliability of the network
findings.
Potential biases in the review process
By including studies from existing Cochrane reviews and perform-
ing additional electronic searches to both update the data and fill
gaps not covered by other reviews, it is likely that the relevant lit-
erature has been covered by this review. Around 80% of the stud-
ies included in this review had already been included in another
Cochrane review and so had already been assessed for risk of bias
and had data extracted by two review authors. We were not able
to contact study authors to ask for additional data, but we were
able to extract and include data for the vast majority of studies
that measured the outcomes.
Agreements and disagreements with other
studies or reviews
Several recent network meta-analyses of treatments for COPD
have been published with varying inclusion criteria and outcomes.
Decramer 2013 and Dong 2013 focused on safety outcomes and
included only longer-term studies of at least six months’ dura-
tion. Decramer 2013 included only LABA therapy and found no
association between LABA and increased COPD-related adverse
events or mortality. In addition, “LABA treatment was generally
associated with significant or numerical reductions in COPD ex-
acerbations compared with placebo,” which is in keeping with the
effects of LABA shown in our review. Dong 2013 had very similar
inclusion criteria to those of our network and focused on mortal-
ity. Alongside our findings on the additive efficacy of the LABA/
ICS combination, theDong 2013 network provided evidence that
“LABA-ICS was associated with the lowest risk of death among
all treatments,” and that “no excess risk was noted for tiotropium
HandiHaler or LABA.” These reviews provide comparative evi-
dence relating to safety, especially Dong 2013, which included a
similar network of treatments and listed similar trial inclusion cri-
teria.
Cope 2012 included a similar list ofCOPDtreatments in their net-
work and assessed efficacy using similar outcomes on shorter time
scales (SGRQ and lung function at three months). Although their
focus was on indacaterol, their conclusions regarding its efficacy in
comparison with older LABAs were in keeping with our findings.
Similarly, a subsequent network meta-analysis including glycopy-
rronium but not including LABA/ICS combinations (Cope 2013)
concluded that indacaterol, glycopyrronium and tiotropium were
themost favourable bronchodilators (based on evidence for SGRQ
and FEV1 at three months and at six months). Although these
treatments were amongst the best LABAs and LAMAs, differences
between the two network meta-analyses (i.e. the list of included
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treatments, time points and analysis model) explain the discrep-
ancies in conclusions.
With regard to other important outcomes, a networkmeta-analysis
by Puhan 2009 focusing on exacerbations and the same treatment
classes found “no evidence that one single inhaled drug regimen
is more effective than another in reducing exacerbations.” The
authors also concluded that “inhaled corticosteroids when added
to long-acting beta-agonists reduce exacerbations only in patients
with COPD with FEV1 ≤ 40%.” Because of issues of network
connectivity, we did not consider it reasonable to analyse our data
sets with baseline severity as a co-variate, but Puhan 2009 raises
the question of whether certain treatments may be more beneficial
or may cause different adverse effects for particular patient groups.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This network meta-analysis compares three different classes of
long-acting inhalers for people with COPD who need more than
short-acting bronchodilators. Quality of life and lung function
were improved most on combination inhalers (LABA and ICS)
and least on ICS alone at 6 and at 12 months. Overall LAMA
and LABA inhalers had similar effects, particularly at 12 months.
The network has demonstrated the benefit of ICS when added
to LABA for these outcomes in participants who largely had an
FEV1 that was less than 50% predicted, but the additional expense
of combination inhalers and any potential for increased adverse
events (which has been established by other reviews) require con-
sideration. Our findings are in keeping with current NICE guide-
lines.
Implications for research
Studies assessing emerging treatments in head-to-head trials with
older members of their class would be particularly useful for as-
sessing relative efficacy.When including active treatment controls,
studies should deliver all treatments in a double-blind fashion to
minimise performance and detection bias for all comparisons. As
more studies are conducted and published for emerging LABAs,
LAMAs, ICSs and LABA/ICS combinations, widening the scope
of the network might increase the usefulness of this review.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abrahams 2013
Methods Design: multinational, randomised, double-blind, parallel study
Duration: 24 weeks (+ 2 week run-in)
Location: 178 investigational centres in 10 countries
Participants Population: 2080 participants were randomised to tiotropium (427) and placebo (429)
, and three other arms not eligible for this review (1224)
Baseline characteristics
Age (mean years): Tio 63.9, Pbo 64.4
% Male: Tio 65.8, Pbo 63.9
% FEV1 predicted (Pre BD): Tio 43.3, Pbo 43.2
Pack-years (mean): Tio 47.3, Pbo 46.4
Inclusion criteria: Male and female smokers or ex-smokers with a smoking history
of more than 10 pack-years who were >40 years old and able to perform PFTs were
included in the study. All patients were diagnosed with COPD and demonstrated post-
bronchodilator FEV1 <80% predicted with FEV1/forced vital capacity (FVC) <70%.
Exclusion criteria: never smoked or smoked <10 pack-years; a history of asthma; been
treated for a myocardial infarction within the past year; unstable or life-threatening car-
diac arrhythmia (or associated hospitalisations); been hospitalised for heart failure within
the past 3 years; regular use of daytime oxygen therapy and the inability to abstain from
the use of oxygen therapy during test days; thoracotomy with pulmonary resection and/
or the presence of a significant disease other than COPD that could preclude participa-
tion in the study or interfere with the study results
Interventions 1. Tiotropium 5 qd (LAMA)
2. Placebo (PBO)
Inhaler device: Respimat Soft Mist
Allowed co-medications: The use of antibiotics was not restricted. The following med-
ications were allowed as long as they had been administered in stable doses over 6 weeks
prior to the study: oral corticosteroids (10 mg daily); inhaled LABAs, oral ICS, theo-
phylline preparations andmucolytic agents not containing bronchodilators. Short-acting
anticholinergic drugs were allowed during the 2-week baseline period and the 3-week
follow-up period
Outcomes Trough FEV1, Transition Dyspnoea Index (TDI) focal score, St George’s Respiratory
Questionnaire (SGRQ) total score, exacerbations and adverse events
Notes Funding: Boehringer-Ingelheim
Identifier(s): NCT00528996
Risk of bias
Bias Authors’ judgement Support for judgement
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Abrahams 2013 (Continued)
Random sequence generation (selection
bias)
Low risk Randomised, no specific details but indus-
try-funded
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout relatively low in both included
groups (tio 10%, placebo 15%). 98.6% of
those randomisedwere included in the ITT
population
Selective reporting (reporting bias) Unclear risk Located trial registration - outcomes well
reported
ACCLAIM 2009
Methods Design: double-blind, randomised, placebo-controlled, parallel-group study
Duration: 52 weeks (+ 2 week run-in)
Location: 139 centres in 16 European countries
Participants Population: 843 participants were randomised to aclidinium (627) and placebo (216)
Baseline characteristics
Age (mean years): Acl 62.6, Pbo 61.9
% Male: Acl 77.8, Pbo 81.0
% FEV1 predicted (post BD): Acl 54.2, Pbo 52.9
Pack-years (mean): Acl 40.4, Pbo 38.4
Inclusion criteria: Male and non-pregnant, non-lactating female patients aged ≥40
years were included if they had a diagnosis of COPD according to GOLD criteria, with
a post-bronchodilator FEV1/FVC ratio of ≤70% and FEV1 <80% of the predicted
value. The pre-dose FEV1 at randomisation had to be within 80-120% of the pre-
bronchodilator FEV1 at screening. All patients were current or previous cigarette smokers
with a smoking history of ≥10 pack-years. A previous history of exacerbations was not
required.
Exclusion criteria: history or current diagnosis of asthma, allergic rhinitis or atopy; blood
eosinophil count >600 cell/mm3; respiratory tract infection or COPD exacerbation
within 6 weeks prior to screening or during the run-in period; hospitalisation for an
acute COPD exacerbation within 3 months prior to screening; use of long-term oxygen
therapy; clinically significant respiratory diseases other than COPD; unstable cardiac
conditions
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Interventions 1. Aclidinium 200 qd (LAMA)
2. Placebo (PBO)
Inhaler device: Genuair
Allowed co-medications: Inhaled salbutamol was permitted on an as-needed basis, but
had to be discontinued 6 hours prior to and during a study visit. Inhaled corticosteroids
or oral sustained-release theophyllines; oral or parenteral corticosteroids atmaximal doses
equivalent to 10 mg/day of prednisone or 20 mg every other day; oxygen therapy (<15
hours per day) were allowed, provided their administration had been stable for at least 4
weeks prior to screening:
Outcomes TroughFEV1, StGeorge’sRespiratoryQuestionnaire (SGRQ), and time tofirstmoderate
or severe COPD exacerbation
Notes Funding: Almirall, S. A., Barcelona, Spain, and Forest Laboratories, Inc, NY, USA
Identifier(s): NCT00363896
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Eligible patients were randomised in a 3:
1 ratio to receive aclidinium 200 mcg or
matching placebo. Industry funded
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, matching placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk A centralised quality-assurance review of all
spirometry data was conducted through-
out the study. The spirometry data were
electronically transmitted to a data-man-
agement centre where an independent,
blinded, spirometric expert reviewed the
acceptability and repeatability of the data
according to ATS/ERS acceptability crite-
ria. SGRQ self-rated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout higher in placebo group (21.8%
versus 14.2 in aclidinium group). ITT in-
cluded 98% of those randomised
Selective reporting (reporting bias) Low risk Trial registration located. Outcomes well
reported.
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ACCLAIM II 2009
Methods Design: double-blind, randomised, placebo-controlled, parallel-group study
Duration: 52 weeks (+ 2 week run-in)
Location: 119 sites in 7 countries (primarily in North America)
Participants Population: 804 participants were randomised to aclidinium (600) and placebo (204)
Baseline characteristics
Age (mean years): Acl 65.1, Pbo 65.2
% Male: Acl 63.8, Pbo 60.8
% FEV1 predicted (post BD): Acl 50.6, Pbo 49.4
Pack-years (mean): Acl 57.8, Pbo 58.2
Inclusion criteria: Male and non-pregnant, non-lactating female patients aged ≥40
years were included if they had a diagnosis of COPD according to GOLD criteria, with
a post-bronchodilator FEV1/FVC ratio of ≤70% and FEV1 <80% of the predicted
value. The pre-dose FEV1 at randomisation had to be within 80-120% of the pre-
bronchodilator FEV1 at screening. All patients were current or previous cigarette smokers
with a smoking history of ≥10 pack-years. A previous history of exacerbations was not
required.
Exclusion criteria: history or current diagnosis of asthma, allergic rhinitis or atopy; blood
eosinophil count >600 cell/mm3; respiratory tract infection or COPD exacerbation
within 6 weeks prior to screening or during the run-in period; hospitalisation for an
acute COPD exacerbation within 3 months prior to screening; use of long-term oxygen
therapy; clinically significant respiratory diseases other than COPD; unstable cardiac
conditions
Interventions 1. Aclidinium 200 qd (LAMA)
2. Placebo (PBO)
Inhaler device: Genuair
Allowed co-medications: Inhaled salbutamol was permitted on an as-needed basis, but
had to be discontinued 6 hours prior to and during a study visit. Inhaled corticosteroids
or oral sustained-release theophyllines; oral or parenteral corticosteroids atmaximal doses
equivalent to 10 mg/day of prednisone or 20 mg every other day; oxygen therapy (<15
hours per day) were allowed, provided their administration had been stable for at least 4
weeks prior to screening:
Outcomes TroughFEV1, StGeorge’sRespiratoryQuestionnaire (SGRQ), and time tofirstmoderate
or severe COPD exacerbation
Notes Funding: Almirall, S. A., Barcelona, Spain, and Forest Laboratories, Inc, NY, USA
Identifier(s): NCT00358436
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Eligible patients were randomised in a 3:
1 ratio to receive aclidinium 200 mcg or
matching placebo. Industry funded
Allocation concealment (selection bias) Unclear risk Not described
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, matching placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk A centralised quality-assurance review of all
spirometry data was conducted through-
out the study. The spirometry data were
electronically transmitted to a data-man-
agement centre where an independent,
blinded, spirometric expert reviewed the
acceptability and repeatability of the data
according to ATS/ERS acceptability crite-
ria. SGRQ self-rated
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropout much higher in placebo group
and high in both (42.2% versus 25.7 in
aclidinium group). ITT included 99% of
those randomised but high dropout is likely
to have introduced bias
Selective reporting (reporting bias) Low risk Trial registration located. Outcomes well
reported.
Anzueto 2009
Methods Design: Randomised, double-blind, parallel-group, multicenter study
Duration: 52 weeks (+ 4 week run-in)
Location: 98 centres in the USA and Canada
Participants Population: 797 participants were randomised to salmeterol alone (403) and salmeterol/
fluticasone combination therapy (394)
Baseline characteristics
Age (mean years): sal 65.3, sal/flut 65.4
% Male: sal 57, sal/flut 51
% FEV1 predicted (pre BD): sal 33.9, sal/flut 34.1
Pack-years (mean): sal 56.5, sal/flut 57.8
Inclusion criteria: >40 years of age with a diagnosis of COPD, a cigarette smoking
history≥ 10 pack-years, a pre-albuterol FEV1/FVC≤ 0.70, a FEV1≤ 50% of predicted
normal and a documented history of at least 1 COPD exacerbation the year prior to the
study that required treatment with antibiotics, oral corticosteroids, and/or hospitalisa-
tion.
Exclusion criteria: current diagnosis of asthma, a respiratory disorder other thanCOPD,
historical or current evidence of a clinically significant uncontrolled disease, or had a
COPD exacerbation that was not resolved at screening
Interventions 1. Salmeterol 50 bid (LABA)
2. Salmeterol/fluticasone 50/250 bid (LABA/ICS)
Inhaler device: Diskus
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Allowed co-medications: As-needed albuterol was provided for use throughout the
study. As needed ipratropium was not provided; however, it could be used during the
study. The use of concurrent inhaled long-acting bronchodilators (beta2-agonist and an-
ticholinergic), ipratropium/albuterol combination products, oral beta-agonists, inhaled
corticosteroids (ICS), leukotriene modifiers, inhaled nedocromil and cromolyn, theo-
phylline preparations, ritonavir and other investigational medications were not allowed
during the treatment period. Oral corticosteroids and antibiotics were allowed for the
acute treatment of a COPD exacerbation
Outcomes Annual rate of moderate/severe exacerbations, time to first moderate/severe exacerbation,
the annual rate of exacerbations requiring oral corticosteroids, and pre-dose FEV1. Diary
records andhealth statusmeasured on the StGeorge’sRespiratoryQuestionnaire (SGRQ)
Notes Funding: GlaxoSmithKline
Identifier(s): NCT00115492, GSK NCT00115492
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Treatments were assigned in blocks us-
ing a centre-based randomisation sched-
ule. Since bronchodilator response to FSC
250/50 is generally larger in subjects with
COPD who demonstrate FEV1 reversibil-
ity to albuterol, assignment to blinded
study medication was stratified based on
subjects’ FEV1 response to albuterol at
screening to provide a similar distribution
of albuterol-responsive and non-responsive
subjects in each treatment group
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind [assumed par-
ticipants and personnel/investigators]
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The withdrawal rates were very high com-
pared to the number of events for the dif-
ferent outcomes
Selective reporting (reporting bias) Low risk All outcomes stated in the protocol were
reported and could be included
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ATTAIN 2011
Methods Design: double-blind, randomised, placebo-controlled, parallel-group study
Duration: 24 weeks (+ 2 week run-in)
Location: 9 European countries and South Africa
Participants Population: 828 participants were randomised to two doses of aclidinium (280 and
272), and placebo (276)
Baseline characteristics
Age (mean years): acl200 62.3, acl400 62.9, pbo 62.0
% Male: acl200 65.3, acl400 67.7, pbo 69.2
% FEV1 predicted: acl200 53.0, acl400 52.0, pbo 52.4
Pack-years (mean): acl200 40.0, acl400 41.7, pbo 38.9
Inclusion criteria: Male and female patients aged > 40 yrs were included if they were
current or former cigarette smokers with a smoking history of > 10 pack-yrs
and had a diagnosis of COPD according to Global Initiative for Chronic Obstructive
Lung Disease criteria (post-bronchodilator FEV1/forced vital capacity (FVC) ratio of
< 70% and FEV1 < 80% of the predicted value). Patients had to demonstrate good
technique during lung function assessments according to American Thoracic Society/
European Respiratory Society criteria.
Exclusion criteria: history or current diagnosis of asthma; respiratory tract infection or
COPD exacerbation within 6 weeks (3 months if hospitalisation was required) before
screening or during the run-in period; clinically relevant respiratory conditions other
than COPD; unstable cardiac conditions, including myocardial
infarction, within the previous 6 months; and contraindications to the use of anticholin-
ergic drugs
Interventions 1. Aclidinium bromide 200 qd (LAMA)
2. Aclidinium bromide 400 qd (LAMA)
3. Placebo (PBO)
Inhaler device: multiple-dose dry powder inhaler (Genuair)
Allowed co-medications: Inhaled salbutamol was permitted as needed, but was discon-
tinued 6h before and during study visits. The following concomitant
medications were allowed if their administration had been stable for > 4 weeks before
screening: inhaled corticosteroids or oral sustained-release theophyllines; systemic corti-
costeroids at doses equivalent to 10 mg per day of prednisone or 20 mg every other day;
and oxygen therapy (,15 h per day)
Outcomes Standard spirometric measurements (FEV1, FVC and inspiratory capacity) pre- and
post- dose, health status using the St George’s Respiratory Questionnaire (SGRQ), Base-
line Dyspnoea Index (BDI) and Transitional Dyspnoea Index (TDI), diary card data,
exacerbations, and safety
Notes Funding: Almirall and Forest Laboratories
Identifier(s): NCT01001494
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Allocation described as randomised in the
reports and on clinicaltrials.gov. Methods
not described, but industry funded
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double blind for subjects and
investigators [from online protocol]
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk Efficacy analyses were performed on the in-
tent-to-treat (ITT) population, defined as
all patients who took one or more dose
of study medication and had a baseline
and one or more post-baseline FEV1 as-
sessment.Missing data were imputed using
last observation carried forward (LOCF).
11%were not included in the ITT popula-
tion, and dropout was higher in the placebo
group but still relatively low (14.9%)
Selective reporting (reporting bias) Low risk Outcomes stated onpre-registered protocol
were well reported
Bateman 2010a
Methods Design: Randomised, double-blind, parallel-group study
Duration: 48 weeks (unclear run-in)
Location: 336 outpatient centres in 31 countries
Participants Population: 3991 participants were randomised to tiotropium (1989) and placebo
(2002)
Baseline characteristics
Age (mean years): tio 64.8, pbo 64.8
% Male: tio 78.1, pbo 77.0
% FEV1 predicted: tio 39.9, pbo 39.8
Pack-years (mean): tio 46, pbo 45
Inclusion criteria: COPD patients of either sex were eligible for study entry if they were
aged 40 years, had pre-bronchodilator FEV1 of 60% of predicted normal and a ratio of
FEV1 to forced vital capacity (FVC) of 70%, and were current or ex-smokers (smoking
history of 10 pack-years).
Exclusion criteria: significant disease other than COPD that, in the investigator’s judg-
ment, could affect the patient’s ability to complete the trial, or if they had clinically sig-
nificant abnormal results of haematology, urinalysis, or blood chemistry tests, a history
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of asthma or allergic rhinitis, or a blood eosinophil count of 600/mm3. Other exclusion
criteria included previous lung resection surgery, participation in a pulmonary rehabili-
tation programme in the previous 6 weeks, and regular daytime oxygen use (>1 h/day)
Interventions 1. Tiotropium 5 qd (LAMA)
2. Placebo (PBO)
Inhaler device: Respimat
Allowed co-medications: Salbutamol pMDIwas provided to all patients for use as rescue
medication at any time during the study. All respiratory medications were permitted
during the trial other than inhaled anticholinergics
Outcomes Trough FEV1 response and time to first COPD exacerbation were the co-primary
endpoints. Secondary included FVC, number of exacerbations per patient, and the St
George’s Respiratory Questionnaire (SGRQ)
Notes Funding: Boehringer-Ingelheim
Identifier(s): NCT00387088, BI 205.372
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Treatment allocation was determined by
a computer-generated randomisation code
provided by Boehringer Ingelheim. Ran-
domisation was stratified by study cen-
tre and within centres, and performed in
blocks to ensure balanced distribution of
the treatment groups at any time
Allocation concealment (selection bias) Low risk Individuals directly involved in the conduct
and analysis of the trial had no access to the
allocation sequence until after the trial was
completed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identity of treatments was blinded to in-
vestigators, assessors and patients
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Identity of treatments was blinded to in-
vestigators, assessors and patients
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was relatively low and even be-
tween groups (16 and 19%). The co-pri-
mary endpoints were analysed in all pa-
tients who were randomly assigned and
treated and who provided a trough FEV1
measurement at baseline and at least one
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subsequent visit
Selective reporting (reporting bias) Low risk Trial registration was located. Outcomes
were well reported.
Bateman 2010b
Methods Design: two identical multicenter, randomized, double-blind, parallel-group studies
Duration: 48 weeks (+ 2 week run-in)
Location: 73 centres in 14 countries (NCT00168844) , and 78 in 15 countries
(NCT00168831)
Participants Population: 1990 participants were randomised to two doses of tiotropium (670 and
665), and placebo (653)
Baseline characteristics
Age (mean years): tio5 64.7, tio10 65.1, pbo 65.2
% Male: tio5 73.3, tio10 74.7, pbo 74.6
% FEV1 predicted: tio5 38.0, tio10 37.7, pbo 37.5
Pack-years (mean): not reported
Inclusion criteria: Males and females aged > 40 years with a diagnosis of COPD and
stable, moderate-to-severe airway obstruction as defined by the American Thoracic So-
ciety (pre-bronchodilator FEV1 < 60% predicted and FEV1 < 70% of FVC), and with
a smoking history of >10 pack years were included.
Exclusion criteria: Patients with a confounding disease, including other significant res-
piratory conditions, were excluded, as were those who had a disease that might put them
at risk because of study participation. Other exclusion criteria included known hyper-
sensitivity to anticholinergics or any component of the Respimat® inhalation solution;
drugs contraindicated with anticholinergics; prior use of Spiriva® HandiHaler®; regu-
lar use of daytime oxygen therapy, oral β-adrenergics, or long-acting β-adrenergics; or
significant alcohol or drug abuse
Interventions 1. Tiotropium 5 qd (LAMA)
2. Tiotropium 10 qd (LAMA)
3. Placebo (PBO)
Inhaler device: Respimat® Soft Mist Inhaler
Allowed co-medications: Oral (up to 10 mg daily of prednisone) and inhaled
corticosteroids, theophylline preparations, mucolytic agents and antileukotrienes were
allowed if stabilized for at least 6 weeks prior to and during the study. Patients on
long-acting β-adrenergics and inhaled corticosteroids were switched to a monoproduct
inhaled corticosteroid prior to run-in. Salbutamol MDI was used as rescue medication
Outcomes Trough FEV1, St George’s Respiratory Questionnaire (SGRQ)<Mahler Transition Dys-
pnoea Index (TDI) focal score, exacerbations per patient year, FVC, PEF, diary card data
and safety
Notes Funding: Boehringer Ingelheim
Identifier(s): BI 205.254 and 205.255, corresponding to NCT00168844 and
NCT00168831 respectively
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation described as randomised in the
reports and on clinicaltrials.gov. Methods
not described, but industry funded
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind. Not defined, assumed at
least participants and personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Only those patients with baseline and on-
treatment data for at least one primary end-
point were included in the efficacy analy-
ses. Randomized patients who received at
least 1 dose of study medication were in-
cluded in the safety analysis. The primary
article stated that the data reportedwere the
per protocol analysis. Dropout was much
higher in the placebo group (31.4%) than
the two tiotropium groups (17.2% and 20.
4%)
Selective reporting (reporting bias) Low risk Studies were prospectively registered and
results were well reported
Bateman 2013 [SHINE]
Methods Design: multi-centre, randomised, double-blind, parallel-group, placebo- and active-
controlled trial
Duration: 26 weeks (+ 2 week run-in)
Location: academic and clinical research centres inEurope,NorthAmerica, SouthAmer-
ica, Asia (Philippines, Japan, India), Australia, China, Taiwan and South Africa
Participants Population: 2144 participants were randomised to indacaterol (477), glycopyrronium
(475), open-label tiotropium (483), placebo (234), and one other arm that was not
included in this review (QVA149 combination, 475)
Baseline characteristics
Age (mean years): ind 63.6, gly 64.3, tio 63.5, pbo 64,4
% Male: ind 74.4, gly 77.2, tio 75.0, pbo 72.8
% FEV1 predicted: ind 54.9, gly 55.1, tio 55.1, pbo 55.2
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Pack-years (mean): not reported
Inclusion criteria: Participants were aged ≥40 years, had moderate-to-severe stable
COPD (Stage II or III according to GOLD 2008 criteria), and a smoking history of
≥10 pack-years. At screening, they were required to have a post-bronchodilator forced
expiratory volume in 1 second (FEV1) ≥30% and <80% of predicted normal and post-
bronchodilator FEV1/forced vital capacity (FVC) <0.70.
Exclusion criteria: respiratory tract infection within 4 weeks prior to Visit 1; concomi-
tant pulmonary disease; history of asthma; lung cancer or a history of lung cancer; history
of certain cardiovascular co-morbid conditions; known history and diagnosis of alpha-
1 antitrypsin deficiency; in the active phase of a supervised pulmonary rehabilitation
program; contraindicated for inhaled anticholinergic agents and β2 agonists; other pro-
tocol-defined inclusion/exclusion criteria may apply
Interventions 1. Indacaterol 150 qd (LABA)
2. Glycopyrronium 50 qd (LAMA)
3. Tiotropium 18 qd (LAMA) - open label
4. Placebo (PBO)
Inhaler device: All medications were administered once daily in the morning via the
Breezhaler® device except for tiotropium, which was administered open-label via the
Handihaler® device
Allowed co-medications: Participants remained on a stable dose of inhaled corticos-
teroid (ICS) and salbutamol/albuterol was available for use as rescuemedication through-
out the study
Outcomes Trough FEV1, dyspnoea, health status measured on the SGRQ, rescue medication use
and safety
Notes Funding: Novartis
Identifier(s): NCT01202188
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk No specific details of sequence generation
but done electronically and presumed valid
Allocation concealment (selection bias) Low risk Eligible patients were assigned a randomi-
sation number via Interactive Response
Technology (IRT), linking the patient to
a treatment arm and specific unique med-
ication number for the study drug. The
randomisation number was not communi-
cated to the investigator contacting the IRT
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding procedures were sound, but
tiotropium was delivered open label which
introduced bias for these comparisons
Blinding of patients, investigator staff, per-
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sonnel performing assessments and data
analysts was maintained by ensuring ran-
domisation data remained strictly confi-
dential and inaccessible to anyone involved
in the study until the time of unblind-
ing. In addition, the identity of the treat-
ments was concealed by the use of study
drugs that were all identical in packaging,
labelling, and schedule of administration,
appearance, taste and odour. Unblinding
occurred in the case of emergencies and at
the conclusion of the study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Same as for participants and personnel.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was between 9% and 20% across
the five groups, and over 99% were in-
cluded in the analysis
Selective reporting (reporting bias) Low risk Prospectively registered and well reported
with additional online supplemental mate-
rial available
Bourbeau 1998
Methods Design: double blind, randomised, parallel group trial
Duration: 6 months (originally intended to be 12 months)
Location: single centre in Canada
Participants Population: 79 people were randomised to budesonide (39) and placebo (40)
Baseline characteristics
Age (mean years): bud 66, pbo 66
Male %: bud 84.6, pbo 72.5
% FEV1 predicted: bud 36, pbo 37
Pack-years (mean): bud 52, pbo 50
Inclusion criteria: Age 40 years old or older; smokers or ex-smokers; absence of an
exacerbation in respiratory symptoms during the two months prior to the study; pre-
bronchodilator FEV1 less than 65% of predicted12 and FEV1/forced vital capacity
(FVC) less than 0.65; post-bronchodilator FEV1 less than 80%; regular treatment with
at least one bronchodilator
Exclusion criteria: history of allergic asthma during childhood or as an adult; inhaled
corticosteroids in the previous month or oral corticosteroids in the previous two months;
any other active lung disease; diabetes, active peptic ulcer disease, uncontrolled high
blood pressure, or congestive heart failure; disease other than COPD that might interfere
with quality of life
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Interventions 1. Budesonide 800 bid (ICS)
2. Placebo (PBO)
Inhaler device: Turbohaler
Allowed co-medications: All medication for the well-being of the patients was permitted
except inhaled corticosteroids other than budesonide. In case of treatment failure, rescue
medication with beta-2 agonists or systemic steroids was available
Outcomes Pre- and post-bronchodilator FEV1 and FVC, pre-bronchodilator six minute walking
test, dyspnoea with exercise, quality of life questionnaires, morning and evening PEFR,
symptom scores and adverse events
Notes Funding: Astra Pharma Inc
Identifier(s): unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central computer-generated list of random
numbers
Allocation concealment (selection bias) Low risk Identification of individual treatment as-
signments was only possible in case of
emergency by breaking the sealed envelope
kept by the investigator. The envelopes had
to be kept with the case record forms and be
returned unbroken at the end of the study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk To assure that outcomes were measured
similarly in the treatment groups, the pa-
tients and the investigators were blinded to
the study treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk To assure that outcomes were measured
similarly in the treatment groups, the pa-
tients and the investigators were blinded to
the study treatment
Incomplete outcome data (attrition bias)
All outcomes
High risk Uneven dropout. Much higher in placebo
group (25% versus 7.7% in the ICS group)
Selective reporting (reporting bias) High risk Key outcomes missing (mortality, adverse
events). No reply from author
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Methods Design: pooled results from two randomised, double-blind, double-dummy, parallel-
group studies
Duration: 6 months (+ 2 weeks run-in period)
Location: The studies were performed in 18 countries The only difference in the two
studies was the duration of serial spirometry in the clinic (12 hours in one study, 3 hours
in the second)
Participants Population: 805 participants were randomised to salmeterol (405) and placebo (400)
Baseline characteristics
Age (mean years): sal, 64.1; pbo, 64.6
% Male: sal, 75.1; pbo, 76.3
% FEV1 predicted: sal 37.7; pbo, 38.7
Pack-years (mean): sal, 44.8; pbo, 42.4
Inclusion criteria: Participants were required to have relatively stable airway obstruction
with FEV1 < 65% of predicted normal and < 70% of FVC, > 40 years of age, with a
smoking history of > 10 pack-years
Exclusion criteria: Patients with a history of asthma, allergic rhinitis or atopy or with
an increased total eosinophil count were excluded. Other exclusion criteria included
use of supplemental oxygen or an upper respiratory tract infection in the six weeks
before screening. Patients with a significant disease other than COPD were not enrolled.
Significant disease was defined as a disease that, in the opinion of the investigator, would
put the patient at risk because of participation in the study, or a disease that would
influence the results of the study
Interventions 1. Salmeterol 50 bid (LABA)
2. Tiotropium 18 qd (LAMA)
3. Placebo (PBO)
Inhaler device: metered dose
Allowed co-medications: Participants were allowed to continue previously prescribed
regular inhaled steroids or regular oral steroids, not exceeding a dose equivalent to ap-
proximately 10 mg prednisone daily. The number of participants taking these medica-
tions during the study was not located
Outcomes Mean change from baseline on the SGRQ and number whose score decreased by at
least 4 units; exacerbations (number, time to first etc.), hospital admissions, FEV1, FVC,
dyspnoea (evaluated using the Baseline Dyspnoea Index (BDI) and the TDI), diary card
data
Notes Funding: Boehringer Ingelheim
Identifier(s): 205.130/205.137
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation list was generated by
Boehringer Ingelheim using a validated
system, which involved a pseudo-random
number generator so that the resulting
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treatment sequence was both reproducible
and non-predictable
Allocation concealment (selection bias) Low risk All investigational medication for each pa-
tient was identified by a unique medication
number. Each eligible patient was assigned
the lowest medication number available to
the investigator at the time of randomisa-
tion
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Boehringer Ingelheim was responsible for
preparing and coding study medication in
a blinded fashion (Boehringer Ingelheim
study drug and control were indistinguish-
able). Patients, investigators and study per-
sonnel remained blinded with regard to
the treatment assignments up to database
lock. Double dummy technique was used
to blind different application devices
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk In all studies, a selection of standard respi-
ratory endpoints like pulmonary function,
SGRQ, TDI, treadmill, exacerbations, etc.
, were used. Outcome assessors remained
blinded with regard to the treatment as-
signments up to database lock
Incomplete outcome data (attrition bias)
All outcomes
Low risk The withdrawal rates were relatively
even between groups (salmeterol [18.8%],
placebo [25.8%])
Selective reporting (reporting bias) Low risk Results for all expected and specified out-
comes were reported (except FEV1 [sec-
ondary outcome] was not reported in a way
that could be included in the qualitative
synthesis
Burge 2000 [ISOLDE]
Methods Design: Double blind, placebo controlled study
Duration: 3 years
Location: Conducted at 18 hospitals in the UK
Participants Population: 751 people were randomised to fluticasone (376) and placebo (375)
Baseline characteristics:
Age (mean years): flut 63.7, placebo 63.8
Male %: flut 75.0, placebo 74.1
% FEV1 predicted: flut 50.3, placebo 50.0
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Pack-years (mean): flut 44, pbo 44
Inclusion criteria: Current or former smokers aged 4075 years with nonasthmatic
chronic obstructive pulmonary disease. Baseline FEV1 after bronchodilator was at least
0.8 litres but less than 85% of predicted normal, and the ratio of FEV1 to forced vital
capacity was less than 70%. Previous use of inhaled and oral corticosteroids was permit-
ted.
Exclusion criteria: Patients were excluded if their FEV1 response to 400 µg salbutamol
exceeded 10% of predicted normal, they had a life expectancy of less than five years from
concurrent diseases, or they used beta blockers
Interventions 1. Fluticasone 500 bid (ICS)
2. Placebo (PBO)
Inhaler device: Metered dose inhaler with a spacer device
Allowed co-medications: Nasal and ophthalmic corticosteroids, theophyllines, and all
other bronchodilators were allowed during the study
Outcomes Decline (ml/year) in FEV1 after bronchodilator, frequency of exacerbations, changes
in health status, withdrawals because of respiratory disease, morning serum cortisol
concentrations, and adverse events
Notes Funding: GlaxoWellcome Research and Development
Identifier(s): unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated allocation (block size
of six)
Allocation concealment (selection bias) Low risk Patients were randomised sequentially
from a list comprising treatment numbers
only
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Three year double blind phase using an
identical placebo inhaler
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Very high dropout in both groups (43%
and 53%)
Selective reporting (reporting bias) Unclear risk No outcomes appear to be missing but
couldn’t locate protocol to ensure all were
reported. Author attempted contact with
GSK statistician but no data were provided
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in time for publication
Calverley 2003 [TRISTAN]
Methods Design: randomised, double-blind, placebo-controlled, parallel-group design
Duration: 12 months (+ 2 weeks run-in period)
Location: 196 centres in 25 countries
Participants Population: 1466 participants were randomised to salmeterol (372), fluticasone (375),
salmeterol/fluticasone combination (358) and placebo (361)
Baseline characteristics
Mean age (years): salm 63.2, flut 63.5, salm/flut 62.7, pbo 63.4
% Male: salm 70, flut 69.5, salm/flut 75.4, pbo 75
% FEV1 predicted: salm 44.3, flut 45.0, salm/flut 44.8, pbo 44.2
Pack-years: salm 43.7, flut 41.5, salm/flut 42.0, pbo 43.4
Inclusion criteria: ≥ 10-Pack-year history of cigarette smoking; a history of cough
productive of sputum on most days for at least 3 months of the year, for at least 2
years; documented history of COPD exacerbations each year for the previous 3 years,
including at least one exacerbation in the last year that required oral corticosteroids and/or
antibiotics; a baseline (pre-bronchodilator) FEV1 ≥ 25% to≤ 70% of predicted normal;
poor reversibility of airflowobstruction (defined as an increase < 10%of predictednormal
FEV1 value 30 minutes after inhalation of 400 µg salbutamol) and FEV1/forced vital
capacity (FVC) ratio ≤ 70%
Exclusion criteria: respiratory disorders other than COPD. Patients were also excluded
if they had received systemic corticosteroids, high doses of inhaled corticosteroids or
antibiotics in the 4 weeks before the 2 weeks run-in
Interventions 1. Salmeterol 50 bid (LABA)
2. Fluticasone 500 bid (ICS)
3. Salmeterol/fluticasone 50/500 bid (LABA/ICS)
4. Placebo (PBO)
Inhaler device: multi-dose dry powder
Allowed co-medications: Inhaled salbutamol was used as relief medication throughout
the study, and regular treatment with anticholinergics, mucolytics and theophylline was
allowed. Medications not allowed during the study period were inhaled corticosteroids
and LABAs
Outcomes St George’s Respiratory Questionnaire (SGRQ), COPD exacerbations, FEV1 (at least
6 hours after medication), pretreatment FVC and post-bronchodilator FEV1 and FVC,
morning PEF, diary card data
Notes Funding: GlaxoSmithKline
Identifier(s): GSK SFCB3024
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk We used a randomisation schedule gener-
ated by the patient allocation for clinical
trials (PACT) program to assign patients to
study treatment groups
Allocation concealment (selection bias) Low risk Every participating centre was supplied
with a list of patient numbers (assigned to
patients at their first visit) and a list of treat-
ment numbers. Patients who satisfied the
eligibility criteria were assigned the next se-
quential treatment number from the list
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study drugswere labelled in away to ensure
that both the patient and the investigator
were unaware of the allocated treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No subjective assessor-rated outcomes and
investigators remained blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal relatively evenbut high in both
groups (salmeterol 32.0%, placebo 38.8%)
but the Intent-to-Treat (ITT) population,
consisting of all subjects who were ran-
domised to treatment and received at least
one dose of the study medication, was used
for all analyses of efficacy and safety. Un-
clear what method of imputation was used
for each outcome
Selective reporting (reporting bias) Low risk All outcomes stated in the protocol were
reported in detail
Calverley 2003a
Methods Design: randomised, double-blind, placebo-controlled, parallel-group study
Duration: 12 months (+ 2 weeks run-in)
Location: 109 centres in 15 countries or regions
Participants Population: 1022 participants were randomised to formoterol (255), budesonide (257)
, formoterol/budesonide combination (254) and placebo (256)
Baseline characteristics
Mean age (years): form 63, bud 64, form/bud 64, pbo 65
%Male: form 75, bud 74, form/bud 78, pbo 75
% FEV1 predicted: form 36, bud, form/bud, pbo 36
Pack-years: form 38, bud 39, form/bud 39, pbo 39
Inclusion criteria: Males and females > 40 years old; history of at least 10 pack-years;
COPD for at least 2 years; < 70% FEV1/FVC, FEV1 < 50% predicted; 1+ COPD
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exacerbations requiring medication in previous 2 to 12 months
Exclusion criteria: history of asthma or seasonal allergic rhinitis before age 40; any
relevant cardiovascular disorders or other disease
Interventions 1. Formoterol 9 bid (LABA)
2. Budesonide 400 bid (ICS)
3. Formoterol/budesonide 9/320 bid (LABA/ICS)
4. Placebo (PBO)
Inhaler device: dry powder inhaler
Allowed co-medications: terbutaline (0.5 mg) as needed; maximum 3-week course of
oral corticosteroids and antibiotics were allowed in the event of exacerbations; parenteral
steroids and/or nebulised treatment were allowed at emergency visits. Medications ex-
cluded during the study period were oxygen therapy; beta-blocking agents; inhaled corti-
costeroids; disodium cromoglycate; leukotriene antagonists or 5-lipoxygenase inhibitors;
other bronchodilators; antihistamines and medications containing ephedrine
Outcomes St Georges Respiratory Questionnaire (SGRQ), COPD exacerbations, FEV1, FVC,
morning and evening PEF, diary card data
Notes Funding: AstraZeneca
Identifier(s): AZ SD-039-0670
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomized to treatment. No
details of sequence generation methods but
assumed to adhere to usual AstraZeneca
methods
Allocation concealment (selection bias) Unclear risk No details reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study reported as double-blind (patient
and investigators)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No subjective assessor-rated outcomeswere
reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal even but high in both groups
(formoterol, 43.5%; placebo, 41.4%). An
intention-to-treat analysis was used and all
hypothesis testing but no information re-
garding method of imputation was pro-
vided
79Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Calverley 2003a (Continued)
Selective reporting (reporting bias) Low risk All relevant outcomes could be included in
meta-analysis
Calverley 2003b
Methods Design: Randomised, placebo-controlled study
Duration: 52 weeks (+ 2 week run-in)
Location: not reported
Participants Population: 631 participants were randomised to mometasone (318) and placebo (313)
Baseline characteristics - not given per arm
Mean age (years): not reported
% Male: not reported
% FEV1 predicted: 47
Pack-years: not reported
Inclusion criteria: adults≥40 years old with moderate COPD and a history of smoking
Exclusion criteria: not reported
Interventions 1. Mometasone 800 qd (ICS)
2. Placebo (PBO)
Inhaler device: dry powder
Allowed co-medications: not reported
Outcomes Changes from baseline in post-bronchodilator FEV1 and COPD symptom scores; % of
patients with ≥1 COPD exacerbation; time to first COPD exacerbation
Notes Funding: unknown
Identifiers(s): unknown
Abstract only - minimal information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised trial [no other details - funded
by AstraZeneca and presumed to adhere to
usual methods]
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind [assume participants and
personnel/investigators]
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
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Incomplete outcome data (attrition bias)
All outcomes
High risk An intention-to-treat analysis was used but
dropout was high in all groups (ranging
from 29% to 44%)
Selective reporting (reporting bias) Low risk All outcomes stated in the industry docu-
ment were reported in full. Checked with
authors
Calverley 2007 [TORCH]
Methods Design: multi-centre, randomised, double-blind, parallel-group, placebo-controlled
study
Duration: 3 years (+ 3 weeks run-in period)
Location: 466 centres in 42 countries comprising 190 centres in USA, 134 centres in
Western Europe, 46 centres in Eastern Europe, 37 centres in Asia Pacific, and 59 centres
in other regions
Participants Population: 6184 participants were randomised to salmeterol (1542), fluticasone (1551)
, salmeterol/fluticasone combination (1546) and placebo (1545)
Baseline characteristics
Mean age (years): salm 65.1, flut 65.0, salm/flut 65.0, pbo 65.0
% Male: salm 76.3, flut 75.4, salm/flut 75.1, pbo 76.3
% FEV1 predicted: salm 43.6, flut 44.1, salm/flut 44.3, pbo 44.1
Pack-years: salm 49.3, flut 49.2, salm/flut 47.0, pbo 48.6
Inclusion criteria: male or female current or former smokers; history of at least 10 pack-
years; clinical diagnosis of COPD; aged 40 to 80 years inclusive, with pre-bronchodilator
FEV1 < 60% predicted at entry to the study
Exclusion criteria: current diagnosis of asthma; current respiratory disorders other than
COPD; lung volume reduction surgery and/or transplant; serious uncontrolled disease;
evidence of alcohol, drug or solvent abuse, hypersensitivity to ICS, bronchodilators or
lactose; deficiency of alpha1-antitrypsin; exacerbation during run-in period
Interventions 1. Salmeterol 50 bid (LABA)
2. Fluticasone 500 bid (ICS)
3. Salmeterol/fluticasone 50/500 bid (LABA/ICS)
4. Placebo (PBO)
Inhaler device: multi-dose dry powder
Allowed co-medications: Ventolin as relief, inhaled long-acting bronchodilators and
long-term oral corticosteroids (theophyllines long- and short-acting, SABAs and short-
acting anticholinergic agents allowed). Medications not allowed during the study period
were inhaled corticosteroids, inhaled long-acting bronchodilators, long-term oral corti-
costeroids and long-term oxygen therapy
Outcomes St. George’s Respiratory Questionnaire (SGRQ), COPD exacerbations, adjusted mean
change FEV1
Notes Funding: GlaxoSmithKline
Identifier(s): NCT0026821, GSK SCO30003
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk [Fromprotocol] Subjectswill be assigned to
study treatment in accordancewith the ran-
domisation schedule, which will be gener-
ated using the GW computer program Pa-
tient Allocation for Clinical Trials (PACT)
Allocation concealment (selection bias) Low risk [From protocol] Subjects will be centrally
randomised to one of the four treatment
groups via the System for Central Alloca-
tion of Drug (SCAD) and will be stratified
by smoking status
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk [From protocol] Once the database has
been frozen, the treatment allocations will
be unblinded and all of the analyses detailed
in this document will be performed. The
treatment allocations will be unblinded us-
ing standard GSK systems. The database
will be frozen by BDS Respiratory Data
Management, GSK
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk An independent clinical end point com-
mittee, whose members were unaware of
the treatment assignments, determined the
primary cause of death and whether death
was related to COPD. No other outcomes
were assessor-rated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal rates quite similar but both
high by the end of the 36 month treatment
period. Acceptable methods of imputation
used in all cases. For any subject who with-
draws prematurely from the study, all avail-
able data up to the time of discontinua-
tion were included in the analyses. Mor-
tality data were collected for subjects who
withdrew early
Selective reporting (reporting bias) Low risk All relevant outcomes stated in the protocol
were reported in detail
82Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Calverley 2008
Methods Design: randomized, double-blind, placebo-controlled study
Duration: 52 weeks (+ 2 week run-in)
Location: 95 sites in 11 countries
Participants Population: 911 participants were randomised to two doses of mometasone (308 and
308), and placebo (295)
Baseline characteristics
Mean age (years): mom800 65.3, mom400 65.0, pbo 65.0
% Male: mom800 69, mom400 67, pbo 69
% FEV1 predicted (pre-BD): mom800 43, mom400 42, pbo 42
Pack-years: not reported
Inclusion criteria: All subjects had a diagnosis of COPD based on currently accepted
criteria, and were current smokers who failed a mandatory smoking cessation program
or self-reported ex-smokers who had stopped smoking ≥ 12 months before the study.
Eligible subjects had a pre-bronchodilator FEV1/FVC (forced vital capacity) ratio ≤
70%, post-bronchodilator FEV1 between 30% and 70% predicted, and low post-bron-
chodilator FEV1 reversibility (< 10% of predicted normal)
Exclusion criteria: Subjects with a clinical history of asthma or any other clinically
significant medical illness other than COPD were excluded. Other exclusion criteria
included a COPD exacerbation within 3 months before the baseline visit; ventilator
support for respiratory failure within the past year; lobectomy, pneumonectomy, or lung
volume reduction surgery; lung cancer within the past 5 years; nasal continuous positive
airway pressure or oxygen use > 2 L/min or for > 2 hours per day; initiation of pulmonary
rehabilitation within the past 3 months; treatment with chronic or prophylactic antibi-
otics; inability to use the MF-DPI inhaler; and < 80% adherence in recording diary data
between screening and baseline
Interventions 1. Mometasone 400 qd (ICS)
2. Mometasone 800 qd (ICS)
3. Placebo (PBO)
Inhaler device: dry powder
Allowed co-medications: per protocol, subjects did not receive inhaled, oral, or par-
enteral corticosteroids for 6 weeks prior to screening. During the study, ipratropium
bromide, theophylline, short- and long-acting b2-adrenergic agonists (with appropriate
washout before study visits) were allowed
Outcomes Change from baseline in post-bronchodilator forced expiratory volume in 1 second
(FEV1), total COPD symptom scores, health status (SGRQ), percentage of subjects
with a COPD exacerbation, and adverse events
Notes Funding: Schering-Plough
Identifier(s): unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomized via computer-generated code
in a ratio of 2:2:1:1
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Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind but ’dosing regimens (QDor
BID) were not blinded’
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Double-blind but ’dosing regimens (QDor
BID) were not blinded’. No reference to
outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropout was >30% all groups, and espe-
cially high in the placebo group (42.4%)
. The ITT population did not include 11.
5% of the randomised population
Selective reporting (reporting bias) Unclear risk We could not locate a prospectively regis-
tered protocol to check all outcomes were
reported
Calverley 2010
Methods Design: double-blind, double-dummy, randomised, active-controlled, parallel-group
study
Duration: 11 months (+ 4 week run-in)
Location: Conducted at 76 centres in 8 countries across Europe
Participants Population: 718 participants were randomised to formoterol (239) and formoterol/
budesonide combination (242), and one other treatment arm which was not eligible for
this review (237)
Baseline characteristics
Age (mean years): bud/form 64.1, form 63.7
% Male: bud/form 81.5, form 81.1
% FEV1 predicted: bud/form 42.3, form 42.5
Pack-years (mean): bud/form 37.8, form 39.7
Inclusion criteria: Hospital outpatients with severe stable COPD according to the
GOLD guidelines; aged 40 years with a diagnosis of symptomatic COPD for >2 years,
at least a 20 pack-years smoking history, a post-bronchodilator FEV1 between 30% and
50%of the predicted normal and at least 0.7 L absolute value and a pre-dose FEV1/forced
vital capacity (FVC) of 0.7; at least one exacerbation requiring medical intervention
(oral corticosteroid and/or antibiotic treatment and/or need for a visit to an emergency
department and/or hospitalisation) within 2-12 months before the screening visit and
to be clinically stable for the 2 months before study entry; change in FEV1 <12% of
predicted normal value 30 min following inhalation of 200 mg of salbutamol pMDI
Exclusion criteria: History of asthma, allergic rhinitis or other atopic disease, variability
of symptoms from day to day and frequent symptoms at night and early morning (sug-
gestive of asthma); receiving long term oxygen therapy or they had a lower respiratory
tract infection or had been hospitalised for an acute COPD exacerbation within two
months before screening or during the run-in period. Treatment with oral, injectable
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or depot corticosteroids and antibiotics, long-acting antihistamines or changes in the
dose of an oral modified release theophylline in the two months preceding screening and
during the run-in period were excluded
Interventions 1. Formoterol 12 bid (LABA)
2. Formoterol/budesonide 12/400 bid (LABA/ICS)
Inhaler device: Dry powder
Allowed co-medications: not described
Outcomes Change in pre-dose morning FEV1 and mean rate of COPD exacerbations per patient
per year, FVC, PEF, SGRQ total score, six-minute walking test, BMI, BODE index,
safety evaluations including ECG
Notes Funding: Chiesi Farmaceutici
Identifier(s): NCT00476099
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation scheme followed a bal-
anced-block centre-stratified design and
was prepared via a computerised system
Allocation concealment (selection bias) Low risk Patients were centrally assigned, in each
centre, to one of the three treatment arms
at the end of the run-in period through
an Interactive Voice/Web Response System
(IXRS)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk On each study day, patients took both
active medications and matched placebo
twice daily, in order to maintain blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk On each study day, patients took both
active medications and matched placebo
twice daily, in order to maintain blinding.
In case of emergency, un-blinding of the
treatment code was done through IXRS
Incomplete outcome data (attrition bias)
All outcomes
Low risk 12.3% withdrew from the combination
group and 14.2% from the formoterol
group. Judged to be relatively low and even
between groups, and the intention-to-treat
populationwere usedusing last observation
carried forward
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Selective reporting (reporting bias) Low risk All outcomes stated in the prospectively
registered protocol were reported in full
Campbell 2005
Methods Design: randomised, double-blind, placebo-controlled, parallel-group study
Duration: 6 months (+ 3 weeks run-in period)
Location: 73 centres in 8 countries
Participants Population: 432 participants were randomised to formoterol (215) and placebo (217)
Baseline characteristics
Mean age (years): form 60; pbo, 60
% Male: form 61, pbo, 73
% FEV1 predicted: form 53.0, pbo 54.1
Pack-years (mean): form 37, pbo, 37
Inclusion criteria: older than 40 years of age; clinical diagnosis of COPD with at least
2 years of symptoms, FEV1 40% to 70% predicted, FEV1/slow VC < 70%; history of
at least 10 pack-years
Exclusion criteria: history of asthma or seasonal allergic rhinitis; onset before age 40;
inhaled corticosteroid dose change; oral steroid use or significant COPD exacerbation
in the past mo
Interventions 1. Formoterol 12 bid (LABA)
2. Placebo (PBO)
Inhaler device: dry powder turbuhaler
Allowed co-medications: Allowed medications were terbutaline (0.5 mg) used as re-
liever [in the two arms used in the review]; inhaled and nasal corticosteroids without
modification of dosage or frequency of administration. Disallowedmedications included
domiciliary oxygen; disodium cromoglycate; ephedrine; antihistamines; beta-blockers
and bronchodilators other than the study medication
Outcomes St George’s Respiratory Questionnaire (SGRQ), COPD exacerbations, FEV1 % change,
morning PEF, slow VC, combined symptom score (CSS), reliever medication use
Notes Funding: AstraZeneca
Identifier(s): unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Treatment was randomized in balanced
blocks using a computer generated scheme
Allocation concealment (selection bias) Low risk Randomisation scheme was provided in
coded envelopes
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind treatment period (patients
and investigators)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No outcomes used from this study in the
present review were assessor-rated
Incomplete outcome data (attrition bias)
All outcomes
Low risk An intention-to-treat approach was used
throughout. Unclear how data were im-
puted butwithdrawal rateswere similar and
below 20% in both groups (formoterol 14.
0%, placebo 18.0%)
Selective reporting (reporting bias) Low risk All stated outcomes were reported and in-
cluded in meta-analysis
Casaburi 2002
Methods Design: 2 identical randomized double-blind placebo-controlled studies
Duration: 52 weeks (+ 2 week run-in)
Location: 50 clinical centres (? countries)
Participants Population: 921 participants were randomised to tiotropium (550) and placebo (371)
Baseline characteristics
Mean age (years): tio 65, pbo 65
%Male: tio 66.5, pbo 62.8
% FEV1 predicted: tio 39.1, pbo 38.1
Pack years (mean): tio 63, pbo 59
Inclusion criteria: outpatients of either sex who were > 40-yrs-old and had a clinical
diagnosis of COPD, as defined by the American Thoracic
Society (ATS). Participants were required to have at least a 10 pack-yr smoking history,
clinically stable airway obstruction, and a forced expiratory volume in one second (FEV1)
of <65% of predicted normal values and <70% of forced vital capacity (FVC)
Excusion criteria: history of asthma, allergic rhinitis or atopy or a total blood eosinophil
count of > 600 cells/mm-3. Bronchodilator responsiveness was not an entry criterion.
Patients were also excluded if they required regular daytime supplemental oxygen or were
on doses exceeding the equivalent of 10 mg prednisone daily during the month prior
to entering the study. In addition, patients were excluded if they had a recent history of
myocardial infarction (<1 yr), heart failure (<3 yrs) or cardiac arrhythmia requiring drug
therapy
Interventions 1. Tiotropium 18 bid (LAMA)
2. Placebo (PBO)
Inhaler device: dry powder
Allowed co-medications: Patients were permitted an albuterol metered-dose inhaler, as
needed, stable doses of theophylline (i.e. unchanging doses that had been used for > 6
weeks prior to entry), inhaled glucocorticosteroids and the equivalent of <10 mg/day-1
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oral prednisone throughout the study period. Finally, to treat acute COPD exacerbations
during the trial, investigators were permitted to administer any additional medication
deemed necessary (excluding anticholinergic or long-acting b-agonists). After 13 weeks,
the investigators were permitted to prescribe glucocorticosteroids or theophylline prepa-
rations as necessary
Outcomes The primary spirometric outcome was trough FEV1. Changes in dyspnoea were mea-
sured using the Transition Dyspnea Index, and health status with the disease-specific St.
George’s Respiratory Questionnaire and the generic Short Form 36. Medication use and
adverse events were recorded
Notes Funding: Boehringer Ingelheim
Identifier(s): unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomized in a 3:2
tiotropium:placebo ratio in order to expose
a greater number of patients to tiotropium
for safety evaluation [industry funded]
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind. Subjects took, by inhala-
tion, active medication (tiotropium in lac-
tose) or placebo (lactose) once each morn-
ing from identically appearing capsules
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information
Incomplete outcome data (attrition bias)
All outcomes
Low risk The intention-to-treat principle of includ-
ing all randomized patients was used in all
efficacy analyses. Patients who had missing
baseline data, or <2 weeks of data for cer-
tain end points, were excluded from the 1-
yr comparisons for those end points. When
patients discontinued due to worsening of
disease (5% of patients), missing data were
imputed using the least favourable data ob-
served prior to discontinuation. In all other
cases, missing data following patient with-
drawal were imputed by carrying the last
observation forward. In order to assess the
impact of imputation, data were also anal-
ysed based on patients who completed the
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study to 12 months alone. This sensitivity
analysis showed that the results were consis-
tent with those obtained after imputation
of missing data
Selective reporting (reporting bias) Unclear risk We could not locate a prospectively regis-
tered protocol to check all outcomes were
reported
Chan 2007
Methods Design: randomized, double-blind, parallel-group study
Duration: 48 weeks
Location: 101 centres in Canada involving 72 specialists and 29 general practitioners
Participants Popoulation: 913 participants were randomised to tiotropium (608) and placebo (305)
Baseline characteristics
Mean age (years): tio 66.8, pbo 66.9
% Male: tio 59, pbo 61
% FEV1 predicted: tio 39.4, pbo 39.3
Pack years (mean): tio 50.2, pbo 51.0
Inclusion criteria: Male and female outpatients aged 40 years or older, with a clinical
diagnosis of COPD (FEV1 65% predicted or less and FEV1/forced vital capacity [FVC]
70%or less) were considered for inclusion in the present study. Participants were required
to have a smoking history of 10 pack-years or greater.
The inclusion criteria relating to ‘exacerbation history’ initially required that patients
had experienced one or more exacerbations within the past year (requiring treatment
with antibiotics and/or oral steroids), but not within the six weeks before entering the
study. However, due to slower than expected enrolment, this criterion was amended to
include patients with fewer exacerbations (one exacerbation in the past two years)
Exclusion criteria: history of asthma, allergic rhinitis or atopy; a recent lower respiratory
tract infection or any exacerbation (within the previous six weeks); a recent history of
myocardial infarction (within the previous six months) or cardiac arrhythmia requiring
drug therapy; and oral corticosteroid use at unstable doses during the six weeks before
entering the study or at a stable dose exceeding the equivalent of 10 mg prednisone daily.
In addition, those patients with a significant disease other than COPD that would put
the patient at risk because of participation in the study, or patients with a disease that
may have influenced the results of the study, were not enrolled
Interventions 1. Tiotropium 18 bid (LAMA)
2. Placbeo (PBO)
Inhaler device: dry powder Handihaler
Allowed co-medications: During the treatment period, patients were permitted oral
corticosteroids (at a stable dose of 10 mg or less of prednisone daily or equivalent), stable
doses of inhaled corticosteroids, theophylline preparations, mucolytic preparations (not
containing bronchodilators), LABAs and, for acute symptom relief, as-needed salbu-
tamol metered-dose inhaler. Patients were not allowed to use inhaled anticholinergics
(other than the study drug) or oral beta2-agonists during the treatment period. To treat
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COPD exacerbations during the trial, the investigators were permitted to administer any
additional medication deemed necessary
Outcomes Lung function (FEV1, FEV6 and forced vital capacity), symptoms, health-related quality
of life (St George’s Respiratory Questionnaire) and exacerbations
Notes Funding: Boehringer Ingelheim Canada Ltd and Pfizer Canada
Identifier(s): 205.259
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomly assigned to receive
either tiotropium 18 once daily or placebo
for 48 weeks (in a ratio of 2:1) [industry
funded]
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, both medications delivered
via the Handihaler
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk analyses were applied to the full analy-
sis set (FAS) patient population with the
last observation carried forward method,
except when patients discontinued be-
cause of worsening COPD, when the
least favourable data before discontinua-
tion were carried forward. The FAS popu-
lation included all patients who were ran-
domly assigned, took at least one dose of
study medication, and had a valid baseline
measurement and an additional measure-
ment after at least oneweek ofmultiple dos-
ing. 24% dropout overall, fairly even be-
tween groups
Selective reporting (reporting bias) Low risk All outcomes stated in the prospectively
registered protocol were reported in full
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Methods Design: randomized, double-blind, placebo-controlled trial
Duration: 2 years
Location: 61 sites in 11 different countries
Participants Population: 519 participants were randomised to tiotropium (260) and placebo (259)
Baseline characteristics - given for the whole population, not per group
Mean age (years): 64.6
% Male: 77.3
% FEV1 predicted (pre-BD): 38.2
Pack years (mean): 51.7
Inclusion criteria: men and women, aged 40-80 years, with a clinical diagnosis of
COPD, ratio of FEV1/FVC < 70% and a smoking history greater than 10 pack-years
Exclusion criteria: Patients with pulmonary disease other than COPD, including
asthma, clinically significant bronchiectasis, interstitial lung disease, pleural disease, and
previous history of thoracic surgery, such as lung resection or lung volume reduction
surgery, were excluded. Patients requiring supplemental oxygen at rest or during exercise
to prevent desaturation (<85%) were also excluded. Patients with disorders that could
impact their ability to participate in exercise testing, such as obesity (body mass index
>30 kg/m2), and cardiovascular or musculoskeletal disease were excluded
Interventions 1. Tiotropium 18 bid (LAMA)
2. Placebo (PBO)
Inhaler device: Spiriva HandiHaler
Allowed co-medications: Patients were allowed to continue taking other prescribed
medications, including long-acting β-sympathomimetic bronchodilators and inhaled
corticosteroids, with the same timing and dosage throughout the study
Outcomes exercise endurance measures, FEV1, SGRQ
Notes Funding: Boehringer Ingelheim
Identifier(s): NCT00525512
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, methods unclear but indus-
try funded
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
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Incomplete outcome data (attrition bias)
All outcomes
High risk Overall dropout 31.2%, higher in the
placebo group (37%).
Selective reporting (reporting bias) Low risk The published paper did not report out-
comes for the full multi-centre study, just
the feasibility phase. Full results posted on
cinicaltrials.gov were not found until after
the analysis had been conducted
Dahl 2010
Methods Design: randomised double-blind double-dummy parallel-group study
Duration: 12 months (+ 2 weeks run-in period)
Location: Denmark, UK, Germany, Russia, USA (unclear how many centres)
Participants Population: 1732 participants were randomised to formoterol (435), two doses of in-
dacaterol (437 and 428) and placebo (432)
Baseline characteristics
Mean age (years): form 64, ind300 64, ind600 63, pbo 63
%Male: form 80.2, ind300 80.3, ind600 76.9, pbo 81.5
% FEV1 predicted: form 52.5, ind300 51.5, ind600 50.8, pbo 52.0
Pack-years: form 40, ind300 40, ind600 40, pbo 43
Inclusion criteria: males and females aged 40 and older; clinical diagnosis of moderate
to severe COPD; history of at least 20 pack-years
Exclusion criteria: history of asthma; current respiratory tract infection or hospitalisa-
tion for COPD exacerbation within the previous 6 weeks
Interventions 1. Formoterol 12 bid (LABA)
2. Indacaterol 300 qd (LABA)
3. Indacaterol 600 qd (LABA)
4. Placebo (PBO)
Inhaler device: dry powder turbuhaler and single dose dry powder inhaler
Allowed co-medications: Fixed-dose combinations of inhaled corticosteroids (ICS) plus
LABA were replaced by monotherapy ICS at an equivalent dose and regimen plus salbu-
tamol as needed. Participants receiving ICSmonotherapy continued treatment at a stable
dose throughout the study. Oral corticosteroids were not allowed, or a change in ICS
was noted during the previous month
Outcomes St George’s Respiratory Questionnaire (SGRQ), COPD exacerbations, trough FEV1
and PEF, dyspnoea (baseline and transition scores), diary card data, 6-minute walk test,
ECG, vital signs and haematology
Notes Funding: Novartis
Identifier(s): NCT00393458
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised to treatment (1:1:1:1) with
stratification for smoking status (current/
ex-smoker) using an automated interactive
system
Allocation concealment (selection bias) Low risk Using an automated interactive system
[concealment assumed by automatisation]
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind double-dummy trial
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Protocol state double blind for sub-
ject, caregiver, investigator and outcomes
assessor http://www.clinicaltrials.gov/ct2/
show/NCT00393458
Incomplete outcome data (attrition bias)
All outcomes
High risk Efficacy results are presented for the mod-
ified intention-to-treat (ITT) population
including all randomised patients who re-
ceived at least one dose of study drug but
excluding patients from six sites owing to
non-conformance with good clinical prac-
tice. Withdrawal relatively high in both
groups (formoterol, 25.7; placebo 31.7)
Selective reporting (reporting bias) Low risk All stated and expected outcomes reported
in detail [exacerbation rates only presented
without imputation]
Dal Negro 2003
Methods Design: Randomised, double-blind, parallel group, pilot study
Duration: 12 months (+ 2 week run-in)
Location: single centre in Italy
Participants Population: 18 participants were randomised to salmeterol (6), salmeterol/fluticasone
combination (6), and placebo (6)
Baseline characteristics
Mean age (years): ranged from 50 to 78 across groups, means not reported
% Male: salm 100, flut/salm 83.3, pbo 83.3
% FEV1 predicted: salm 48.0, flut/salm 50.0, pbo 50.0
Pack-years: salm 43.1, flut/salm 40.1, pbo 42.7
Inclusion criteria: Basal FEV1 < 80% predicted normal value, but > 800 ml; FEV1/FVC
ratio <70% predicted; a FEV1 change of <12% as a percent of the predicted normal
value following salbutamol 400 mg; regular treatment with oral theophylline 200 mg
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bid and short acting b2-adrenergics prn for a period of at least 6 month; current or ex
smokers with a smoking history of at least 10 pack-years
Exclusion criteria: Current evidence of asthma or other pulmonary diseases; regular
treatment with ICS; unstable respiratory disease requiring oral/parenteral corticosteroids
within 4 weeks prior to the beginning of the study; changes in COPDmedication in the
last 4 weeks before entering the run-in period; upper or lower respiratory tract infection
within 4 weeks before the screening visit; unstable angina or unstable arrhythmias; recent
myocardial infarction or hearth failure; insulin-dependent diabetes mellitus; neuropsy-
chiatric disorders; concurrent use of medications that affected COPD (e.g. beta-block-
ers) or interacted with methylxanthine products such as macrolides or fluoroquinolones;
known or suspected hypersensitivity to ICS, b2-agonist or lactose; evidence of alcohol
abuse
Interventions 1. Salmeterol 50 bid (LABA)
2. Salmeterol/fluticasone 50/250 bid (LABA/ICS)
2. Placebo (PBO)
Inhaler device: Diskus
Allowed co-medications: Theophylline and salbutamol as required
Outcomes Exacerbations per year, FEV1, morning PEF, daily symptom scores, use of rescue medi-
cation and adverse events
Notes Funding: Unclear
Identifier(s): unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk At the end of the run-in, eligible subjects
will be randomly assigned to receive one
of the three double-blind treatments [no
other details and does not appear to be in-
dustry funded]
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Assigned to receive one of the three double-
blind treatments, all via Diskus
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropout
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Selective reporting (reporting bias) High risk Several key outcomes not reported (mor-
tality, adverse events). Difficulty contacting
authors
Doherty 2012
Methods Design: randomised, double-blind, placebo-controlled trial
Duration: 6 months (+ 2 weeks run-in period)
Location: 164 centres in North, Central and South America, Europe, Africa and Asia
Participants Population: 1196 participants were randomised to formoterol (243),mometasone (253)
, formoterol combination therapy at two doses (225 and 239), and placebo (236)
Baseline characteristics
Age (mean years): form 59.7, mom 60.5, form/mom400 59.2, form/mom200 60.1,
pbo, 58.8
% Male: form 74.9, mom 77.9, form/mom400 74.7, form/mom200 73.2, pbo, 75.4
% FEV1 predicted: form 38.2, mom 40.2, form/mom400 38.1, form/mom200 38.7,
pbo, 38.0
Pack-years (mean): form 45.9, mom 41.1, form/mom400 54.8, form/mom200 40.3,
pbo, 43.5
Inclusion criteria: males and females aged 40 and older; FEV1/FVC < 70%; PFEV 25%
to 60%; COPD symptoms for at least 24 months; history of at least 10 pack-years
Exclusion criteria: current diagnosis of asthma; marked bronchodilator reversibility;
recent COPD exacerbation; history of lung cancer/surgery; other significant medical
illness
Interventions 1. Formoterol 10 bid (LABA)
2. Mometasone 400 bid (ICS)
3. Formoterol/mometasone 10/400 bid (LABA/ICS)
4. Formoterol/mometasone 10/200 bid (LABA/ICS)
5. Placebo (PBO)
Inhaler device: metered dose
Allowed co-medications: open-label, short-acting beta2-agonist (SABA)/short-acting
anticholinergic combination was allowed. All long-acting COPD treatments (LABA,
inhaled corticosteroids, LABA/ICSFDCor long-acting anticholinergics)were disallowed
Outcomes StGeorge’s RespiratoryQuestionnaire (including number reaching aminimally clinically
important difference), COPD exacerbations, FEV1 area under the curve from 0 to 12
hours post-dose, trough FEV1 (not for LABA placebo comparison), diary card data
Notes Funding: Merck & Co
Identifier(s): NCT00383721
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Subjects were randomized in a 1:1:1:1:1 ra-
tio [industry sponsored]
Allocation concealment (selection bias) Unclear risk Subjects who discontinued early were not
replaced [no other details given]
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy. Protocol
states subjects and investigators were blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Protocol and paper do not provide details
about blinding of outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal rates were quite different (for-
moterol 20.6%; placebo 28.4%) but effi-
cacy analyses and safety summaries were
based on the intent-to-treat principle for all
randomized subjects
Selective reporting (reporting bias) High risk Quality of life [primary outcome] was not
reported in a way that could be analysed for
the comparison in question. All other stated
and expected outcomes were reported and
analysed
Donohue 2010 [INHANCE]
Methods Design: This study was performed in two stages in an adaptive seamless design. In stage
1, patients were randomized to receive indacaterol 75, 150, 300, or 600 mg once daily,
formoterol 12 mg twice daily, or placebo, all double-blind, or open-label tiotropium 18
mg once daily.
An independent committee used predefined efficacy criteria to select two indacaterol
doses based on 2-week efficacy and safety data. As reported elsewhere, the two indacaterol
doses selected were 150 and 300 mg (18). In stage 2, the four treatment groups were the
two selected doses of indacaterol, tiotropium, and placebo. Treatment continued to 26
weeks, with additional patients recruited and randomized
Duration: 26 weeks (+ 2 week run-in)
Location: 345 centres in 12 countries
Participants Population: 1683 participants were randomised to indacaterol at two doses (416 and
416), open-label tiotropium (415), and placebo (418)
Baseline characteristics
Age (mean years): ind150 63.4, ind300 63.3, tio 64.0, pbo 63.6
% Male: ind150 62.3, ind300 63.2, tio 64.8, pbo 61.0
% FEV1 predicted: ind150 56.1, ind300 56.3, tio 53.9, pbo 56.1
Pack-years (mean): ind150 48.3, ind300 50.8, tio 50.0, pbo 49.7
Inclusion criteria: Male and female adults aged ≥ 40 years, who have signed an In-
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formed Consent Form prior to initiation of any study-related procedure. Co-operative
outpatients with a diagnosis of COPD (moderate to severe as classified by the Global
Initiative for Chronic Obstructive Pulmonary Disease (GOLD) Guidelines, 2005) and
smoking history of at least 20 pack yearsPost-bronchodilator FEV1 < 80% and ≥ 30%
of the predicted normal value. Post-bronchodilator FEV1/FVC < 70% (Post refers to
within 30 min of inhalation of 400 µg of salbutamol)
Exclusion criteria: lactating females; hospitalised for a COPD exacerbation in the 6
weeks prior to Visit 1 or during the run-in period; requiring long term oxygen therapy (>
15 h a day); respiratory tract infection 6 weeks prior to V1; concomitant pulmonary dis-
ease, pulmonary tuberculosis, or clinically significant bronchiectasis; history of asthma;
Type I or uncontrolled Type II diabetes; contraindications for tiotropium; clinically rel-
evant laboratory abnormalities or a clinically significant abnormality; active cancer or a
history of cancer with less than 5 years disease free survival time; history of long QT
syndrome or whose QTc interval is prolonged; hypersensitivity to any of the study drugs
or drugs with similar chemical structures; treatment with the investigational drug (with
further criteria); live attenuated vaccinations within 30 days prior to visit 1, or during
run-in period; known history of non compliance to medication; unable to satisfactorily
use a dry powder inhaler device or perform spirometry measurements
Interventions 1. Indacaterol 150 qd (LABA)
2. Indacaterol 300 qd (LABA)
3. Tiotropium 18 qd (LAMA) - open-label
4. Placebo (PBO)
Inhaler device: 1, 2, and 4 via single-dose dry powder inhaler, open-label tiotropium
via HandiHaler
Allowed co-medications: Patients could continue inhaled corticosteroid (ICS)
monotherapy if stable for 1 month before screening; dose and regimen were to remain
stable throughout the study. Before the start of the run-in period, treatment with an-
ticholinergic bronchodilators or with β2-agonists was discontinued with appropriate
washout, and patients receiving fixed-combination β2-agonist/ICS were switched to ICS
monotherapy at an equivalent dose. All patients were supplied with albuterol for use as
needed
Outcomes The primary efficacy outcome was trough FEV1 at 12 weeks. Additional analyses (not
adjusted for multiplicity) included transition dyspnoea index (TDI), health status (St
George’s Respiratory Questionnaire [SGRQ]), and exacerbations. Serum potassium,
blood glucose, and QTc interval were measured
Notes Funding: Novartis
Identifier(s): NCT00463567 and CQAB149B2335S
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization was performed using an
automated interactive voice response sys-
tem, and was stratified by smoking status
(current or ex-smoker)
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Allocation concealment (selection bias) Low risk Interactive voice response system
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding procedures were sound, but
tiotropium was delivered open label which
introduced bias for these comparisons
On completion of stage 1, the independent
dose selection committee had access to un-
blinded data. The only information com-
municated with the sponsor and investiga-
tors was the two selected indacaterol doses,
and personnel involved in the continuing
clinical study remained blinded for the re-
mainder of the study.
The blinding of indacaterol and placebo
continued until the study database was
locked at the end of stage 2
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding procedures were sound, but
tiotropium was delivered open label which
introduced bias for these comparisons.
Double Blind (Subject, Caregiver, Inves-
tigator, Outcomes Assessor) [clinicaltrials.
gov]
Incomplete outcome data (attrition bias)
All outcomes
Low risk Efficacy was evaluated for the intention-to-
treat population, comprising all random-
ized patients who received at least one dose
of study
drug. Dropout was variable and generally
high across groups (ranging from 18 to
31%). 98.9% were included in the analysis
Selective reporting (reporting bias) Low risk Study was prospectively registered, and all
results were available from the published
reports and clinicaltrials.gov
Dusser 2006
Methods Design: parallel group, double-blind, randomized, placebo-controlled study
Duration: 48 weeks (+ 3 week screening visit)
Location: 177 centres in France
Participants Population: 1010 participants were randomised to tiotropium (500) and placebo (510)
Baseline characteristics
Age (mean years): tio 64.5, pbo 65.0
% Male: tio 89, pbo 87
% FEV1 predicted: tio 48.2, pbo 47.6
Pack-years (mean): not reported
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Inclusion criteria: Male and female patients aged >40 yrs old with a clinical diagnosis
of COPD (pre-bronchodilator FEV1 30-65% predicted and FEV1/slow vital capacity
(SVC) <70% pred) were eligible for inclusion in the study. Participants were also required
to have a smoking history of >10 pack-yrs and one or more exacerbations in the last year
(as reported in the patient’s medical file), but not within the 6 weeks prior to entering
the
study.
Exclusion criteria: history of asthma, allergic rhinitis or atopy; a recent lower respiratory
tract infection or any exacerbation (within the previous 6 weeks); regular use of daytime
oxygen therapy; oral corticosteroid use at unstable doses 6 weeks prior to entering the
study or at a dose exceeding the equivalent of 10 mg prednisone daily. In addition, those
patients with a significant disease other than COPD that would put the patient at risk
because of participation in the study, or a disease that would influence the results of the
study, were not enrolled
Interventions 1. Tiotropium 18 qd (LAMA)
2. Placebo (PBO
Inhaler device: HandiHaler
Allowed co-medications: Patients were permitted short-acting b2-agonists, as needed,
for acute symptom relief. Concomitant use of inhaled corticosteroids (ICS) and oral
steroids (at a dose of ,10 mg prednisone daily or equivalent) was allowed if the dosage
was stable for > 6 weeks before study entry. To treat COPD exacerbations during the
trial, the investigators were permitted to administer any additional medication deemed
necessary (excluding anticholinergics and long-acting b2-agonists). During the treatment
period, patients were not allowed to use oral or inhaled long-acting b2-agonists, inhaled
anticholinergics (other than the study drug) or theophylline
Outcomes Primary endpoint was morning PEFR. Secondary endpoints were incidence, severity
and duration of exacerbations, use of rescue medications, number of lost working days,
number of days of hospitalisations, number of short courses of steroids/antibiotics, spiro-
metric parameters at clinic visits, viral characterisation of severe exacerbations
Notes Funding: Boehringer Ingelheim
Identifier(s): 205.214
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised 1:1, methods not described
but industry funded
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, treatment and placebo were
both delivered via the HandiHaler
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk More patients in the tiotropium group
completed the trial than those in the
placebo group (76.6% versus 71.2%). An
intent-to-treat (ITT), last-observation-car-
ried forward (LOCF) method was used
for spirometric end-point analyses, except
when patients discontinued due to worsen-
ing COPD, when the least favourable data
prior to discontinuation were carried for-
ward. All randomised patientswith baseline
and post-treatment data who took at least
one capsule of study drug were included in
the primary data set
Selective reporting (reporting bias) Low risk Data were available for the outcomes stated
in the industry protocol
Fang 2008
Methods Design: randomised, parallel-group, controlled study
Duration: 12 months (+ 2 week run-in)
Location: outpatients and inpatients of The First Affiliated Hospital of Kunming Med-
ical Collage, China
Participants Population: 126 participants were included in the per protocol analysis: tiotropium (32)
, salmeterol/fluticasone combination therapy (32), and two other arms that were not
relevant to this review (salmeterol/fluticasone combination plus tiotropium, 33; and a
blank control group, 29). Actual numbers randomised are unclear
Baseline characteristics
Age (mean years): tio 63, salm/flut 62
% Male: tio 70. salm/flut 77.5
% FEV1 predicted: not reported
Pack-years (mean): not reported
Inclusion criteria: FEV1 is 25% to 70 % predicted pre-bronchodilator; FEV1/FVC <
70%; FEV1 increased by < 15% predicted post-bronchodilator (400 µg salbutamol).
Exclusion criteria: diseases other thanCOPD; need long-termoxygen therapy; currently
receiving system hormone therapy
Interventions 1. Tiotropium 18 qd (LAMA)
2. Salmeterol/fluticasone 50/250 bid (LABA/ICS)
Inhaler device: unclear
Allowed co-medications: unclear, other than rescue medication
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Outcomes FVC, FEV1, PEF, worsening (judged by counting the use of hormone or antibiotics
amount; St. George’s Respiratory Questionnaire (SGRQ); adverse events
Notes Funding: unknown
Identifier(s): none
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table was used
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not mentioned, treatment group
translated as ’blank’ therefore assumed not
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Intention-to-treat analysis (n = 161) and
per-protocol analysis (n = 126, age 45 - 71
years) were performed. The abstract refers
to the per-protocol analysis (representing
78% of the ITT, and presumably less of the
total randomised population)
Selective reporting (reporting bias) Unclear risk Could not locate protocol to check out-
come reporting
Ferguson 2008
Methods Design: Randomized, double-blind, parallel-group study
Duration: 12 months (+ 4 week run-in)
Location: 94 research sites in the United States and Canada
Participants Population: 782 people were randomised to salmeterol (388) and fluticasone/salmeterol
combination (394)
Baseline characteristics
Age (mean years): salm 65.0, flut/salm 64.9
% Male: salm 52, flut/salm 58
% FEV1 predicted: salm 32.8, flut/salm 32.8
Pack-years (mean): salm 54.4, flut/salm 58.5
Inclusion criteria: 40 years of age or older with a diagnosis of COPD a cigarette smoking
history of greater than or equal to 10 pack-years, a pre-albuterol FEV1/FVC of 0.70 or
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less, a FEV1 of 50% of predicted normal or less and a history of 1 or more exacerbations
of COPD in the year prior to the study that required treatment with oral corticosteroids,
antibiotics, or hospitalisation.
Exclusion criteria: diagnosis of asthma, a significant lung disease other than COPD,
a clinically significant and uncontrolled medical disorder including but not limited to
cardiovascular, endocrine or metabolic, neurological, psychiatric, hepatic, renal, gastric,
and neuromuscular diseases, or had a COPD exacerbation that was not resolved at
screening
Interventions 1. Salmeterol 50 bid (LABA)
2. Salmeterol/fluticasone 50/250 bid (LABA/ICS)
Inhaler device: Diskus dry powder
Allowed co-medications: As-needed albuterol was provided for use throughout the
study. The use of concurrent inhaled long-acting bronchodilators (beta2-agonist and an-
ticholinergic), ipratropium/albuterol combination products, oral beta-agonists, inhaled
corticosteroids, and theophylline preparations were not allowed during the treatment pe-
riod. Oral corticosteroids and antibiotics were allowed for the acute treatment of COPD
exacerbations
Outcomes COPD exacerbations, pre-dose FEV1, diary records of dyspnoea, night-time awakenings
due to COPD, and use of supplemental albuterol
Notes Funding: GlaxoSmithKline
Identifier(s): NCT00144911, GSK SCO40043
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centre based randomisation schedule
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind [presumed par-
ticipants and personnel/investigators]
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropout high and fairly even (30% vs.
38%). Method of imputation only de-
scribed for the primary outcome (‘End-
pointwas defined as the last scheduledmea-
surement of pre-dose AMFEV1 during the
52-week treatment period’)
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Selective reporting (reporting bias) Low risk Checked GSK documents - all stated and
expected outcomes are reported
FLTA3025
Methods Design: randomised, double-blind, parallel-group, comparative trial
Duration: 6 months (+ 2 week run-in)
Location: 55 centres in the United States
Participants Population: 640 people were randomised to two doses of fluticasone (216 and 218),
and placebo (206)
Baseline characteristics
Age (mean years): flut250 65.2, flut500 63.3, placebo 64.8
% Male: flut250 72.2, flut500 66.1, placebo 68.0
% FEV1 predicted: not reported
Pack-years (mean): not reported
Inclusion criteria: Male or female subjects were eligible if they: were diagnosed with
COPD; were at least 40 years of age; had a current or prior history of at least 20 pack-
years of cigarette smoking; had a history of cough productive of sputum on most days
for at least 3 months of the year, for at least 2 years, that was not attributable to another
disease process; had a baseline FEV1 <65% of predicted normal but >0.70 L or FEV1
≤0.70L and >40% of predicted normal and FEV1/forced vital capacity (FVC) ratio of
<0.70; had a score of ≥2 on theModified Medical Research Council (MMRC) Dyspnea
Scale at screening and a score of≥4 on theCBSQ at randomisation, and had not received
systemic corticosteroids or high-dose inhaled corticosteroid therapy for at least 6months
prior to screening
Exclusion criteria: Current diagnosis of asthma, concurrent participation in a pul-
monary rehabilitation program, a respiratory disease other than COPD or other signif-
icant concurrent disease, an abnormal and clinically significant ECG at screening, and
the occurrence of a moderate or severe COPD exacerbation during the run-in period
Interventions Population:
1. Fluticasone 250 bid (ICS)
2. Fluticasone 500 bid (ICS)
3. Placebo (PBO)
Inhaler device: Diskus dry powder
Allowed co-medications: Concurrent use of the following respiratory medications was
not allowed: beta-agonists (other than salbutamol), cromolyns, corticosteroids (oral,
inhaled, and intranasal), anti-leukotrienes, and ipratropium. Concurrent use of theo-
phylline was allowed. Use of antibiotics for the treatment of up to three COPD exacer-
bations was allowed
Outcomes Morning pre-dose FEV1, Chronic Bronchitis Symptoms Questionnaire (CBSQ), Tran-
sition Dyspnoea Index (TDI, exacerbations of COPD, subject-recorded daily morn-
ing PEF rate, supplemental salbutamol use, night-time awakenings and quality of life
(CDRQ)
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Notes Funding: GlaxoSmithKline
Identifier(s): GSK FLTA3025
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised trial [GSK funded, likely to
be computerised randomisation schedule]
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded trial [presumed partici-
pant and personnel/investigator]
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout high but even across groups. The
Intent-to-Treat (ITT) population consisted
of all randomized subjects who received at
least 1 dose of study medication. The ITT
population was the primary population for
all efficacy and safety analyses
Selective reporting (reporting bias) Low risk All outcomes were reported in the results
summary
Gelb 2012
Methods Design: randomised, double-blind, dose-comparison study
Duration: 52 weeks (run-in unclear)
Location: unclear number of centres
Participants Population: 605 participants were randomised to two doses of aclidinium bromide (310
and 290)
Baseline characteristics
Age (mean years): not reported
% Male: not reported
% FEV1 predicted: acl200 47.5, acl400 45.5
Pack-years (mean): not reported
Inclusion criteria: unclear, abstracts only
Exclusion criteria: unclear, abstracts only
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Interventions 1. Aclidinium 200 bid (LAMA)
2. Aclidinium 400 bid (LAMA)
Inhaler device: unclear
Allowed co-medications: unclear
Outcomes The primary endpoint was change from baseline to Week 52 in trough FEV1. Other
efficacy parameters included change from baseline to Week 52 in peak FEV1, trough
and peak FEV1 by study visit, normalized FEV1AUC0-3, and change from baseline to
Week 52 in SGRQ and EuroQol scores
Notes Funding: Forest and Almirall
Identifier(s): unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomized (1:1) to receive
aclidinium 200 µg or 400 µg BID in a
double-blind manner
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Treatments were delivered in a double-
blind manner
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not enough information in abstracts to
make a judgement
Selective reporting (reporting bias) High risk Minimal information available. Full trial
report could not be located
GLOW1 2011
Methods Design: double-blind, placebo-controlled study
Duration: 26 weeks (+ 7 day pre-screening period and 14 day run-in)
Location: 97 centres in 11 countries
Participants Population: 822 participants were randomised to glycopyrronium (552) and placebo
(270)
Baseline characteristics
Age (mean years): gly 63.8, pbo 64.0
% Male: gly 82.5, pbo 80.5
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% FEV1 predicted: gly 54.8, pbo 54.3
Pack-years (mean): gly 44.9, pbo 44.6
Inclusion criteria: Patients with COPDwith a smoking history of >10 pack-years, post-
bronchodilator forced expiratory volume in 1 second (FEV1) < 80% and . 30% predicted
normal and FEV1/forced vital capacity < 0.70
Exclusion criteria: lower respiratory tract infection within 6 weeks, concomitant pul-
monary disease, history of asthma, lung cancer or long QT syndrome or QTc > 450 ms
(males) or > 470 (females), symptomatic prostatic hyperplasia, bladder-neck obstruc-
tion, moderate/ severe renal impairment, urinary retention, narrow angle glaucoma and
history of alpha-1 antitrypsin deficiency. Patients were also excluded if they were partic-
ipating in a supervised pulmonary rehabilitation programme, had contraindications for
tiotropium or ipratropium or had experienced adverse reactions to inhaled anticholin-
ergics
Interventions 1. Glycopyrronium bromide 50 qd (LAMA)
2. Placebo (PBO)
Inhaler device: low-resistance single-dose dry-powder inhaler (Breezhaler)
Allowed co-medications: inhaled/intranasal corticosteroids and H1 antagonists were
permitted in patients stabilized on them prior to study entry. Patients were required to
cease taking long-acting bronchodilator therapy before beginning the run-in period
Outcomes The primary outcome measure was trough FEV1 at Week 12. Secondary outcome mea-
sures included breathlessness on the transition dyspnoea index (TDI) and health-related
quality of life (HRQoL) according to the St. George’s RespiratoryQuestionnaire (SGRQ)
at Week 26, time to first moderate or severe COPD exacerbation and mean daily rescue
medication use over 26 weeks
Notes Funding: Novartis
Identifier(s): NCT01005901
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk randomized in a 2:1 ratio [sequence gen-
eration not described, but industry funded
so presumed electronic]
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double Blind (Subject, Caregiver, Inves-
tigator, Outcomes Assessor) [clinicaltrials.
gov]
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double Blind (Subject, Caregiver, Inves-
tigator, Outcomes Assessor) [clinicaltrials.
gov]
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was relatively even and around
20% in both groups. Efficacy was based on
centralized spirometry and assessed in the
full analysis set (FAS), which included all
randomized patients who received at least
one dose of study drug; patients were anal-
ysed according to the
treatment to which they were randomized.
The last observation of pre-dose trough
FEV1 was carried forward (LOCF) for
missing values
Selective reporting (reporting bias) Low risk Full results were available from the pub-
lished report and on clinicaltrials.gov in ac-
cordance with the protocol
GLOW2 2012
Methods Design:Multi-centre, double-blind, placebo-controlledwith open-label tiotropiumarm,
parallel group study
Duration: 52 weeks (+ 7 day pre-screening period and 14 day run-in
Location: 139 centres in 16 countries
Participants Population: 1066 participants were randomised to glycopyrronium (529), open-label
tiotropium (268), and placebo (269)
Baseline characteristics
Age (mean years): gly 63.5, tio 63.9, pbo 63.6
% Male: gly 64.6, tio 62.9, pbo 64.6
% FEV1 predicted: gly 55.7, tio 56.0, pbo 56.4
Pack-years (mean): gly 49.0, tio 50.2, pbo 48.0
Inclusion criteria: Patients with COPDwith a smoking history of >10 pack-years, post-
bronchodilator forced expiratory volume in 1 second (FEV1) < 80% and . 30% predicted
normal and FEV1/forced vital capacity < 0.70
Exclusion criteria: lower respiratory tract infection within 6 weeks, concomitant pul-
monary disease, history of asthma, lung cancer or long QT syndrome or QTc > 450 ms
(males) or > 470 (females), symptomatic prostatic hyperplasia, bladder-neck obstruc-
tion, moderate/ severe renal impairment, urinary retention, narrow angle glaucoma and
history of alpha-1 antitrypsin deficiency. Patients were also excluded if they were partic-
ipating in a supervised pulmonary rehabilitation programme, had contraindications for
tiotropium or ipratropium or had experienced adverse reactions to inhaled anticholin-
ergics
Interventions 1. Glycopyrronium 50 qd (LAMA)
2. Tiotropium 18 qd (LAMA) - open-label
3. Placebo (PBO)
Inhaler device: Glycopyrronium and placebo were delivered via theBreezhaler,
Tiotropium was delivered open-label via the HandiHaler
Allowed co-medications: In addition to the study treatment, concomitant medications
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(inhaled or intranasal corticosteroids andH1 antagonists) were permitted in patients who
had been stabilised on a recommended and constant dose prior to study entry. Patients
were provided with a salbutamol/albuterol inhaler to be used as rescue medication during
the study
Outcomes The primary efficacy variable was trough FEV1 following 12 weeks of treatment. Sec-
ondary variables included dyspnoea measured using the TDI at week 26 and health
status according to the total score on SGRQ at week 52, time to first moderate or severe
COPD exacerbation and mean daily rescue medication use over
52 weeks
Notes Funding: Novartis
Identifier(s): NCT00929110
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomised 2:1:1 ratio [se-
quence generation not described, but in-
dustry funded so presumed electronic]
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding procedures were sound, but
tiotropium was delivered open label which
introduced bias for these comparisons
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding procedures were sound, but
tiotropium was delivered open label which
introduced bias for these comparisons
Incomplete outcome data (attrition bias)
All outcomes
Low risk A higher percentage of patients in the
placebo groupdiscontinued (28.3%), com-
pared with the patients in NVA237 (22.
3%) and tiotropium groups (23.1%). Ef-
ficacy was assessed in the full analysis set
(FAS) which included all randomised pa-
tients who received at least one dose of the
study drug; patients in the FAS were anal-
ysed according to the treatment to which
they were randomised
Selective reporting (reporting bias) Low risk Full results were available from the pub-
lished report and on clinicaltrials.gov in ac-
cordance with the protocol
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Hanania 2003
Methods Design: randomised, double-blind, placebo-controlled, parallel-group trial
Duration: 6 months (+ 2 weeks run-in period)
Location: 75 centres in the USA, one in Puerto Rico
Participants Population: 723 participants were randomised to salmeterol (177), fluticasone (183),
salmeterol/fluticasone combination (178) and placebo (185)
Baseline characteristics
Age (mean years): salm 64.2, flut 63.3, salm/flut 63.4, pbo 64.8
% Male: salm 57.6, flut 66.1, salm/flut 60.7, pbo 68.1
% FEV1 predicted: salm 42, flut 42, salm/flut 41, pbo 42
Pack-years (mean): salm 57, flut 60, salm/flut 53, pbo 56
Inclusion criteria: males and females aged 40 and older; clinical diagnosis of COPD;
history of at least 20 pack-years and cough productive of sputum on most days for at
least 3 months of the year for at least 2 years; FEV1/FVC ratio < 70% and baseline FEV1
< 65% predicted but > 0.70 L
Exclusion criteria: current diagnosis of asthma; abnormal clinically significant ECG;
moderate or severe exacerbation during the run-in period; any significant medical dis-
order
Interventions 1. Salmeterol 50 bid (LABA)
2. Fluticasone 250 bid (ICS)
3. Salmeterol/fluticasone 50/250 bid (LABA/ICS)
4. Placebo (PBO)
Inhaler device: Diskus dry powder
Allowed co-medications: Stable regimens of theophylline were allowed (no change in
dose for 1month before screening) [only 11%were taking thesemedications].Disallowed
medications included oral corticosteroids within the past 6 weeks and long-term oxygen
therapy, and participants discontinued the use of corticosteroids and bronchodilators
Outcomes Chronic Respiratory Disease Questionnaire (CRQ), COPD exacerbations, morning pre-
dose and 2-hour post-dose FEV1, morning peak expiratory flow (PEF), dyspnoea (as
assessed by the transition dyspnoea index [TDI])
Notes Funding: GlaxoSmithKline
Identifier(s): GSK SFCA3007
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization was stratified by reversibil-
ity (defined as a 12% and 200 mL increase
in FEV1 from baseline following the ad-
ministration of 400 g albuterol) and inves-
tigative site [sequence generation not de-
scribed but study was industry sponsored]
Allocation concealment (selection bias) Unclear risk No details provided
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double blind [presumed sub-
ject and investigator]
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Reported outcomes not subject to detec-
tion bias [exacerbations, all-cause mortal-
ity, adverse events and withdrawal]
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal high and even between groups
(formoterol 31.7%, placebo 31.9%). In
order to account for patient withdrawals,
endpoint was used as the primary time
point and was defined as the last on-treat-
ment post baseline assessment excluding
any data from the discontinuation visit
Selective reporting (reporting bias) Low risk All expected and stated outcomes were re-
ported [KK check CDRQ]
Kardos 2007
Methods Design: Randomized, double-blind, parallel-group study
Duration: 10 months (+ 4 week run-in)
Location: 95 respiratory centres in Germany
Participants Population: 994 participants were randomised to salmeterol (487) and salmeterol/flu-
ticasone combination (507)
Baseline characteristics
Age (mean years): salm 64.0, salm/flut 63.8
% Male: salm 77.6, salm/flut 74.0
% FEV1 predicted: salm 40.3, salm/flut 40.4
Pack-years (mean): salm 37.0, salm/flut 36.8
Inclusion criteria: Outpatients with post-bronchodilator FEV1 < 50% predicted.,
FEV1/FVC of 70% predicted or less, age of 40 yr or more, smoking history of 10 pack-
years or more, and a documented history of two or more moderate to severe exacerba-
tions in the last year before the study.
Exclusion criteria: Patients with COPD exacerbations, hospital admissions, or change
in COPD therapy during the 4 wk before Visit 1 or during the 4-wk run-in period were
excluded. Patients with asthma, significant lung diseases other than COPD, and need
for long-term oxygen therapy or chronic systemic steroid use were also excluded
Interventions 1. Salmeterol 50 bid (LABA)
2. Salmeterol/fluticasone 50/500 bid (LABA/ICS)
Inhaler device: Diskus dry powder
Allowed co-medications: Inhaled salbutamol was used as reliever medication, and reg-
ular treatment with short-acting bronchodilators, antioxidants/mucolytics, short-acting
oral beta2 agonists, and theophylline was permitted
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Outcomes Number of exacerbations, pre-bronchodilator PEF, post-bronchodilator FEV1, SGRQ,
symptoms and breathlessness, diary card data
Notes Funding: GlaxoSmithKline
Identifier(s): unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Consecutive numbers were assigned to pa-
tients that determined the blinded treat-
ment based on a centrally generated list
with blocks of six
Allocation concealment (selection bias) Low risk Randomisation list was centrally generated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind treatment [pre-
sumed participants and personnel/investi-
gators]
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Similar withdrawal rates in each group.
ITT included 99.6% of the randomised
population (4 patients were excluded due
to a randomisation error)
Selective reporting (reporting bias) Unclear risk Unable to locate prospective trial registra-
tion to check that all outcomes were re-
ported. Author contacted who forwarded
request to GSK - no data were provided in
time for publication
Kornmann 2011
Methods Design: randomised, double-blind, placebo-controlled trial
Duration: 6 months (+ 2 weeks run-in period)
Location: 142 centres in 15 countries
Participants Participants: 1002 participants were randomised to salmeterol (334), indacaterol (333)
, and placebo (335)
Baseline characteristics
Age (mean years): salm 63, ind 63, pbo 64
%Male: salm 75, ind 72, pbo 77
% FEV1 predicted: salm 53, ind 54, pbo 53
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Pack-years (mean): salm 40, ind 40, pbo 41
Inclusion criteria: Males and females aged 40 and older; diagnosis of moderate to severe
COPD; history of at least 20 pack-years; < 80% and > 30% predicted FEV1; FEV1/
FVC < 0.70
Exclusion criteria: history of asthma; hospitalisation for COPD exacerbation in the 6
weeks beforeVisit 1 or during run-in; requiring oxygen therapy; respiratory tract infection
within 6 weeks before Visit 1 and during the run-in period; concomitant pulmonary
disease; history of long QTc syndrome or QTc interval > 450 ms for males and > 470
ms for females; clinically significant condition
Interventions 1. Salmeterol 50 bid (LABA)
2. Indacaterol 150 qd (LABA)
3. Placebo (PBO)
Inhaler device: dry powder (indacaterol in a single-dose version taken in the morning)
Allowed co-medications: Concomitant medication with inhaled corticosteroids was
allowed if stable for 1 month before screening and remained stable throughout the study;
salbutamol was provided for relief. Participants previously taking fixed combinations of
ICS and LABA were switched to equivalent ICS monotherapy
Outcomes St George’s Respiratory Questionnaire (including proportion meetingminimal clinically
important difference), trough FEV1, transition dyspnoea index, morning and evening
PEF, diary card data, vital signs and ECGs
Notes Funding: Novartis
Identifier(s): NCT00567996
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomly allocated to treat-
ment in a 1:1:1 ratio (with stratification for
smoking status) using an automated system
Allocation concealment (selection bias) Low risk Using an automated system [concealment
assumed by automatisation]
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Subject, investigator, outcomes assessor all
blind [from protocol]. Blinding was main-
tained from randomisation until database
lock unless any patient emergencies arose
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Subject, investigator, outcomes assessor all
blind [from protocol]. Blinding was main-
tained from randomisation until database
lock unless any patient emergencies arose
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal somewhat higher in placebo
group (salmeterol 15%; placebo 20.1%).
Efficacy data were analysed for the inten-
tion-to-treat (ITT) population, compris-
ing all randomised patients who received at
least one dose of the study drug. The pop-
ulation for the safety analysis comprised all
patients who received at least one dose of
the study drug
Selective reporting (reporting bias) High risk FEV1 data only given in graphical form.
No exacerbation data provided
Lapperre 2009
Methods Design: double-blind, parallel, 4-group, placebo-controlled, randomised design
Duration: 2.5 years
Location: 2 centres in the Netherlands
Participants Population: 114participantswere randomised tofluticasone (26), salmeterol/fluticasone
combination therapy (28), placebo (29), and one other arm that was not relevant to this
review (fluticasone for 6 months followed by placebo for 24 months, 31)
Baseline characteristics
Age (mean years): flut 62, salm/flut 62, pbo 59
%Male: flut 88.5, salm/flut 88, pbo 83.3
% FEV1 predicted (pre-BD): flut 57, salm/flut 55, pbo 54
Pack-years (median): flut 44, salm/flut 47, pbo 42
Inclusion criteria: aged 45 to 75 years, were current or former smokers, had smoked for
10 or more pack-years, and had lung function levels compatible with Global Initiative
for Chronic Obstructive Lung Disease (GOLD) stages II and III.
Disease (GOLD) stages II and III
Exclusion criteria: asthma and receipt of ICS within 6months before random assignment
Interventions 1. Fluticasone 500 bid (ICS)
2. Salmeterol/fluticasone 50/500 bid (LABA/ICS)
3. Placebo (PBO)
Inhaler device: Diskus dry powder
Allowed co-medications: patients could continue taking short-acting bronchodilators
Outcomes Cell counts in bronchial biopsies and sputum (primary outcome); methacholine respon-
siveness at baseline, 6, and 30 months; and clinical outcomes every 3 months
Notes Funding: Netherlands Organization for Scientific Research, Netherlands Asthma Foun-
dation, GlaxoSmithKline of The Netherlands, University Medical Center Groningen,
and Leiden University Medical Center
Identifier(s): NCT00158847
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk At entry, an independent randomisation
centre provided patient and medication
numbers by using a minimization pro-
cedure that balanced treatment groups
for centre, sex, smoking status, FEV1/
IVC 60% , and methacholine PC20 (the
provocative concentration of methacholine
that causes a 20% decrease in FEV1) 2 mg/
mL)
Allocation concealment (selection bias) Low risk An independent randomisation centre pro-
vided patient and medication numbers
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study medications were individually num-
bered, and we used Diskus dry-pow-
der inhalers (GlaxoSmithKline, Zeist, The
Netherlands) with 60 doses per inhaler; all
active treatment medication and placebo
were identical in appearance
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk The withdrawal rates were very high com-
pared to the number of events for the dif-
ferent outcomes. Per-protocol analysis used
Selective reporting (reporting bias) Low risk Data not available from the published re-
port for several outcomes but authors pro-
vided data upon request
Laptseva 2002
Methods Design: Randomised, double-blind, parallel-group study
Duration: 6 months
Location: unclear
Participants Population: 49 people were randomised to budesonide (25) and placebo (24)
Baseline characteristics
None reported - abstract only
Inclusion criteria: Patients aged between 40 and 65. FEV140-60%of predicted normal,
FEV1/VC <55%, bronchodilator reversibility of <15%
Exclusion criteria: none reported
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Laptseva 2002 (Continued)
Interventions 1. Budesonide 400 bid (ICS)
2. Placebo (PBO)
Inhaler device: not reported
Allowed co-medications: All the patients received anticholinergic drug and methylxan-
thine or short-acting B2-agent
Outcomes Number and severity of exacerbations, FEV1, FVC, diary card symptoms, PEFR
Notes Funding: unclear
Identifier(s): unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double blind [presumed par-
ticipants and personnel/investigators]
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details provided
Selective reporting (reporting bias) High risk Only abstract available. Outcomes could
not be used. Could not find contact infor-
mation for authors
Mahler 2002
Methods Design: randomised, double-blind, placebo-controlled, parallel-group,multi-centre trial
Duration: 6 months (+ 2 weeks run-in period)
Location: 65 centres in the United States
Participants Population: 674 participants were randomised to salmeterol (160), fluticasone (168),
salmeterol/fluticasone combination (165), and placebo (181)
Baseline characteristics
Age (mean years): salm 63.5, flut 64.4, salm/flut 61.9, pbo 64.0
% Male: salm 64.4, flut 61.3, salm/flut 62.4, pbo 75.1
% FEV1 predicted: salm 40, flut 41, salm/flut 41, pbo 41
Pack-years (mean): salm 52.5, flut 54, salm/flut 55, pbo 60
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Mahler 2002 (Continued)
Inclusion criteria: males and females aged 40 and older; history of at least 20 pack-
years; diagnosis of COPD; FEV1 < 65% of predicted but > 0.70 L, FEV1/FVC ratio <
70%; daily cough productive of sputum for 3 months of the year for 2 consecutive years
and dyspnoea
Exclusion criteria: current diagnosis of asthma; abnormal clinically significant ECG;
moderate or severe exacerbation during the run-in period; any significant medical dis-
order
Interventions 1. Salmeterol 50 bid (LABA)
2. Fluticasone 500 bid (ICS)
3. Salmeterol/fluticasone 50/500 bid (LABA/ICS)
4. Placebo (PBO)
Inhaler device: Diskus dry powder
Allowed co-medications: Albuterol was allowed as needed, as were stable regimens
of theophylline. Disallowed medications included oral corticosteroid use in the past 6
weeks, long-term oxygen therapy, corticosteroids and all bronchodilators
Outcomes Chronic Respiratory Disease Questionnaire, COPD exacerbations, AM pre-dose and 2-
hour post-dose FEV1, serial FEV1 over 12 hours, morning (AM) peak expiratory flow
rate (PEFR), Chronic Bronchitis Symptoms Questionnaire (CBSQ), diary card data
Notes Funding: GlaxoSmithKline
Identifier(s): GSK SFCA3006
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was stratified by reversibil-
ity and investigative site to ensure a bal-
ance between treatment groups at each site
and in terms of the number of reversible
patients [no other details, industry spon-
sored]
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind [presumed subject and inves-
tigator]
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No details provided but outcomes not sub-
ject to detection bias
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawal high and uneven between
groups (salmeterol 28%, placebo 38%).
Analyses based on the intent-to-treat (ITT)
population consisted of all randomized
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subjects who had taken at least one dose of
double-blind study drug
Selective reporting (reporting bias) Low risk All stated and expected outcomes were re-
ported except FEV1 (secondary outcome)
Mahmud 2007
Methods Design: Randomised, parallel-group study (blinding unclear)
Duration: 6 months
Location: National Institute of Diseases of Chest and Hospital, Bangladesh
Participants Population: 100 participants were randomised to salmeterol and tiotropium (unclear
how many per group)
Baseline characteristics - minimal information
Age (mean years): not reported
% Male: 91 both groups merged
% FEV1 predicted: not reported
Pack-years (mean): not reported
Inclusion criteria: patients with moderately severe COPD (definition not given)
Exclusion criteria: not described
Interventions 1. Salmeterol 50 bid (LABA)
2. Tiotropium 18 qd (LAMA)
Inhaler device: not described
Allowed co-medications: Both groups received beclomethasone 500 µg twice daily +
methylxanthines
Outcomes FEV1, health related quality of life (HRQoL), base line dyspnoea index and frequency
of COPD exacerbation. Patients were allowed to use salbutamol as per need basis
Notes Funding: unclear
Identifier(s): unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, no details
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described as double blind - no descrip-
tion of procedures
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Mahmud 2007 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described as double blind - no descrip-
tion of procedures
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 90/100 ultimately completed the study- 43
in group A and 47 in group B
Selective reporting (reporting bias) High risk Abstract only
Niewoehner 2005
Methods Design: Randomised, double-blind, parallel-group study
Duration: 6 months
Location: 26 Veteran Affairs medical centres in the United States
Participants Population: 1829 participants were randomised to tiotropium (914) and placebo (915)
Baseline characteristics
Age (mean years): tio 67.6, pbo 68.1
% Male: tio 98, pbo 99
% FEV1 predicted: tio 35.6, pbo 35.6
Pack-years (mean): tio 67.4, pbo 69.4
Inclusion criteria: age of 40 years or older, a cigarette smoking history of 10 pack-years
or more, a clinical diagnosis of COPD, and an FEV1 of 60% predicted or less and 70%
or less of the FVC.
Exclusion criteria: clinical diagnosis of asthma, a myocardial infarction within the pre-
vious 6 months, a serious cardiac arrhythmia or hospitalizations for heart failure within
the previous year, known moderate to severe renal impairment, moderate to severe symp-
tomatic prostatic hypertrophy or bladder-neck obstruction, narrow-angle glaucoma, cur-
rent radiation or chemotherapy for a malignant condition, or inability to give informed
consent. We also excluded patients who took systemic corticosteroids at unstable doses,
or in regular daily doses of 20 mg or more of prednisone (or equivalent), or who had not
fully recovered from an exacerbation for at least 30 days before the first study visit
Interventions 1. Tiotropium 18 qd (LAMA)
2. Placebo (PBO)
Inhaler device: Dry powder HandiHaler
Allowed co-medications: Patients otherwise received usual care, except for other an-
ticholinergic bronchodilators. They continued taking all other respiratory medications
(including inhaled corticosteroids and long-acting -agonists), and primary providers
were allowed to prescribe additional medications according to medical need. Primary
providers also prescribed antibiotics and systemic steroid prescriptions for exacerbations
without restrictions
Outcomes The co-primary end points were the percentage of patients with a COPD exacerbation
and the percentage of patients with a COPD-related hospitalisation
Notes Funding: Boehringer Ingelheim and Pfizer
Identifier(s): unknown
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Niewoehner 2005 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk We allocated eligible patients in equal num-
bers to receive tiotropium or placebo ac-
cording to a centrally generated blocked
randomisation list. We generated a single
randomisation and assigned blocks to cen-
tres
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding of supplies was performed at
Boehringer Ingelheim before distribution
to investigational sites. The double-blind
remained in place until all patients were
clinically complete or until a serious adverse
event required unblinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear who performed the assessment and
whether they were blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout higher in placebo but less than
15% in both groups. ’We analyzed the data
by using amodified intention-to-treat prin-
ciple. Therefore, we included all available
data for the patients with any follow-up
contact who took at least 1 capsule of study
drug in the analysis. We handled missing
data by using longitudinal data analysis
methods (spirometry), analysis of observed
data only (number of events), or analysis
methods for censored data (time-to-event
data).’
Selective reporting (reporting bias) Unclear risk Study protocol could not be located to con-
firm that all pre-defined outcomes were re-
ported
Ohar 2013
Methods Design: randomised, parallel-group study
Duration: 6 months
Location: unclear
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Ohar 2013 (Continued)
Participants Population: 639 participants were included in the analysis for salmeterol (325) and
salmeterol/fluticasone combination therapy (314), but it is unclear from the abstract
how many were randomised
Baseline characteristics
Not described, abstract only
Inclusion criteria: >40 years of age and a historical FEV1/FVC<0.7, recent event (within
14 days of randomisation) of: <10-day hospitalisation for an acute COPD exacerbation,
or exacerbation requiring treatment with oral corticosteroids (OCS) or OCS+antibiotics
in an ER, or during a physician’s office visit. If the index event was office-based, a six-
month history of hospitalizations attributed to AECOPD was also required.
Exclusion criteria: not described
Interventions 1. Salmeterol 50 bid (LABA)
2. Salmeterol/fluticasone 50/250 bid (LABA/ICS)
Inhaler device: Diskus dry powder
Allowed co-medications: not described
Outcomes Pre-dose FEV1, exacerbation outcomes
Notes Funding: unclear
Identifier(s): unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no details
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described, but both treatments were
delivered via theDiskus dry powder inhaler
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear how many were randomised and
if/how data were imputed for dropouts
Selective reporting (reporting bias) High risk Only abstract available
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Ozol 2005
Methods Design: Randomised, double-blinded and placebo-controlled design
Duration: 6 months
Location: single centre in Turkey
Participants Population: 26 people were randomised to budesonide (13) and placebo (13)
Baseline characteristics
Age (mean years): bud 64.9, placebo 65.9
% Male: bud 84.6, placebo 53.8
% FEV1 predicted: bud 61.1, placebo 57.3
Pack-years (mean): bud 45.6, placebo 44.4
Inclusion criteria: FEV1/FVCo70% and FEV1450% the predicted value, (2) reversibil-
ity with inhaled-b2-agonists (400 mg salbutamol) of less than 200 ml or less than 12% of
predicted FEV1, (3) stable COPD defined as no acute exacerbation within the preceding
3 months, (4) no history of systemic disease or other pulmonary disease, (5) no therapy
with inhaled or systemic corticosteroids within 3 months prior to entry into the study
and (6) no history of asthma or atopy
Exclusion criteria: No additional information
Interventions 1. Budesonide 400 bid (ICS)
2. Placebo (PBO)
Inhaler device: dry powder
Allowed co-medications: All of the patients were on therapy with inhaled salbutamol
and ipratropiumbromide. In nine patients, sustained-released theophyline was also being
given
Outcomes FVC, FEV1, diary card data
Notes Funding: unclear
Identifier(s): unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomised by a computer
generated, blinded randomisation list
Allocation concealment (selection bias) Low risk ‘Blinded’ randomisation list
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double blind [presumed pa-
tients and personnel/investigators]
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The cells were counted by our pathologist
who was also blinded. Not clear for other
outcomes
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk ‘The results presented are an analysis of
22 subjects (12budesonide-treated subjects
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Ozol 2005 (Continued)
and 10 placebo-treated subjects) who com-
pleted the study’. Both dropout rates were
low but uneven between groups (two were
excluded from the placebo group and one
from the budesonide group.One extra, pre-
sumed to have been randomised to placebo
[assuming equal group size at randomisa-
tion] was excluded for failure to take the
medication consistently)
Selective reporting (reporting bias) High risk Key expected outcomes missing (mortality,
serious adverse events). No reply from au-
thors by time of publication
Paggiaro 1998
Methods Design: Multicentre, randomised, placebo-controlled trial
Duration: 6 months (+ 2 week run-in)
Location: 13 European countries, New Zealand and South Africa
Participants Population: 281 participants were randomised to fluticasone (142) and placebo (139)
Baseline characteristics
Age (mean years): flut 62, placebo 64
%Male: flut 70, placebo 78
% FEV1 predicted: flut 59, placebo 55
Pack-years (mean): not reported
Inclusion criteria: Current or ex-smokers, 50-75 years with a history of smoking equiv-
alent to at least 10 pack-years and chronic bronchitis (a cough with excess sputum pro-
duction for at least 3 months in at least 2 consecutive years without any other pathology)
. Patients also had to have a history of at least one exacerbation each year for the previous
3 years that required a visit to their doctor or hospital, a high expectation, according to
the investigator, of experiencing an exacerbation during the 6-month treatment period,
a regular productive cough, a predicted FEV1 of 35-90%, a ratio of FEV1 to forced vital
capacity of 70% or less, and reversibility in FEV1 of less than 15% after inhalation of
400 µg or 800 µg salbutamol via a metered-dose inhaler or Diskhaler
Exclusion criteria: Patients with abnormal chest radiographs or who had received oral
or depot steroids, inhaled steroids of more than 500 µg daily, antibiotic therapy, had
been admitted to hospital in the 4 weeks before the study, or who were currently taking
fluticasone propionate were excluded
Interventions 1. Fluticasone 500 bid (ICS)
2. Placebo (PBO)
Inhaler device: Metered-dose inhalers, with a spacer if desired
Allowed co-medications: Patients could take short-acting 2-agonists for the relief of
symptoms as required throughout the study. Other COPD medications, such as anti-
cholinergics and xanthine derivatives, could be continued throughout the study without
dose changes
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Paggiaro 1998 (Continued)
Outcomes COPD exacerbations, FEV1, morning PEF, FVC, 6-minute walk test, Borg score, diary
card symptom scores, daily sputum volume, total adverse events, serum cortisol concen-
tration
Notes Funding: Unclear (‘code was held by the sponsor company’s statisticians’)
Identifier(s): unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random numbers were computer gener-
ated on PACT (version 2.7)
Allocation concealment (selection bias) Low risk Each investigator was given a set of four
or more sealed envelopes containing the as-
signment codes, from which they assigned
treatment, starting with the lowest number
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind [presumed pa-
tient and personnel/investigator]
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk ’We did analysis by intention to treat of
all patients who took at least one dose of
study medication’. ‘Only available data was
analysed’. Dropout uneven
Selective reporting (reporting bias) High risk Key expected outcomes not reported (mor-
tality and serious adverse events). No reply
from authors by time of publication
Pauwels 1999
Methods Design: Parallel-group, double-blind, placebo-controlled, randomised, multicenter
study
Duration: 3 years (+ 3 month smoking cessation run-in)
Location: 39 study centres in 9 European countries
Participants Population: 1277 participants were randomised to budesonide (634) and placebo (643)
Baseline characteristics
Age (mean years): bud 52.5, pbo 52.4
% Male: bud 73.5, pbo 72.2
% FEV1 predicted: bud 76.8, pbo 76.9
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Pauwels 1999 (Continued)
Pack-years (mean): bud 39.4, pbo 39.2
Inclusion criteria: Persons 30 to 65 years of age were eligible if they were currently
smoking at least five cigarettes per day and had smoked cigarettes for at least 10 years or
had a smoking history of at least 5 pack-years. The FEV1 after the use of a bronchodilator
had to be between 50 percent and 100 percent of the predicted normal value, and the
ratio of pre-bronchodilator FEV 1 to slow vital capacity had to be less than 70 percent.
The increase in FEV1 after the inhalation of 1 mg of terbutaline from a dry-powder
inhaler had to be less than 10 percent of the predicted normal value. The change in
FEV1 between the end of the first three-month period of the run-in phase and the end
of the second had to be less than 15 percent.
Exclusion criteria: Subjects with a history of asthma, allergic rhinitis, or allergic eczema
and those who had used oral glucocorticoids for more than four weeks during the preced-
ing six months were excluded. The use of inhaled glucocorticoids other than the study
medication, beta-blockers, cromones, or long-acting inhaled b2-adrenergic agonists was
not allowed
Interventions 1. Budesonide 400 bid (ICS)
2. Placebo (PBO)
Inhaler device: 1, Pulmicort; 2, dry powder turbuhaler
Allowed co-medications: The use of inhaled glucocorticoids other than the study med-
ication, beta-blockers, cromones, or long-acting inhaled beta2-adrenergic agonists was
not allowed
Outcomes Change in post-dose FEV1, serious adverse events, mortality, glucocorticoid-related side
effects, bone density
Notes Funding: Funded by a grant from Astra Draco, Lund, Sweden
Identifier(s): unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ‘Randomly assigned’. No specific details
given but industry sponsored
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind [presumed par-
ticipant and personnel/investigator]
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Central evaluator who was unaware of the
treatment received and were analyzed ac-
cording to a standardized computerized
protocol
124Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Pauwels 1999 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data on the randomised subjects were anal-
ysed on an intention-to-treat basis. With-
drawal rates under 30% and even in both
groups
Selective reporting (reporting bias) High risk Severalmissing outcomes.Couldnot locate
protocol to check that all prospectively reg-
istered outcomes were reported. Contacted
second author, no reply by time of publi-
cation
Powrie 2007
Methods Design: single-centre, double-blind, randomised, placebo-controlled trial
Duration: 12 months (+ 2 week run-in)
Location: London Chest Hospital, UK
Participants Population: 142 participants were randomised to tiotropium (69) and placebo (73)
Baseline characteristics
Age (mean years): tio 66.3, pbo 66.4
% Male: tio 69.6, pbo 56.2
% FEV1 predicted: tio 50.9, pbo 49.2
Pack-years (mean): tio 54.6, pbo 55.7
Inclusion criteria: Patients aged >40 yrs with a diagnosis of COPD (FEV1 ,80% of
the predicted value and FEV1/FVC ,70%) and a minimum 10-pack-yr smoking history
were recruited from primary care or the outpatients department of the London Chest
Hospital
(London, UK).
Exclusion criteria: patients with a history of asthma or atopy were excluded, as were
those on long-term oxygen therapy or with another clinically significant disease
Interventions 1. Tiotropium 18 qd (LAMA)
2. Placebo (PBO)
Inhaler device: HandiHaler
Allowed co-medications: Anticholinergics other than the study drugwere not permitted
during the course of the study. Otherwise, patients remained on their usual medication
Outcomes Sputum and serum cytokines were assayed by ELISA and exacerbation frequency calcu-
lated using a symptom-based diary
Notes Funding: Boehringer-Ingelheim
Identifier(s): NCT00405236
Risk of bias
Bias Authors’ judgement Support for judgement
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Powrie 2007 (Continued)
Random sequence generation (selection
bias)
Low risk Randomised [not described but industry
funded so presumed to be electronic]
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind. Tiotropium
and placebo were both given via the Hand-
iHaler device
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was high but even between groups
after 1 year (tio 30.5%, placebo 28.8%)
. Analyses were carried out using the full
analysis data set (all
randomised treated patients with efficacy
data). All randomised patients received at
least one dose of the study treatment
Selective reporting (reporting bias) Low risk The study was prospectively registered. No
results are posted on clinicaltrials.gov but
the trial publication reports the stated out-
comes
Renkema 1996
Methods Design: Parallel, double-blind, randomised, placebo-controlled study
Duration: 2 years (+ 3 month run-in)
Location: single centre in the Netherlands
Participants Population: 39 participants were randomised to budesonide (21) and placebo (18)
Baseline characteristics
Age (mean years): bud 56, pbo 54
%Male: bud 100, pbo 100
% FEV1 predicted: bud 67, placebo 60
Pack-years (mean): not reported
Inclusion criteria: Clinical diagnosis of COPD based on history (persistent dyspnoea,
mainly on exertion, without sudden attacks of dyspnoea); FEV1 less than 80% of the
predicted value; residual volume (RV) greater than 100% of the predicted value; specific
compliance expressed as a percentage of the predicted value greater than 100% after
bronchodilation; when, however, air trapping (calculated as thoracic gas volume mea-
sured by body plethysmography minus functional residual capacity measured with an
indicator gas) was greater than 1.5 L Csp was allowed to be less than 100% of predicted;
no signs of allergy (negative skin test results, total serum IgE <200 IU/mL, eosinophils
in peripheral blood <250xl03/mL); and stable phase of the disease.
Exclusion criteria: Excludedwere patients older than 70 years at entry, patients receiving
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continuous corticosteroid therapy, and patients with severe concomitant disease, likely
to interfere with the purpose of the study. All patients had ai-antitrypsin serum levels
within the normal range. All patients were smokers or ex-smokers. Smoking history was
expressed as cigarette years
Interventions 1. Budesonide 800 bid (ICS) plus placebo tablet once daily
2. Placebo (PBO) plus placebo tablet once daily
Inhaler device: metered-dose through a 750-ml spacer
Allowed co-medications: Throughout the study, patients were maintained on regimens
of their usual bronchodilator medication, consisting of anticholinergics. beta-agonists,
theophylline, or a combination of these drugs
Outcomes FEV1, compliance, symptom scores, fasting morning plasma cortisol levels
Notes Funding: Grants from the Netherlands Asthma Foundation, ASTRA BV Holland, and
AB DRACO Sweden.
Identifier(s): unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk By computerized randomisation, stratified
for smoking
Allocation concealment (selection bias) Low risk Allocated blindly
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind [presumed patients and per-
sonnel/investigators]
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Uneven withdrawal rates, no description of
imputation to account for dropout
Selective reporting (reporting bias) High risk Key expected outcomes not reported (mor-
tality and adverse events). No reply from
authors by time of publication
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Rennard 2009
Methods Design: randomised, double-blind, double-dummy, parallel-group, active- and placebo-
controlled, multi-centre study
Duration: 12 months (+ 2 weeks run-in period)
Location: 237 sites in the USA, Europe and Mexico
Participants Population: 1964 participants were randomised to formoterol (495), formoterol/budes-
onide at two doses (494 and 494), and placebo (481)
Baseline characteristics
Age (mean years): form 62.9, form/bud320 63.2, form/bud160 63.6, pbo 62.9
% Male: form 65.3, form/bud320 62.3, form/bud160 62.8, pbo 65.3
% FEV1 predicted: form 39.3, form/bud320 38.6, form/bud160 39.6, pbo 40.8
Pack-years (median): form 40, form/bud320 40, form/bud160 40, pbo 40
Inclusion criteria: Males and females aged 40 and older; moderate to severe COPD for
2+ years; history of at least 10 pack-years
Exclusion criteria: history of asthma or seasonal rhinitis before age 40; significant/
unstable cardiovascular disorder; significant respiratory tract disorder other than COPD;
homozygous alpha1-antitrypsin deficiency or other clinically significant co-morbidities
precluding participation
Interventions 1. Formoterol 12 bid (LABA)
2. Formoterol/budesonide 9/320 (LABA/ICS)
3. Formoterol/budesonide 9/160 (LABA/ICS)
4. Placebo (PBO)
Inhaler device: dry powder
Allowed co-medications: Salbutamol was allowed as relief medication. Previous inhaled
corticosteroids were discontinued, and disallowed medication included long-acting anti-
cholinergics; inhaled LABAs or SABAs (other than salbutamol); oral beta-adrenoreceptor
agonists; ephedrine; leukotriene receptor agonists; xanthine derivatives except for short-
term use
Outcomes St George’s Respiratory Questionnaire (SGRQ), COPD exacerbations, pre-dose FEV1,
one hour post-dose FEV1, morning and evening PEF
Notes Funding: AstraZeneca
Identifier(s): NCT00206167
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Designed to conform with the Declaration
ofHelsinki, and was consistent with the In-
ternational Conference on Harmonisation
and Good Clinical Practice and applicable
regulatory requirements
Allocation concealment (selection bias) Low risk Designed to conform with the Declaration
ofHelsinki, and was consistent with the In-
ternational Conference on Harmonisation
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and Good Clinical Practice and applicable
regulatory requirements
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk To maintain blinding, patients received
both a pressurized metered-dose inhaler
(pMDI) and a dry powder inhaler(DPI)
containing either active treatment or dou-
ble-dummy placebo (PL) as appropriate
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Included outcomes unlikely to be affected
by detection bias
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawal even but high in both groups
[formoterol 31.7%, placebo 36.4%). The
efficacy analysis set (i.e. intent-to-treat pop-
ulation) included all randomized patients
who received at least one dose of random-
ized study medication and contributed suf-
ficient data for at least one co-primary or
secondary efficacy endpoint to be calcu-
lated during the randomized treatment pe-
riod. The safety analysis population in-
cluded all randomized patients who re-
ceived at least one dose of randomized
study medication and from whom any
post-randomisation data were available
Selective reporting (reporting bias) High risk Serial spirometry was only reported for a
subset. Exacerbations not reported in a way
that could be included in meta-analysis
Rossi 2002
Methods Design: multi-centre, randomised, parallel-group, placebo-controlled study
Duration: 12 months (+ 10 to 21 days run-in period)
Location: 81 centres worldwide
Participants Population: 645 participants were randomised to formoterol at two different doses (211
and 214), and placebo (220)
Baseline characteristics
Age (mean years): form12 63, form24 62, pbo 63
%Male: form12 87.2, form24 83.2, pbo 79.5
% FEV1 predicted: not reported
Pack-years (mean): not reported
Inclusion criteria: males and females aged 40 and older; diagnosis of COPD; history
of at least 10 pack-years; FEV1 < 70% predicted; FEV1/FVC ration < 0.89
Exclusion criteria: history of asthma; respiratory tract infection in the past month; need
for long-term oxygen therapy
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Rossi 2002 (Continued)
Interventions 1. Formoterol 12 bid (LABA)
2. Formoterol 24 bid (LABA)
3. Placebo (PBO)
Inhaler device: dry powder
Allowed co-medications: Stable participants receiving inhaled corticosteroid treatment
were instructed to remain on that treatment throughout the study; Salbutamol (up to 8
puffs/d) was allowed as the rescue medication. Short courses of antibiotics, oral corticos-
teroids and/or oxygen were permitted in case of exacerbation or respiratory infection up
to two times during the study. All other bronchodilating medications were discontinued
Outcomes St George’s Respiratory Questionnaire (SGRQ), COPD exacerbations, standardised
AUC for FVC, absolute FEV1 values at all time points, predose FEV1, morning PEF,
daily total symptom score, vital signs, ECG
Notes Funding: Novartis
Identifier(s): unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomized, parallel-group study [no spe-
cific details, industry sponsored]
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk F12, F24, and PL were administered in a
double-blind manner
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Nodetails provided but outcomes included
in meta-analysis unlikely to be subject to
detection bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal rates were relatively similar
across the three groups (formoterol 12 24.
6%, formoterol 24 18.7%, placebo 26.8%)
.The statistical analysis was carried out ac-
cording to the intent-to-treat principle
Selective reporting (reporting bias) Low risk All outcomes stated and expected were re-
ported in detail (except FEV1 [secondary]
as AUC outcome)
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Schermer 2009
Methods Design: randomised, double blind, double dummy, placebo-controlled phase IV trial
Duration: 3 years (preceded by an optional smoking cessation stage, 3 month washout
period and 14 day pre-treatment phase)
Location: 44 general practices in the Netherlands
Participants Population: 190 participants were randomised to fluticasone (94) and placebo (96)
Baseline characteristics
Age (mean years): flut 58.4, pbo 59.6
% Male: flut 73, pbo 68
% FEV1 predicted: flut 63.2, pbo 65.7
Pack-years (mean): flut 30.2, pbo 26.5
Inclusion criteria: Age 35-75 years; current or former smoker; chronic dyspnoea, spu-
tum production and cough for at least three consecutive months per year during the
previous two years; post-bronchodilator forced expiratory volume in one second (FEV1)
<90% of the predicted value, and/or post-bronchodilator FEV1/FVC (forced vital ca-
pacity) of the predicted value <88% for men and <89% for women.
Exclusion criteria: Post-bronchodilator FEV1 <40% of predicted and/or a history of
asthma, allergic rhinitis, or allergic eczema
Interventions 1. Fluticasone 500 bid (ICS)
2. Placebo (PBO)
Inhaler device: Diskus dry powder inhaler. Unclear from trial report whether the placebo
was administered to match the fluticasone inhaler or the other active treatment which
was delivered as effervescent tablets dissolved in a glass of tap
Allowed co-medications: not reported
Outcomes Rate of exacerbations and quality life as measured with the interviewer-administered
version of the Chronic Respiratory Questionnaire (CRQ)
Notes Funding: Dutch Council for Health Insurances, with complementary funding by the
Netherlands Asthma Foundation (authors had received various GSK and other pharma-
ceutical research grants)
Identifier(s): unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk An independent statistician generated a
randomisation list based on a block size of
three for treatment allocation to balance the
three treatment arms by study centre
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Neither investigators nor patients were
aware of the group assignment. Placebo de-
scribed as ‘matching’
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Schermer 2009 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Neither investigators nor patients were
aware of the group assignment [presuming
the investigators were those doing the out-
come assessments]
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropout was high in both groups. The pri-
mary analyses were done on an intention-
to-treat basis. Additional per protocol anal-
yseswere done onpatientswith a trialmedi-
cation compliance rate >80%.Unclear how
data were imputed or who was included in
the ITT population
Selective reporting (reporting bias) High risk All outcomes stated in the protocol were
reported but some key expected outcomes
were missing (serious adverse events and
pneumonia). No reply from author by time
of publication
SCO100470
Methods Design: multi-centre, randomised, double-blind, double dummy, parallel group design
Duration: 6 months (+ run-in of unclear duration)
Location: Conducted at 135 centres in 20 countries
Participants Population: 1050 people were randomised to fluticasone (532) and fluticasone/salme-
terol combination (518)
Baseline characteristics
Age (mean years): salm 63.7, flut/salm 63.5
% Male: salm 77.3, flut/salm 78.4
% FEV1 predicted: not reported
Pack-years (mean): not reported
Inclusion criteria: Male or female, aged 40-80 years with an established history of
GOLD stage II COPD; poor reversibility of airflow obstruction (defined as ≤ 10%
increase in FEV1 as a percentage of the normal predicted value); a minimum score of ≥
2 on the Modified Medical Research Council Dyspnoea Scale, and a smoking history of
at least 10 pack years. In addition, subjects had to achieve a composite symptom score
of ≥ 120 (out of 400 maximum score, measured using visual analogue scales) on at least
4 of the last 7 days of the run-in period, and to have a Baseline Dyspnoea Index (BDI)
score of ≤ 7 units at Visit 2
Exclusion criteria: Subjects would be excluded if they had asthma or atopic disease,
had a lung disease likely to confound the drug response other than COPD, had a recent
exacerbation (within 4 weeks or screening or during run-in); were receiving long-term
oxygen therapy or pulmonary rehabilitation or had taken tiotropium bromide, inhaled
corticosteroids or anti-leukotriene medication within 14 days of visit 1
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SCO100470 (Continued)
Interventions 1. Salmeterol 50 bid (LABA)
2. Salmeterol/fluticasone 50/250 bid (LABA/ICS)
Inhaler device: Diskus accuhaler
Allowed co-medications: Not reported
Outcomes Transitional Dyspnoea Index (TDI), change from baseline in trough FEV1, change from
baseline in trough FVC and FVC/FEV1 ratio, TDI focal score, change from baseline
in post-dose FEV1, FVC and FVC/FEV1 ratio, change from baseline in mean morning
PEF, change from baseline in St George’s Respiratory Questionnaire
Notes Funding: GlaxoSmithKline
Identifier(s): GSK SCO100470
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Described as randomised [assumed to ad-
here to usual GSK methodology]
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind [presumed par-
ticipants and personnel/investigators]
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described - only results summary avail-
able
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout low and even between groups
(11.4% vs. 13.9%). The ITT (Intent to
treat) Population (all subjects randomised
and confirmed as having received at least
one dose of double-blind study medica-
tion) was the primary population for analy-
sis of all efficacy and health outcomes vari-
ables; the Safety Population (identical to
the ITT Population) was used for analysis
of all safety variables
Selective reporting (reporting bias) Low risk All stated outcomes were reported and no
expected outcomes were missing
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SCO30002
Methods Design: Multicentre, Randomised, Double-Blind, Parallel Group, Placebo-Controlled
Study
Duration: 12 months (+ 2 week run-in)
Location: 49 centres in Italy and 7 in Poland
Participants Population: 387 participants were randomised to fluticasone (131), fluticasone/salme-
terol combination (131), and placebo (125)
Baseline characteristics
Age (mean years): flut 64.6, flut/salm 63.9, pbo 65.7
% Male: flut 83.2, flut/salm 84.0, pbo 80.0
% FEV1 predicted: not reported
Pack-years (mean): not reported
Inclusion criteria: Male or female subjects aged > 40 years with an established clinical
history of COPD; subjects who demonstrated at Visit 1 a pre-bronchodilator baseline
FEV1/VC <88% for men and <89% for women of predicted normal values and FEV1
≤70% of predicted normal value, but >800mL; subjects who demonstrated at Visit 1,
poor reversibility of airflow obstruction, defined as an increase of FEV1 <10% of the
normal predicted FEV1 value (or <200 ml from baseline), 30 minutes after inhalation
of 400 µg salbutamol via MDI;. current or ex-smokers with a smoking history of at least
10 pack-years
Exclusion criteria: As above
Interventions 1. Fluticasone 500 bid (ICS)
2. Salmeterol/fluticasone 50/500 bid (LABA/ICS)
3. Placebo (PBO)
Inhaler device: metered dose
Allowed co-medications: not reported
Outcomes COPD exacerbations, clinic FEV1, VC, FEV1/VC, daily record card symptoms, PEFR,
distance walked in the six minute walk test (SWT), perceived breathlessness before and
after SWT, quality of life (SGRQ), use of relief medication, adverse events, SAEs on
therapy
Notes Funding: GlaxoSmithKline
Identifier(s): GSK SCO30002
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised to treatment. No details given
but assumed to adhere to GSK methodol-
ogy
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind [presumed par-
ticipants and personnel/investigators]
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SCO30002 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout high at 26% and 32% for ICS
and placebo respectively but even. The Sa-
fety population/Intent-to-treat (ITT) pop-
ulation consisted of all randomised patients
who took study medication (all of those
randomised)
Selective reporting (reporting bias) Low risk All outcomes stated in the GSK summary
were reported in detail
SCO40041
Methods Design: Randomized, double-blind parallel group trial
Duration: 3 years
Location: 31 centres in the United States
Participants Population: 186 people were randomised to salmeterol (94) and fluticasone/salmeterol
combination (92)
Baseline characteristics
Age (mean years): salm 65.9, flut/salm 65.4
% Male: salm 62.8, flut/salm 59.8
% FEV1 predicted: not reported
Pack-years (mean): not reported
Inclusion criteria: Male/female subjects with an established clinical history of COPD
(including a history of exacerbations), a baseline (pre-bronchodilator) FEV1 < 70% of
the predicted normal value, a baseline (pre-bronchodilator) FEV1 / FVC ratio 70%,
have at least one evaluable native hip and have a smoking history of ≥ 10 pack-years.
Exclusion criteria: No information
Interventions 1. Salmeterol 50 bid (LABA)
2. Salmeterol/fluticasone 50/250 bid (LABA/ICS)
Inhaler device: Diskus
Allowed co-medications: no information
Outcomes Change in bone mineral density at the lumbar spine and hip, adverse events, serious
adverse events, fatal SAEs
Notes Funding: GlaxoSmithKline
Identifier(s): GSK SCO40041
Risk of bias
Bias Authors’ judgement Support for judgement
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SCO40041 (Continued)
Random sequence generation (selection
bias)
Low risk Randomised to treatment [no specific in-
formation but assumed to adhere to GSK
methods]
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind [presumed participant and
personnel/investigator]
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawal very high in both groups (39
and 41%)
Selective reporting (reporting bias) Low risk All outcomes described in the GSK sum-
mary were reported
Senderovitz 1999
Methods Design: Placebo-controlled, randomised, double-blind multi-centre trial
Duration: 6 months (+ 2 week prednisolone run-in)
Location: 5 centres in Denmark
Participants Population: Unclear how many people were randomised. 26 were evaluable in the
budesonide (14) and placebo (12) groups
Baseline characteristics
Age (mean years): bud 58.5, pbo 62.5
% Male: bud 57, pbo 50
% FEV1 predicted: not reported
Pack-years (mean): not reported
Inclusion criteria: Outpatients aged 18-75 years with stable COPD were included.
FEV1, forced vital capacity (FVC) < 0.7, a post-bronchodilator FEVl < 70%of predicted,
FEVl >40% of predicted and an increase in FEVl < 15% after inhalation of O-5 mg
terbutaline
Exclusion criteria: Clinical evidence of asthma (e.g. pollen season related symptoms,
exercise-induced symptoms only and significantly elevated levels of eosinophils and IgE)
, a history of atopy (hay fever and/or atopic dermatitis), treatment with inhaled corti-
costeroids within the last 6 months, treatment with oral corticosteroids, cromoglycate
or nedocromil within the last 4 weeks, other systemic disease making compliance and
participation in the study difficult, pregnancy and breast feeding, and an increase in FEV,
>30% of baseline after 2 weeks of prednisolone treatment
Interventions 1. Budesonide 400 bid (ICS)
2. Placebo (PBO)
Inhaler device: Spirocort Turbuhaler
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Senderovitz 1999 (Continued)
Allowed co-medications: not reported
Outcomes FEV1, exacerbations, adverse events and symptom scores
Notes Funding: not reported
Identifier(s): unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Reversible patients with 15% < AFEVl <
30% of baseline and irreversible patients
with AFEV, < 15% were separately ran-
domized
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind [presumed par-
ticipants and personnel/investigators]
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 26 out of 37 were evaluable (12 in placebo
group, 14 in active group - 30% dropout
overall). Number randomised and number
of dropouts not provided for each group.
ITT not adopted
Selective reporting (reporting bias) High risk Several key expected outcomes not re-
ported (mortality, adverse events, with-
drawal per group). Author contacted but
not able to provide data
Shaker 2009
Methods Design: Randomised, double-blinded, placebo-controlled, parallel-group, single-centre
study
Duration: 2 to 4 years (+ 2 week prednisolone run-in)
Location: single centre in Denmark
Participants Population: 254 participants were randomised to budesonide (127) and placebo (127)
Baseline characteristics
Age (mean years): bud 63.6, pbo 63.6
% Male: bud 62.2, pbo 54.3
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Shaker 2009 (Continued)
% FEV1 predicted: bud 51, placebo 53
Pack-years (mean): bud 56, pbo 56
Inclusion criteria: Patients aged 50-80 years were eligible if they were current smokers
with a clinical diagnosis of COPD for not less than 2 years. All patients should have a
significant smoking history of at least 10 cigarettes per day during the last 6 months and
a previous history of at least 20 pack-years. Ex-smokers were excluded. Baseline lung
function criteria were: FEV1 between 35% and 70% of predicted (pre-bronchodilator)
, and FEV1/forced vital capacity (FEV1/FVC) ≤60%
Exclusion criteria: Reversibility of≥12% and 200 mL in FEV1 from baseline values,
15 minutes after inhalation of 1 mg terbutaline or ≥15% and 300 mL after 2 weeks
on oral prednisolone (25 mg) was an exclusion criterion. Patients were also excluded if
they: had any severe concomitant disease; had an exacerbation within 30 days prior to
the first visit; received oral steroids for more than 4 weeks within 6 months of the first
visit; or were on long-term oxygen therapy
Interventions 1. Budesonide 400 bid (ICS)
2. Placebo (PBO)
Inhaler device: Pulmicort Turbuhaler
Allowed co-medications: Bronchodilators, mucolytics, and short courses of oral cor-
ticosteroids (maximum 3 courses of 4-week duration per year) and antibiotics were al-
lowed during the study
Outcomes 15th percentile density (PD15), change over time in the relative area of emphysema at a
threshold of -910 Hounsfield units (RA-910), FEV1, diffusion capacity (DLCO), and
number of exacerbations
Notes Funding: AstraZeneca
Identifier(s): unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were allocated into either group in
a proportion of 1:1 by block randomisation
using a random sequence generated by a
computer program at AstraZeneca
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind. To maintain blinding all
Turbuhalers were of identical appearance
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
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Shaker 2009 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk High proportion of dropouts in both
groups (43% intervention and 49%
placebo)
Selective reporting (reporting bias) Low risk Couldn’t locate protocol to check that all
prospectively registered outcomes were re-
ported but authors provided all relevant
outcomes upon request
Sharafkhaneh 2012
Methods Design: Randomised, double-blind, double-dummy, parallel-group, multi-centre study
Duration: 12 months (+ 2 week run-in)
Location: 180 study sites in the United States, Central and South America, and South
Africa
Participants Population: 1219 participants were randomised to formoterol (404) and two doses of
formoterol/budesonide combination (407 and 408)
Baseline characteristics
Age (mean years): form 62.5 ,form/bud320 63.8, form/bud160 62.8
% Male: form 56.8 ,form/bud320 64.4, form/bud160 64.7
% FEV1 predicted: form 37.5, form/bud320 37.9, form/bud160 37.6
Pack-years (mean): form 43, form/bud320 46, form/bud160 44
Inclusion criteria: Patients were current smokers or ex-smokers with a smoking history
of 10 pack-years, aged 40 years, with a clinical diagnosis of COPDwith symptoms for >2
years. Patients were required to have a history of 1 COPD exacerbation requiring treat-
ment with a course of systemic corticosteroids, antibiotics, or both, within 12 months
before screening (visit 1) and documented use of an inhaled short-acting bronchodilator
as rescue medication. At screening, a pre-bronchodilator FEV1 of 50% of predicted
normal and a pre-bronchodilator FEV1/FVC of <70% also were required.
Exclusion criteria: Exclusion criteria included current, previous (within past 60 days)
, or planned enrolment in a COPD pulmonary rehabilitation program, treatment with
oral corticosteroids, and incidence of a COPD exacerbation or any other significant
medical diagnosis between the screening and randomisation visits
Interventions 1. Formoterol 9 BID (LABA)
2. Formoterol/budesonide 9/320 BID (LABA/ICS)
3. Formoterol/budesonide 9/160 BID (LABA/ICS)
Inhaler device: 1, dry powder; 2 and 3 pressurised metered dose
Allowed co-medications: Aalbuterol pMDI 90 mg 2 inhalations) was provided for as-
needed use during screening and run-in, and throughout the study
Outcomes COPD exacerbations, FEV1, FVC, morning and evening PEF, diary card symptoms,
rescue medication use, BODE index, exercise capacity, health-related quality of life
(SGRQ), adverse events
Notes Funding: AstraZeneca
Identifier(s): NCT00419744, AZ D589CC00003
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Sharafkhaneh 2012 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Assignments were made sequentially by in-
teractive voice response system following
a computer generated allocation schedule
produced in advance
Allocation concealment (selection bias) Low risk Assignments were made sequentially by in-
teractive voice response system following
a computer generated allocation schedule
produced in advance
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Tomaintain patient and investigator blind-
ing, all active treatments were provided
in blinded treatment kits. Patients in the
budesonide/formoterol pMDI groups re-
ceived a placebo DPI and those in the
formoterol DPI group received a placebo
pMDI
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk The withdrawal rates were relatively even
but high, especially compared to the low
event rates for the outcomes of interest
Selective reporting (reporting bias) Low risk All outcomes stated in the protocol were
reported in detail
SLMF4010
Methods Design: multi-centre, randomised, parallel-group, placebo-controlled, double-blind
study
Duration: 6 months (run-in not defined)
Location: 9 centres in France
Participants Population: 34 participants were randomised to salmeterol (17) and placebo (17)
Baseline characteristics
Age (mean years): salm 62.9, pbo 64.6
% Male: salm 94.1, pbo 82.4
% FEV1 predicted: not reported
Pack-years (mean): not reported
Inclusion criteria: males and females aged 40 and older; history of at least 20 pack-
years; diagnosis of COPD; FEV1 > 60% of theoretical value, FEV1/TLC ratio > 75%
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SLMF4010 (Continued)
in absolute value and > 85% of theoretical value, FEV1 reversibility > 12% and > 200
mL 20 minutes after 400 µg of salbutamol
Exclusion criteria: history of asthma or allergy including non-respiratory signs
(bronchial cancer, thoracic surgery, etc.); severe cardiovascular disease; exacerbation and/
or other acute respiratory disease within 4 weeks before enrolment
Interventions 1. Salmeterol 50 bid (LABA)
2. Placbeo (PBO)
Inhaler device: dry powder
Allowed co-medications: Disallowed medications included long-term oxygen therapy;
inhaled or systemic corticosteroids and LABAs or theophyllines within 4 weeks of en-
rolment
Outcomes StGeorge’s Respiratory Questionnaire (SGRQ), COPD exacerbations, length of hospital
stay, variations in IC, FRC, FEV1, FIV1 and total lung capacity (post-salbutamol - pre-
salbutamol), exercise capacity, use of rescue medication, tobacco status
Notes Funding: GlaxoSmithKline
Identifier(s): GSK SLMF4010
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised and stratified on tobacco sta-
tus [no other details, industry sponsored]
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind (presumed subject and inves-
tigator)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No details provided. Included outcomes
unlikely to be subject to detection bias
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawal very high in both groups [41.
2% each]. The ITT population included
all randomised subjects having received at
least one dose of study medication and for
whom the assessment data for at least one
assessment criterion was available and was
analysed based on treatment allocated. Sa-
fety population consisted of all randomised
subjects having received at least one dose of
study medication and was analysed based
on treatment really received
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SLMF4010 (Continued)
Selective reporting (reporting bias) High risk Quality of life [primary outcome] and
trough FEV1 [secondary] were not re-
ported in a way that could be included in
meta-analysis. All other outcomes reported
and included
SPARK 2013
Methods Design: randomised, double-blind, parallel-group study
Duration: 64 weeks
Location: 345 study locations
Participants Population: 2224 participants were randomised to open-label tiotropium (742), gly-
copyrronium (741), and a combination therapy not relevant to this review (741)
Baseline characteristics
Age (mean years): gly 63.1, tio 63.6
% Male: gly 73.2, tio 75.0
% FEV1 predicted: not reported
Pack-years (mean): not reported
Inclusion criteria: Male or female adults aged ≥40 years, who had signed an informed
consent form prior to initiation of any study-related procedure; severe to very severe
ChronicObstructive PulmonaryDisease COPD (Stage III or IV) according to theGlobal
Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines 2008; current
or ex-smokers with a smoking history of at least 10 pack years (Ten pack-years were
defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20 years); post-
bronchodilator Forced Expiratory Volume in one second ( FEV1) <50% of the predicted
normal value, and post-bronchodilator FEV1/ Forced Vital Capacity (FVC) <0.70 at
Visit 2; documented history of at least 1 COPD exacerbation in the previous 12 months
that required treatment with systemic glucocorticosteroids and/or antibiotics
Exclusion criteria: Pregnant women or nursing mothers; women of child-bearing po-
tential; requiring long term oxygen therapy;COPD exacerbation that required treatment
with antibiotics, systemic steroids (oral or intravenous) or hospitalisation in the 6 weeks
prior to visit 1; respiratory tract infection within 4 weeks prior to visit 1; concomitant
pulmonary disease; lung lobectomy, or lung volume reduction or lung transplantation;
clinically relevant laboratory abnormality or a clinically significant condition; history of
asthma, allergic rhinitis, eczema or alpha1 antitrypsin deficiency; contraindication for
study drugs
Interventions 1. Glycopyrronium 50 qd (LAMA)
2. Tiotropium 18 qd (LAMA) - open-label
Inhaler device: Glycopyrronium was delivered via a Novartis single-dose dry powder
inhaler, and tiotropium was delivered open-label via the HandiHaler
Allowed co-medications: Salbutamol could be taken as needed throughout the study;
Outcomes The primary outcome was rate of moderate/severe COPD exacerbations. Secondary
outcomes included pre-dose FEV1 and FVC, rescue medication use, and the St George’s
Respiratory Questionnaire
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SPARK 2013 (Continued)
Notes Funding: Novartis
Identifier(s): NCT01120691
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised, not defined but industry
funded
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding procedures were sound, but
tiotropium was delivered open label which
introduced bias for these comparisons.
Double Blind (Subject, Caregiver, Investi-
gator, Outcomes Assessor)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding procedures were sound, but
tiotropium was delivered open label which
introduced bias for these comparisons.
Double Blind (Subject, Caregiver, Investi-
gator, Outcomes Assessor)
Incomplete outcome data (attrition bias)
All outcomes
Low risk The full analysis set included over 99% of
the randomised population. 25% dropped
out overall, and dropout was relatively even
across groups (24 and 27%)
Selective reporting (reporting bias) Low risk Outcomes were fully reported on clinical-
trials.gov
Szafranski 2003
Methods Design: randomised, double-blind, placebo-controlled, parallel-group, multi-centre
study
Duration: 12 months (+ 2 weeks run-in period)
Location: 89 centres from 11 countries
Participants Population: 812 participants were randomised to formoterol (201), budesonide (198),
formoterol/budesonide combination (208), and placebo (205)
Baseline characteristics
Age (mean years): form 63, bud 64, form/bud 64, pbo 65
%Male: form 76, bud 80, form/bud 76, pbo 83
% FEV1 predicted: form 36, bud 37, form/bud 36, pbo 36
Pack-years (mean): form 45, bud 44, form/bud 44, pbo 45
Inclusion criteria: males and females aged 40 and older; symptoms for 2+ years; history
of at least 10 pack-years
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Szafranski 2003 (Continued)
Exclusion criteria: history of asthma or seasonal rhinitis before 40 years of age; relevant
cardiovascular disorders; use of beta-blockers; current respiratory tract disorders other
than COPD or any other significant diseases or disorders; requiring regular use of oxygen
therapy; exacerbation during run-in
Interventions 1. Formoterol 12 bid (LABA)
2. Budesonide 400 bid (ICS)
3. Formoterol/budesonide 9/320 bid (LABA/ICS)
4. Placebo (PBO)
Inhaler device: Dry powder turbuhaler
Allowed co-medications: terbutaline (0.5 mg) as reliever. Disallowed medication in-
cluded parenteral steroids, oral steroids, antibiotics and nebulised treatment from4weeks
before; inhaled steroids from 2 weeks before; inhaled long-acting beta2-agonists from
48 hours before; inhaled short-acting beta2-agonists from 6 hours before; other bron-
chodilators from 6 to 48 hours before
Outcomes St George’s Respiratory Questionnaire (SGRQ), COPD exacerbations, FEV1, vital ca-
pacity, morning and evening PEF, diary card data
Notes Funding: AstraZeneca
Identifier(s): AZ SD-039-CR-0629
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A total of 812 patients were randomised
[no other details, industry sponsored]
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind [presumed subject and inves-
tigator]
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No details provided. Inlcuded outcomes
unlikely to be affected by detection bias
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawal high and uneven between
groups (formoterol 31.8%, placebo 43.
9%). An intention-to-treat analysis was
used
Selective reporting (reporting bias) High risk Quality of life [primary] stated as outcome
but not reported in enough detail to in-
clude in meta-analysis
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Tashkin 2008 [SHINE]
Methods Design: randomised, double-blind, double-dummy, placebo-controlled, parallel-group,
multicenter study
Duration: 6 months (+ 2 weeks run-in period)
Location: 194 centres in the USA, Czech Republic, the Netherlands, Poland and South
Africa
Participants Population: 1704 participants were randomised to formoterol (284), budesonide (275)
, three doses of formoterol/budesonide combination (281, 277 and 287, one of which
was not included in the review as they were delivered in separate inhalers), and placebo
(300)
Baseline characteristics
Age (mean years): form 63.5, bud 63.4, form/bud160 63.6, 1form/bud320 63.1, pbo
63.2
% Male: form 65.5, bud 67.6, form/bud160 64.4, 1form/bud320 67.9, pbo 69
% FEV1 predicted: form 39.6, bud 39.7, form/bud160 39.9, 1form/bud320 39.1, pbo
41.3
Pack-years (median): form 40, bud 41, form/bud160 40, 1form/bud320 40, pbo 40
Inclusion criteria: male and female current or former smokers; history of at least 10
pack-years; clinical diagnosis of COPD; 40+ years; symptoms for longer than 2 years; at
least one exacerbation treated with oral corticosteroids and/or antibacterials within 1 to
12 months before screening
Exclusion criteria: history of asthma or seasonal rhinitis before age 40; significant/
unstable cardiovascular disorder; significant respiratory tract disorder other than COPD;
homozygous alpha1-antitrypsin deficiency or other clinically significant co-morbidities
precluding participation
Interventions 1. Formoterol 12 bid (LABA)
2. Budesonide 320 bid (ICS)
3. Formoterol/budesonide 9/160 bid in one inhaler (LABA/ICS)
4. Formoterol/budesonide 9/320 bid in one inhaler (LABA/ICS)
5. Placebo (PBO)
Inhaler device: dry powder
Allowed co-medications: Allowed medications were ephedrine-free antitussives and
mucolytics; nasal corticosteroids; stable-dose non-nebulised ipratropium; cardioselective
beta-adrenoceptor antagonists; salbutamol as rescue; oral steroids, xanthines, inhaled
beta-agonists and ipratropium as medication for exacerbations. Medications disallowed
during the study period were long-acting anticholinergics; inhaled LABAs or SABAs
(other than salbutamol); oral beta-adrenoreceptor agonists; ephedrine; leukotriene re-
ceptor agonists and xanthine derivatives except for short-term use
Outcomes St George’s Respiratory Questionnaire (SGRQ) including number of people reaching
threshold for minimal clinically important difference from baseline (4 units), COPD
exacerbations per patient year, pre-dose fFEV1 and 1-hour post-dose FEV1, dyspnoea,
morning and evening PEF
Notes Funding: AstraZeneca
Identifier(s): NCT00206154, AZ D5899C00002
Risk of bias
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Tashkin 2008 [SHINE] (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Eligable patients were randomized in bal-
anced blocks according to a computer-gen-
erated randomisation scheme at each site
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk To maintain blinding, patients received
both a pressurized metered-dose inhaler
(pMDI) and a dry powder inhaler (DPI)
containing either active treatment or
placebo (PL), or combinations of active
treatment and placebo, as appropriate
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ECG results were evaluated by a cardiolo-
gist in a blinded fashion through an inde-
pendent ECG service provider
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal rates were similar (21.5% for-
moterol, 25.7% placebo) and ’the efficacy
analysis set included all randomised pa-
tients who received at least one dose of
study medication and contributed suffi-
cient data for at least one co-primary or sec-
ondary efficacy endpoint’
Selective reporting (reporting bias) Low risk All stated outcomes were reported in full
and included in the quantitative synthesis
Tashkin 2008a [UPLIFT]
Methods Design: randomised, double-blind, parallel-group trial
Duration: 4 years
Location: 487 investigational centres in 37 countries
Participants Population: 5933 participants were randomised to tiotropium (2987) and placebo
(3006)
Baseline characteristics
Age (mean years): tio 64.5, pbo 64.5
% Male: tio 75.4, pbo 73.9
% FEV1 predicted: tio 39.5, pbo 39.3
Pack-years (mean): tio 49.0, pbo 48.4
Inclusion criteria: diagnosis of COPD, an age of 40 years or more, a smoking history
of at least 10 pack-years, a post-bronchodilator FEV1 of 70% or less of the predicted
value, and an FEV1 of 70% or less of the FVC (after supervised administration of 80
µg of ipratropium, followed by 400 µg of albuterol 60 minutes later).
146Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Tashkin 2008a [UPLIFT] (Continued)
Exclusion criteria: history of asthma, a COPD exacerbation or respiratory infection
within 4 weeks before screening, a history of pulmonary resection, use of supplemental
oxygen for more than 12 hours per day, and the presence of a coexisting illness that could
preclude participation in the study or interfere with the study results
Interventions 1. Tiotropium 18 qd (LAMA)
2. Placebo (PBO)
Inhaler device: HandiHaler
Allowed co-medications: All respiratory medications, except other inhaled anticholin-
ergic drugs, were permitted during the trial
Outcomes The two co-primary end points were the yearly rate of decline in the mean FEV1 be-
fore the use of a study drug and short-acting bronchodilators in the morning (pre-
bronchodilator) and after the use of a study drug (post-bronchodilator) from day 30
(steady state) until completion of double-blind treatment. Secondary outcome measures
included the rate of decline in the mean forced vital capacity (FVC) and slow vital ca-
pacity (SVC); health-related quality of life, as measured by the total score on St. George’s
Respiratory Questionnaire (SGRQ) and exacerbations
Notes Funding: Boehringer Ingelheim
Identifier(s): NCT00144339
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Eligible patients were randomly assigned
in a 1:1 ratio to receive either tiotropium
or placebo with the use of centralized ran-
domisation in blocks of four, stratified ac-
cording to site
Allocation concealment (selection bias) Low risk Centralised randomisation implies that it
was concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Refers to ’double-blind treatment period’.
Placebo was delivered via a matching in-
haler
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Total dropout over 4 years was high (37%
and 45% for tio and placebo respectively)
, but dropout was balanced. Around 83%
were included in the final analyses across
both groups. Given the length of the study,
it is difficult to assess the effect of missing
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data on the results
Selective reporting (reporting bias) Low risk Study results are posted in full on clinical-
trials.gov, and well reported in numerous
publications
Tashkin 2012
Methods Design: randomised, double-blind, placebo-controlled trial
Duration: 6 months (+ 2 weeks run-in period)
Location: 131 centres located in South America, Asia, Africa, Europe andNorth America
Participants Population: 1055 participants were randomised to formoterol (209),mometasone (210)
, two doses of formoterol/mometasone combination (217 and 207), and placebo (212)
Baseline characteristics
Age (mean years): form 59.6, mom 59.8, form/mom400 59.7, form/mom200 60.9, pbo
58.8
% Male: form 72.7, mom 78.1, form/mom400 78.8, form/mom200 77.8, pbo 80.2
% FEV1 predicted: not reported
Pack-years (mean): form 40.3, mom 40.0, form/mom400 39.7, form/mom200 41.7,
pbo 40.3
Inclusion criteria: males and females aged 40 and older; history of at least 10 pack-
years; moderate to severe COPD for at least 2 years; predicted FEV1 between 25% and
60% normal
Exclusion criteria: exacerbation in the four weeks before randomisation; significant
medical illness; diagnosis of asthma, lung cancer or alpha1-antitrypsin deficiency, lobec-
tomy, pneumonectomy, lung volume reduction surgery or ocular problems
Interventions 1. Formoterol 10 bid (LABA)
2. Mometasone 400 bid (ICS)
3. Formoterol/mometasone 10/400 bid (LABA/ICS)
4. Formoterol/mometasone 10/200 bid (LABA/ICS)
5. Placebo (PBO)
Inhaler device: metered dose
Allowed co-medications: Participants were given open-label, short-acting beta2-agonist
(SABA)/short-acting anticholinergic fixed-dose combination to use as relief medication
throughout the study. All long-acting COPD treatments (LABA, ICS, LABA/ICS FDC
or long-acting anticholinergics), supplemental oxygen and beta-blocking agents were not
allowed during the study period
Outcomes St George’s Respiratory Questionnaire (SQRQ), reported as both final scores and the
number of people experiencing aMCID (improvement or worsening by 4 units), COPD
exacerbations, serial FEV1 post-dose, standardised FEV1 area under the curve, systemic
and ocular effects
Notes Funding: Merck & Co/Schering-Plough
Identifier(s): NCT00383435
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The sponsor’s statistician produced a com-
puter-generated randomisation schedule
with treatment codes in blocks using SAS.
Randomisation was stratified according to
the subject’s smoking status at the time of
randomisation
Allocation concealment (selection bias) Low risk Randomized treatment assignment was
provided to the investigative site by means
of an interactive voice response system at
the time subjects were randomized
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Protocol describes the study masking as
double-blind (subject, investigator)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Protocol describes the study masking as
double-blind (subject, investigator)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal rates 17.7% in formoterol and
25% in the placebo group, unclearmethods
of imputation for some outcomes
Selective reporting (reporting bias) High risk Can’t extract FEV1 (table 3), other out-
comes poorly reported for the comparison
used in this review
To 2011
Methods Design: randomised, parallel-group, open-label study
Duration: 12 months
Location: Japan
Participants Population: 186 participants were randomised to salmeterol (61) and indacaterol (125)
Baseline characteristics - for whole population only
Age (mean years): 69.1
% Male: not reported
% FEV1 predicted: 53
Pack-years (mean): not reported
Inclusion criteria: patients with moderate-to-severe COPD (post-bronchodilator
FEV1/FVC <70% and FEV1 >30% to <80% predicted) and smoking history of at least
20 pack-years
Exclusion criteria: not reported, abstract only
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To 2011 (Continued)
Interventions 1. Salmeterol 50 bid (LABA)
2. Indacaterol 300 qd (LABA)
Inhaler device: unclear
Allowed co-medications: not described
Outcomes trough FEV1, TDI and safety assessments
Notes Funding: Novartis
Identifier(s): unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Patients meeting inclusion criteria were
randomised in the ratio 2:1 to indacaterol
and salmeterol (methods not described)
Allocation concealment (selection bias) Unclear risk no details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Both treatments were administered open-
label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Both treatments were administered open-
label
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, abstract only
Selective reporting (reporting bias) High risk Data could not be included in meta-analy-
sis, only abstract available
Tonnel 2008 [TIPHON]
Methods Design: randomised, double-blind, multi-centre study
Duration: 9 months (+ 2 week run-in)
Location: 123 centres in France
Participants Population: 554 participants were randomised to tiotropium (266) and placebo (288)
Baseline characteristics
Age (mean years): tio 64.9, pbo 63.5
% Male: tio 86.8, pbo 85.4
% FEV1 predicted: tio 47.5, pbo 46.2
Pack-years (mean): tio 44.4, pbo 43.0
Inclusion criteria: male and female outpatients ages >40 years with a clinical diagnosis of
COPD (pre- and post-bronchodilator FEV1 20-70% predicted and FEV1/SVC <70%)
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Tonnel 2008 [TIPHON] (Continued)
corresponding to mild, moderate, or severe COPD according to 1995 ATS criteria, and
a smoking history of >10 pack-years were eligible for inclusion.
Exclusion criteria: history of asthma, allergic rhinitis, or atopy; regular use of daytime
oxygen therapy; a recent respiratory tract infection (within the previous 6 week); a recent
history of myocardial infarction (within the previous 6 months); cardiac arrhythmia
requiring drug therapy (within the previous year); or hospitalisation for either heart
failure or pulmonary edema (within the previous 3 years)
Interventions 1. Tiotropium 18 qd (LAMA)
2. Placebo (PBO)
Inhaler device: HandiHaler
Allowed co-medications: Patients were permitted to use salbutamol as needed. Con-
comitant use of theophylline preparations, mucolytics, inhaled corticosteroids, and oral
steroids at a dose of < 10 mg prednisone daily or equivalent, was allowed if the dosage
was stabilized for >6 weeks before study entry. During the treatment period, patients
were not allowed to use beta blockers, antileukotrienes, oral or inhaled long-acting beta2-
agonists, short-acting anticholinergics, or any other investigational drug
Outcomes The primary efficacy endpoint was proportion of patients achieving a reduction of at least
4 units in the SGRQ total score at the end of the study. Secondary endpoints included
FEV1, FVC, inspiratory capacity, SVC, FIV1, exacerbations and adverse events
Notes Funding: Boehringer Ingelheim, France
Identifier(s): 205.256
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were assigned using a computer-
generated randomisation schedule, with no
stratification (block size of 4)
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, tiotropium and placebo
were delivered via the same type of inhaler
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unlcear who performed the assessments
Incomplete outcome data (attrition bias)
All outcomes
Low risk Efficacy was measured in the full anal-
ysis population, which included all ran-
domised patients who received study med-
ication and had baseline and at least 1
valid post-treatment measurement. Miss-
ing SGRQ component or total scores were
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imputed using the last observation carried
forward.Dropoutwas higher in the placebo
group (25.7 vs 14.7%)
Selective reporting (reporting bias) Low risk Outcomeswerewell reported in accordance
with the manufacturer protocol
Trooster 2011
Methods Design: randomized, double-blind, placebo-controlled, multi-national study
Duration: 24 weeks
Location: 62 centres in 10 countries
Participants Population: 457 participants were randomised to tiotropium (238) and placebo (219)
Baseline characteristics
Age (mean years): tio 61.2, pbo 62.3
% Male: tio 69.7, pbo 67.1
% FEV1 predicted: not reported
Pack-years (mean): not reported
Inclusion criteria: moderate COPD (post-bronchodilator forced expiratory volume in
1 second [FEV1] 50-80% predicted; GOLD Stage II) who have not previously been
treated with maintenance therapy, i.e. who have only been treated with short-acting
b2agonists on an as-needed basis in the 6 months prior to study enrolment and who
have symptomatic shortness of breath.
Exclusion criteria: (1) were treated with maintenance respiratory medications within
the 6 months prior to screening; (2) had an upper respiratory tract infection or COPD
exacerbation in the 6 weeks prior to the screening visit or during the screening visit
prior to Visit 3; (3) had non-pulmonary disease that would limit physical activity (e.g.
arthritis, amputation); (4) had a history of asthma, cystic fibrosis, pulmonary fibrosis,
bronchiectasis, pulmonary resection or other significant respiratory disorders other than
COPD; (5) had significant diseases other than COPD which, in the opinion of the
investigator, may influence the results of the study or the patient’s ability to participate;
(6) contraindication to exercise testing; (7) had prior participation (within 2 years) of
either cardiac or pulmonary rehabilitation
Interventions 1.Tiotropium 18 qd (LAMA)
2. Placebo (PBO
Inhaler device: HandiHaler
Allowed co-medications: as-needed albuterol. There was no restrictions for medications
prescribed for treatment of exacerbations as long as they are used for fewer than 2
cumulative weeks
Outcomes The primary endpoint is lung function improvement as captured by the area under the
curve (AUC) of FEV1 versus time (FEV1AUC 0-3h). Physical activity is assessed during
the week prior to each study visit, using a validated activity monitor as a secondary
endpoint. Additional secondary objectives include the effect of tiotropium treatment on
other lung function variables, patient and physician global evaluations, worker produc-
tivity as assessed by the Work Productivity and Activity Impairment questionnaire, and
the use of rescue medication. Information on COPD exacerbations is collected through
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serious adverse event monitoring
Notes Funding: Boehringer Ingelheim/Pfizer
Identifier(s): NCT00523991 and 205.365, A4471008
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomized in a ratio of 1:1 [industry
funded]
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind treatment phase. Placebo
was delivered in an identical inhaler
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Full Analysis Set (FAS): All subjects who
were randomized, received at least 1 dose of
the study drug, andhadbaseline and at least
1 post-baseline data measurement available
for the primary efficacy variable. All effi-
cacy analyses, except analyses for physical
activity endpoints, were performed using
the FAS population (95% of those ran-
domised). 89% and 90% completed the
study
Selective reporting (reporting bias) Low risk Results were well reported in the publica-
tion and posted on clinicaltrials.gov
Verhoeven 2002
Methods Design: Randomised, double-blind, placebo-controlled study
Duration: 6 months (+ 2 week run-in)
Location: single centre in the Netherlands
Participants Population: 23 participants were randomised to fluticasone (10) and placebo (13)
Baseline characteristics
Age (mean years): flut 54, pbo 56
%Male: flut 80, pbo 84.6
% FEV1 predicted: flut 66, pbo 61
Pack-years (mean): flut 25, pbo 26
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Inclusion criteria: Chronic productive cough, FEV1 <70% of predicted normal value,
FEV1 reversibility of <10% predicted after 750 mg terbutaline administered by metered
dose inhalation, negative serological examination (Phadiatop test), and negative skin
prick tests for standard inhaled allergens).22 Patients with an FEV1/inspiratory vital
capacity (IVC) ratio of <0.70 were also included, provided their total lung capacity
(TLC) was greater than the predicted value + 1.64SD. Reference values were obtained
from ECGS standards.23 Participants had to be current and persistent smokers aged 40-
70 years.
Exclusion criteria: History of asthma characterised by attacks of dyspnoea, chest tight-
ness or wheezing, respiratory tract infection in the 4 weeks preceding the first visit, or
were suffering from serious or unstable concomitant disease
Interventions 1. Fluticasone 500 BID (ICS)
2. Placebo (PBO)
Inhaler device: Diskhaler
Allowed co-medications: Eligible patients using anti-inflammatory treatment including
non-steroidal anti-inflammatory drugs were asked to refrain from oral prescriptions for
at least 3 months and from inhaled corticosteroids, sodium cromoglycate, or nedocromil
sodium for at least 6 weeks before the start of the study. Long acting b2 agonists, xanthine
derivatives, and antihistamine drugs also had to be stopped at least 6 weeks before the
start of the study
Outcomes Use of secondary medication, compliance, FEV1, PC20, FEV1/FVC, cortisol levels and
inflammatory markers
Notes Funding: GlaxoWellcome
Identifier(s): FLIL44/FMS40060
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly allocated [no details, but indus-
try funded]
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind [presumed par-
ticipants and personnel/investigators]
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts in either group
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Selective reporting (reporting bias) Low risk Adverse event data not adequately reported
but information supplied by the author
Vestbo 1999
Methods Design: Double-blind, parallel-group, randomised clinical trial nested in a continuing
epidemiological study, the Copenhagen City Heart Study (CCHS)
Duration: 3 years
Location: single centre in Denmark
Participants Population: 290 people were randomised to budesonide (145) and placebo (145)
Baseline characteristics
Age (mean years): bud 59, pbo 59.1
% Male: bud 85, pbo 90
% FEV1 predicted: bud 86.2, pbo 86.9
Pack-years (mean): not reported
Inclusion criteria: CCHS participant; age 30-70 years; FEV1/vital capacity ratio 0.7 or
less; FEV1 reversibility after inhalation of 1·0 mg terbutaline fromTurbuhaler (Bricanyl,
Lund, Sweden) of less than 15% of pre-bronchodilator FEV1; FEV1 reversibility after
10 days of treatment with oral prednisolone 37.5 mg daily of less than 15% of pre-
bronchodilator FEV1; and informed consent. Pack-years or other measures of cigarette
smoking were not part of inclusion criteria.
Exclusion criteria: Long-term treatment (more than two episodes of more than 4weeks)
with oral or inhaled steroids within 6 months of study entry. Other exclusion criteria
were pregnancy or lactation, intention to become pregnant, other serious systemic disease
that could influence the results of this study (investigators’ judgment), chronic alcohol
or drug use, and participation in other clinical studies of COPD within 1 month of
inclusion
Interventions 1. Budesonide 800µg amand400µgpm [first sixmonths]; 400µg twice daily [following
30 months] (ICS)
2. Placebo (PBO)
Inhaler device: Turbuhaler
Allowed co-medications: Continuous use of inhaled corticosteroids other than study
medication was not allowed. Oral, inhaled, or parenteral steroids could be used during
exacerbations for up to three periods of 4 weeks each year. Treatment with beta-2 agonists
of all kinds, theophylline, disodium cromoglycate, and mucolytics was allowed but kept
constant. Concomitant use of beta-blockers was not allowed during the study
Outcomes FEV1, VC, FVC, respiratory symptoms, exacerbations, chronic mucus hyper-secretion,
adverse events
Notes Funding: AstraZeneca
Identifier(s): unknown
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Randomisation was masked and the ran-
domisation sequence generated by com-
puter at Astra. Study numbers were allo-
cated in a consecutive order
Allocation concealment (selection bias) Low risk The randomisation code was held by Astra
and was not available to the researchers un-
til the study had been completed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind. All study inhalers (budes-
onide and placebo) had the same appear-
ance
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropout higher in placebo group (35% vs
25% in budesonide group). ITT used
Selective reporting (reporting bias) Unclear risk All stated outcomes reported but unable to
check against trial registration. Difficulty
contacting authors
Vogelmeier 2008
Methods Design: randomised, partially blinded, placebo-controlled trial
Duration: 6 months (+ 2 weeks run-in)
Location: outpatient and specialist clinics at 86 centres in 8 countries
Participants Population: 640 participants were randomised to formoterol (210), tiotropium (221),
and placebo (209)
Baseline characteristics
Age (mean years): form 61.8, tio 63.4, pbo 62.5
% Male: form 75.7, tio 79.2, pbo 77.5
% FEV1 predicted: form 51.6, tio 51.6, pbo 51.1
Pack-years (mean): form 35.4, tio 38.6, pbo 40.1
Inclusion criteria: males and females aged 40 and older; history of at least 10 pack-
years; FEV1 < 70% predicted normal; FEV1/FVC < 70%
Exclusion criteria: respiratory tract infection or hospitalised for an acute exacerbation
within the month before screening; clinically significant condition other than COPD
such as ischaemic heart disease
Interventions 1. Formoterol 10 bid (LABA)
2. Tiotropium 18 qd (LAMA) - open-label
3. Placebo (PBO)
Inhaler device: Multi-dose dry powder inhaler - tiotropium open label
Allowed co-medications: salbutamol as rescue (but not in the 8 hours before a study
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visit); inhaled corticosteroids (ICS) were allowed at a stable daily dose. Any participants
receiving fixed combinations of ICS and beta2-agonists were switched to receive the same
dose of ICS and on-demand salbutamol
Outcomes St George’s Respiratory Questionnaire (SGRQ), COPD exacerbations, FEV1 and FEV
measured at 5 minutes, 2 hours and 3 hours post-dose, PEF, 6-minute walk test, haema-
tology, blood chemistry, ECG, diary card data
Notes Funding: Novartis
Identifier(s): NCT00134979
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization was not stratified [no other
information given but assumed to follow
convention Novartis sequence generation
methods]
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Tiotropium was delivered open-label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Tiotropium was delivered open-label
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The intent-to-treat (ITT) population con-
sisted of all randomized patients who re-
ceived at least one dose of study medica-
tion. This population was used for efficacy
and safety analyses
Selective reporting (reporting bias) High risk FEV1 and SGRQ outcomes only provided
in graphical form with inexact P-value
Vogelmeier 2011 [POET]
Methods Design: randomized, double-blind, double-dummy, parallel-group trial
Duration: 1 year (+ 2 week run-in)
Location: 725 centres in 25 countries
Participants Population: 7376 participants were randomised to tiotropium (3707) and salmeterol
(3669)
Baseline characteristics
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Age (mean years): salm 62.8, tio 62.9
% Male: salm 74.9, tio 74.4
% FEV1 predicted: salm 49.4, tio 49.2
Pack-years (mean): salm 37.8, tio 38.8
Inclusion criteria: at least 40 years of age and had a smoking history of 10 pack-years
or more, a diagnosis of COPD, a forced expiratory volume in 1 second (FEV1) after
bronchodilation of <70% of the predicted value, a ratio of FEV1 to forced vital capacity
(FVC) of <70%, and a documented history of at least one exacerbation leading to treat-
ment with systemic glucocorticoids or antibiotics or hospitalisation within the previous
year
Exclusion criteria: significant disease other thanCOPD; diagnosis of asthma; life-threat-
ening pulmonary obstruction, or a history of CF; active TB; narrow angle glaucoma;
myocardial infarction or hospital admission for heart failure within the year prior to
visit 1; cardiac arrhythmia requiring medical or surgical treatment; severe CV disorders;
hypersensitivity to components of study drugs; respiratory infection or exacerbation in
the 4 weeks prior to visit 1
Interventions 1. Salmeterol 50 bid (LABA) - plus HandiHaler placebo
2. Tiotropium 18 qd (LAMA) - plus pMDI placebo
Inhaler device: HandiHaler and pressurised metered dose inhaler (pMDI)
Allowed co-medications: Patients were allowed to continue their usual medications for
COPD, except for anticholinergic drugs and long-actingβ2-agonists, during the double-
blind treatment phase
Outcomes time to first exacerbation (primary); Secondary and safety end points included time-to-
event end points, number-of-event end points, serious adverse events, and death
Notes Funding: Boehringer Ingelheim and Pfizer
Identifier(s): NCT00563381
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A randomisation list was generated by the
sponsor using a validated system involv-
ing a pseudo-random number generator.
Patients were randomized in a 1:1 ratio
in blocks of four, with equal allocation of
treatment within each block per country
site
Allocation concealment (selection bias) Low risk Patients were randomized to treatment via
an Interactive Voice Response System (Per-
ceptive Informatics Inc., Berlin, Germany)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding was maintained by allocation of
a dummy placebo MDI to those random-
ized to the tiotropium arm and a dummy
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placebo HandiHaler to those in the salme-
terol arm.Tiotropiumandplacebo capsules
were identical in size and colour and were
therefore indistinguishable
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk A committee assessing cause of death was
blind to treatment group. Authors judged
that other outcomes were blind also
Incomplete outcome data (attrition bias)
All outcomes
Low risk The efficacy and safety analyses included
all the patients who underwent randomi-
sation and who received at least one dose
of the study medication. Fewer patients in
the tiotropium group than in the salme-
terol group withdrew from the study pre-
maturely: 585 patients (15.8%) vs. 648 pa-
tients (17.7%) but both were judged to be
low over a year and considering imputation
of missing values
Selective reporting (reporting bias) Low risk Outcomes were well reported in the publi-
cations and on clinicaltrials.gov
Wedzicha 2008 [INSPIRE]
Methods Design: multicenter, randomized, double-blind, double-dummy controlled trial
Duration: 2 years (+ 2 week run-in)
Location: 179 centres from 20 countries
Participants Population: 1323 participants were randomised to tiotropium (665) and salmeterol/
fluticasone combination (658)
Baseline characteristics
Age (mean years): tio 65, SFC 64
%Male: tio 84, SFC 81
% FEV1 predicted: tio 39.4, SFC 39.1
Pack-years (mean): tio 39.5, SFC 41.3
Inclusion criteria: aged 40 to 80 years, with a smoking history of 10 or more pack-
years, a clinical history of COPD exacerbations, a post-bronchodilator FEV1 of less than
50% predicted, reversibility to 400 mg salbutamol 10% or less of predicted FEV1, and
a score of 2 or more on the Modified Medical Research Council dyspnoea scale.
Exclusion criteria: any respiratory disorder other than COPD or who required daily
long-term oxygen therapy (>12 h/d)
Interventions 1. Tiotropium 18 qd (LAMA) - plus Diskus/Accuhaler placebo
2. Salmeterol/fluticasone 50/500 (LABA/ICS) - plus HandiHaler placebo
Inhaler device: Diskus/Accuhaler and Handihaler
Allowed co-medications: After randomisation, in addition to studymedication, patients
were allowed short-acting inhaled beta-agonists for relief therapy and standardized short
courses of oral systemic corticosteroids and/or antibiotics where indicated for treatment
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of COPD exacerbations
Outcomes Primary endpoint was health care utilization exacerbation rate.Other endpoints included
health status measured by St. George’s Respiratory Questionnaire (SGRQ), mortality,
adverse events, and study withdrawal
Notes Funding: GlaxoSmithKline
Identifier(s): NCT00361959
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomized using a pre-
defined, computer-generated, central ran-
domisation list. Treatment allocation was
stratified by centre and smoking status on
a 1:1 basis, in line with current guidelines.
The block size used was four
Allocation concealment (selection bias) Low risk telephone-based interactive voice response
system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1,323 were randomized and comprised
the intent-to-treat population.Withdrawal
was high in both groups but balanced after
two years (35.3 and 42%)
Selective reporting (reporting bias) Low risk Outcomes were well reported in the pub-
lications, and matched the study protocol
(although results have not been posted on
clinicaltrials.gov)
Zheng 2006
Methods Design: multi-centre, randomised, double-blind, parallel group study
Duration: 24 weeks (+ 2 week run-in)
Location: 12 centres in China
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Participants Population: 448 participants were randomised to salmeterol/fluticasone combination
(297) and placebo (148)
Baseline characteristics
Age (mean years): SFC 66.0, pbo 66.6
% Male: SFC 90.6, pbo 86.5
% FEV1 predicted: not reported
Pack-years (mean): not reported
Inclusion criteria: Male and female subjects (aged 40-79 years) with a diagnosis of
COPD as per GOLD criteria; poor reversibility of airflow obstruction which was defined
as an increase of less than 10% of the normal predicted FEV1 value, 30 minutes to 2
hours after inhalation of 400 mcg salbutamol via MDI and spacerGFEV1/FVC ratio
(Postbronchodilator) < 70%.
Exclusion criteria: diagnosis of asthma and other respiratory disease such as lung cancer,
sarcoidosis, active tuberculosis, primary or severe subsequent lung fibrosis and bronchiec-
tasis, and serious, uncontrolled other system disorders; required long-term oxygen ther-
apy (LTOT); had received inhaled corticosteroids at a dose of >1000ug/day (BDP or
BUD) or >500ug/day (FP) or had received systemic corticosteroids in the last 4 weeks
before entry to the run-in period. After the run-in, at randomisation. Subjects who had
received systemic corticosteroids, had changes in COPDmedication, received antibiotic
therapy or had been hospitalised for COPD exacerbation were not randomized
Interventions 1. Salmeterol/fluticasone 50/500 bid (LABA/ICS)
2. Placebo (PBO)
Inhaler device: Accuhaler
Allowed co-medications: Ventolin was permitted to be used as rescue medication on a
required basis and sputum reduction medication could also be taken in the treatment
period at unchanged doses
Outcomes Pre-bronchodilator FEV1; St. George’s Respiratory Questionnaire (SGRQ); use of relief
bronchodilator and night time awakenings fromDaily Record Cards; post-bronchodila-
tor FEV1; COPD exacerbation (CE)
Notes Funding: GlaxoSmithKline
Identifier(s): SCO100540
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk randomised, according to a 2:1 ratio [GSK
sponsored]
Allocation concealment (selection bias) Unclear risk not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk SFC or matching placebo
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear who performed the assessments
Incomplete outcome data (attrition bias)
All outcomes
Low risk The final pre-bronchodilator FEV1 after
treatment period was analysed using the
LastObservationCarriedForward (LOCF)
method. For SGRQ, LOCF was also used
for data of subjects who were withdrawn
Selective reporting (reporting bias) Low risk Outcomes were well reported in the man-
ufacturer document
Zhong 2012
Methods Design: multi-centre, randomised, parallel-group, double-blind, double-dummy design
Duration: 6 months (+ 2 week run-in)
Location: 12 centres in China
Participants Population: 308 participants were randomised to budesonide (152) and formoterol/
budesonide combination therapy (156)
Baseline characteristics
Age (mean years): bud 64.7, form/bud 65.7
% Male: bud 92.1, form/bud 98.1
% FEV1 predicted (pre-BD): bud 32.9, form/bud 32.4
Pack-years (mean): not reported
Inclusion criteria: male or female outpatients > 40 years of age with a diagnosis of
COPD; pre-bronchodilator FEV1 <50% of predicted normal value; FEV1/FVC <70%;
at least 1 COPD exacerbation during 2-12 months prior to the study; a smoking history
of >10 pack-years.
Exclusion criteria: history of asthma; seasonal allergic rhinitis with onset before 40 years
of age; a COPD exacerbation within 4 weeks of study entry or during the run-in; post
BD FEV1 >80% of the predicted normal value at baseline; any other serious diseases
or disorders that were considered to influence the study results or increase the risk of
participation in the study
Interventions 1. Budesonide 400 bid (ICS)
2. Formoterol/budesonide 360/9 (LABA/ICS)
Inhaler device: Turbuhaler
Allowed co-medications: terbutaline was used as reliever during the run-in period and
throughout the study. No other bronchodilator was permitted to be used during the
study period
Outcomes Lung function, daily symptoms, reliever use, and health related quality of life (SGRQ)
Notes Funding: AstraZeneca
Identifier(s): NCT00421122
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation schedule was generated
using a computer program at AstraZeneca,
Sweden. Patients were randomised in equal
proportion to either treatment
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy. Treatment
codeswere not broken for the planned anal-
yses of data until all decisions had been
made and documented
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear who performed the assessments
Incomplete outcome data (attrition bias)
All outcomes
Low risk The full analysis set (FAS) included all ran-
domised subjects after eliminating those
who did not have any post-randomisation
efficacy data (n=16, 5.2%). Dropout was
somewhat unbalanced (15 and 23%) but
considered acceptable given the imputation
Selective reporting (reporting bias) Low risk Outcomeswerewell reported in accordance
with the online protocol, although no re-
sults have been posted on clinicaltrials.gov
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aalbers 2002 12 weeks [LABA-COP]
ACCORD II 2012 Extension phase, initial randomised treatment period too short
Ambrosino 2008 Given alongside pulmonary rehabilitation
Auffarth 1991 8 weeks. Crossover [STER-COP]
Barnes 2006 13 weeks [CCB-COP]
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Beeh 2006 12 weeks [TIO6-COP]
Bogdan 2011 12 weeks [LABA-COP]
Bourbeau 2007 12 weeks [STER-COP]
Briggs 2005 12 weeks [TIO5-COP]
Brightling 2005 Crossover [STER-COP]
Burl 2011 12 weeks [TIO5-COP]
Cazzola 2007 12 weeks [TIO2-COP]
Choudhury 2005 Discontinuation study, ICS
Covelli 2005 12 weeks [TIO6-COP]
Culpitt 1999 4 weeks, crossover [STER-COP]
Dahl 2001 12 weeks [LABA-COP]
Dahl 2013 [BEACON] 4 weeks
Dawber 2005 3 weeks [TIO1-COP]
Derenne 1995 Very high dose, beclomethasone
Dransfield 2013 vilanterol, fluticasone furoate
FCO30002 12 weeks [STER-COP]
Ferreira 2001 2 weeks, crossover [STER-COP]
Ferreira 2003 crossover [STER-COP]
Freeman 2007 12 weeks [TIO6-COP]
Fukuchi 2013 12 weeks [PICS-COP]
Guenette 2011 2 weeks, crossover [STER-COP]
Hanrahan 2008 12 weeks [LABA-COP]
Hattotuwa 2002 12 weeks [STER-COP]
Johansson 2008 Johansson 2008 [TIO6-COP]
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John 2005 crossover [STER-COP]
Kerstjens 1992 beclomethasone, ipratropium
Kerwin 2013 vilanterol, fluticasone furoate
Llewellyn-Jones 1996 8 weeks [STER-COP]
Loppow 2001 4 weeks, crossover [STER-COP]
Lung Health Study 2000 triamcinolone
Magnussen 2008 12 weeks [TIO6-COP]
Mahler 1999 12 weeks [LABA-COP]
Mahler 2010 12 weeks [TIO6-COP]
Mahler 2010a 12 weeks [TIO6-COP]
Martinez 2013 vilanterol, fluticasone furoate
Mirici 2001 12 weeks [STER-COP]
Moita 2008 12 weeks [TIO6-COP]
NCT00144326 12 weeks [TIO6-COP]
Nelson 2007 12 weeks [LABA-COP]
Nishimura 1999 4 weeks, crossover [STER-COP]
O’Donnell 2006 8 weeks [CCB-COP/CCB3-COP]
Rennard 2001 12 weeks [LABA-COP]
Robertson 1986 2 weeks, crossover [STER-COP]
Rutgers 1998 6 weeks [STER-COP]
SCO40034 12 weeks [TIO1-COP]
Sin 2004 8/16 weeks [STER-COP]
Sin 2008 4 weeks [STER-COP]
Sun 2007 12 weeks [TIO6-COP]
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Tashkin 2009 12 weeks [TIO3-COP]
Thompson 1992 6 weeks [STER-COP]
Thompson 2002 12 weeks, crossover [STER-COP]
van der Valk 2002 discontinuation study, ICS
van Grunsven 2003 12 weeks [STER-COP]
Verkinde 2006 12 weeks [TIO6-COP]
Voshaar 2008 12 weeks [TIO6-COP]
Wadbo 2002 12 weeks [LABA-COP]
Watkins 2002 12 weeks [LABA-COP]
Weiner 1995 6 weeks, crossover [STER-COP]
Weiner 1999 6 weeks, crossover [STER-COP]
Weir 1990 2 weeks, crossover [STER-COP]
Weir 1999 beclomethasone
Welte 2009 12 weeks [TIO2-COP]
Wempe 1992 3 weeks, crossover [STER-COP]
Wouters 2005 discontinuation study, ICS
Yang 2012 invalid control, symptomatic treatment
Yildiz 2004 12 weeks [STER-COP]
Characteristics of ongoing studies [ordered by study ID]
INSTEAD
Trial name or title Comparison of Indacaterol 150 µg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 µg/500
µg Twice Daily (b.i.d.) (INSTEAD)
Methods Allocation: randomly assigned
Endpoint classification: safety/efficacy study
Intervention model: parallel assignment
Masking: double-blind (participant, caregiver, investigator, outcomes assessor)
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Participants Patients with moderate COPD (stage II)
Interventions Indacaterol 150 qd
Salmeterol/fluticasone 50/500 bid
Outcomes Primary: trough FEV1. Secondary: other lung function measures, transition dyspnoea index, exacerbations,
SGRQ, adverse events, diary card data
Starting date March 2012 (first received on clinicaltrials.gov)
Contact information Novartis Pharmaceuticals: +41613241111
Notes Funding: Novartis
Identifiers: CQAB149B2401, 2011-003732-31
Vestbo 2013
Trial name or title Study to Understand Mortality and Morbidity in COPD (SUMMIT)
Methods Multicentre, randomised, double-blind, parallel-group, placebo-controlled trial
Participants 16,000 patients with moderate COPD
Interventions Once-daily treatment with fluticasone furoate/vilanterol (100/25mg), fluticasone furoate (100mg), vilanterol
(25 mg) or matched placebo
Outcomes Mortality is the primary endpoint
Starting date Recruitment commenced in March 2011 and is expected to conclude in late 2013
Contact information E-mail: jvestbo@dadlnet.dk; J. Vestbo, Dept of Respiratory Medicine J, Odense University Hospital, Sdr
Ringvej 29, 5000 Odense C, Denmark
Notes -
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. All included studies-summary characteristics
Study ID Weeks Arms included
a
N Ageb % male % pred FEV1b Pack-years
b
Abrahams
2013
24 tiotropium,
placebo
856 64.2 64.9 43.3 46.9
ACCLAIM
2009
52 aclidinium,
placebo
843 62.4 78.6 53.9 39.9
ACCLAIM II
2009
52 aclidinium,
placebo
804 65.1 63.0 50.3 57.9
Anzueto 2009 52 salmeterol, sal-
meterol/
fluticasone
797 65.4 54 34.0 57.2
ATTAIN
2011
24 aclidinium (2),
placebo
828 62.4 67.4 52.5 40.2
Bateman
2010a
48 tiotropium,
placebo
3991 64.8 77.6 39.9 46
Bateman
2010b
48 tiotropium (2),
placebo
1990 65.0 74.2 37.7 nr
Bateman 2013
[SHINE]
26 indacaterol,
tiotropium,
glycopyrro-
nium, placebo
1667 64.0 74.9 55.0 nr
Bourbeau
1998
26 budesonide,
placebo
79 66 78.6 36.5 51
Brusasco 2003 26 salmeterol,
tiotropium,
placebo
1207 64.2 76.3 38.5 43.8
Burge 2000
[ISOLDE]
156 fluticasone,
placebo
751 63.8 74.6 50.2 44
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Calverley
2003a
52 for-
moterol, budes-
onide, for-
moterol/budes-
onide, placebo
1122 64 76 36 39
Calverley
2003
[TRISTAN]
52 salmeterol, flu-
ticasone, salme-
terol/fluticas-
one, placebo
1466 63.2 72.5 44.7 42.3
Calverley
2003b
52 mometasone,
placebo
631 nr nr 47 nr
Calverley
2007
[TORCH]
156 salmeterol, flu-
ticasone, salme-
terol/fluticas-
one, placebo
6185 65.0 75.8 44.0 48.5
Calverley
2008
52 mometasone
(2), placebo
911 65.1 68.3 42.3 nr
Calverley
2010
48 formoterol, for-
moterol/
budesonide
718 63.9 81.3 42.4 38.8
Campbell
2005
26 formoterol,
placebo
432 55 67 53.6 37
Casaburi
2002
52 tiotropium,
placebo
921 65 65.0 38.7 61.4
Chan 2007 48 tiotropium,
placebo
913 66.8 59.7 39.4 50.6
Cooper 2010 104 tiotropium,
placebo
519 64.6 77.3 38.2 51.7
Dahl 2010 52 formoterol,
placebo
867 63.5 31.9 51.7 40.8
Dal Negro
2003
52 salmeterol, sal-
meterol/flutica-
sone, placebo
18 nr 83.3 50.0 41.4
Doherty 2012 26 formoterol,
mometasone,
formoterol/
1196 59.7 75.2 38.6 45.1
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mometasone
(2), placebo
Donohue
2010
[INHANCE]
26 indacaterol (2),
tiotropium,
placebo
1683 63.6 62.8 55.6 49.7
Dusser 2006 48 tiotropium,
placebo
1010 64.7 88 47.9 nr
Fang 2008 52 tiotropium, sal-
meterol/
fluticasone
126 62.5 73.8 nr nr
Ferguson
2008
52 salmeterol, sal-
meterol/
fluticasone
782 64.9 55 32.8 56.5
FLTA3025 26 fluticasone (2),
placebo
640 64.4 68.8 nr nr
Gelb 2012 52 aclidinium (2) 605 nr nr 46.5 nr
GLOW1
2011
26 glycopyrro-
nium, placebo
822 63.9 81.8 54.6 44.8
GLOW2
2012
52 glycopyrro-
nium,
tiotropium,
placebo
1066 63.6 64.2 56.0 49.1
Hanania 2003 26 salmeterol, flu-
ticasone, salme-
terol/fluticas-
one, placebo
723 63.9 63.1 42 56.5
Kardos 2007 43 salmeterol, sal-
meterol/
fluticasone
994 63.9 75.8 40.4 36.9
Kornmann
2011
26 salmeterol,
placebo
339 63.3 74.7 53.3 40.3
Lapperre 2009 130 fluticasone (2)
, salmeterol/flu-
ticasone,
placebo
114 61 86.6 55.3 44.3
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Laptseva 2002 26 budesonide,
placebo
49 nr nr nr nr
Mahler 2002 26 salmeterol, flu-
ticasone, salme-
terol/fluticas-
one, placebo
674 63.5 65.8 41 40.8
Mahmud
2007
26 salmeterol,
tiotropium
90 nr 91 nr nr
Niewoehner
2005
26 tiotropium,
placebo
1829 67.9 98.5 35.6 68.4
Ohar 2013 26 salmeterol, sal-
meterol/
fluticasone
639 nr nr nr nr
Ozol 2005 26 budesonide,
placebo
26 65.4 69.2 59.2 45.0
Paggiaro 1998 26 fluticasone,
placebo
281 63 74 57 nr
Pauwels 1999 156 budesonide,
placebo
1277 52.5 72.9 76.9 39.3
Powrie 2007 52 tiotropium,
placebo
142 66.4 62.9 50.0 55.2
Renkema
1996
104 budesonide,
placebo
39 55 100 63.5 nr
Rennard 2009 52 for-
moterol, budes-
onide, for-
moterol/budes-
onide, placebo
1964 63.2 63.9 39.6 40 (med)
Rossi 2002 52 formoterol (2),
placebo
645 62.7 83.3 nr nr
Schermer
2009
156 fluticasone,
placebo
190 59.0 70.5 64.5 28.3
SCO100470 26 salmeterol, sal-
meterol/
fluticasone
1050 63.6 77.8 nr nr
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SCO30002 52 salmeterol/flu-
ticasone, fluti-
casone, placebo
387 64.8 82 nr nr
SCO40041 156 salmeterol, sal-
meterol/
fluticasone
186 65.7 61.3 nr nr
Senderovitz
1999
26 budesonide,
placebo
26 60.5 53.5 nr nr
Shaker 2009 104+ budesonide,
placebo
254 63.6 58.3 52 56
Sharafkhaneh
2012
52 formoterol,
budesonide/
formoterol (2)
1219 63.0 62.0 37.7 44.3
SLMF4010 26 salmeterol,
placebo
34 63.8 88.3 nr nr
SPARK 2013 64 tiotropium
(OL), glycopy-
rronium
1483 63.4 74.1 nr nr
Szafranski
2003
52 for-
moterol, budes-
onide, for-
moterol/budes-
onide, placebo
812 64 78.8 36.2 44.5
Tashkin 2008
[SHINE]
26 formoterol,
budesonide,
formoterol/
budesonide (3),
placebo
1704 63.4 66.9 39.9 40 (med)
Tashkin
2008a
[UPLIFT]
208 tiotropium,
placebo
5993 64.5 74.7 39.4 48.7
Tashkin 2012 26 formoterol,
mometasone,
formoterol/
mometasone
(2), placebo
1055 59.8 77.5 nr 40.4
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Table 1. All included studies-summary characteristics (Continued)
To 2011 52 salmeterol, in-
dacaterol
186 69.1 nr 53 nr
Tonnel 2008
[TIPHON]
39 tiotropium,
placebo
554 64.2 86.1 46.9 43.7
Trooster 2011 24 tiotropium,
placebo
457 61.8 68.4 nr nr
Verhoeven
2002
26 fluticasone,
placebo
23 55 82.3 63.5 25.5
Vestbo 1999 156 budesonide,
placebo
290 59.1 87.5 86.6 nr
Vogelmeier
2008
26 formoterol,
tiotropium,
placebo
640 62.6 77.5 51.4 38.0
Vogelmeier
2011 [POET]
52 salmeterol,
tiotropium
7384 62.9 74.7 49.3 38.3
Wedzicha
2008
[INSPIRE]
104 tiotropium, sal-
meterol/
fluticasone
1323 64.5 82.5 39.3 40.4
Zheng 2006 24 salmeterol/
fluticasone,
placebo
448 66.3 88.6 nr nr
Zhong 2012 24 budesonide,
formoterol/
budesonide
308 65.2 95.1 32.7 nr
aNumbers in parentheses indicate multiple doses of the same treatment.
bAge, % predicted FEV1 and pack-years smoked are reported as means unless otherwise stated.
bid = twice daily.
FEV1 = forced expiratory volume in one second.
ICS = inhaled corticosteroid.
LABA = long-acting beta2-agonist.
LABA/ICS = long-acting beta2-agonist/inhaled corticosteroid combination therapy.
LAMA = long-acting muscarinic antagonist.
nr = not reported.
PBO = placebo inhaler.
qd = once daily.
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Table 2. SGRQ network composition and transitivity assessmenta
Comparison Comparisons N Ageb % male % FEV1c Packs
d
LABA vs placebo 16 13,808 62.9 74.7 46.2 42.5
LAMA vs
placebo
15 22,406 64.2 71.3 47.1 47.5
ICS vs placebo 10 8153 63.4 74.9 41.7 42.7
LABA/ICS vs
placebo
10 9097 63.1 75.3 39.7 42.4
LABA vs LAMA 2 2680 63.7 69.5 55.2 49.7
LABA vs ICS 7 6226 62.7 73.8 40.0 42.7
LABA vs LABA/
ICS
13 12,505 63.1 71.0 38.8 43.9
LAMA vs ICS 0 - - - - -
LAMA vs
LABA/ICS
1 1323 64.5 82.5 39.3 40.4
ICS vs LABA/
ICS
10 8721 62.9 75.3 38.8 42.9
aSummary population data are for all study comparisons excluding those made in the 29 studies that could not be included in either
the six-month or the 12-month SGRQ network.
bAge = mean years.
c% FEV1 = mean percentage predicted FEV1.
dPacks = mean pack-years.
FEV1 = forced expiratory volume in one second.
ICS = inhaled corticosteroid.
LABA = long-acting beta2-agonist.
LABA/ICS = long-acting beta2-agonist/inhaled corticosteroid combination therapy.
LAMA = long-acting muscarinic antagonist.
SGRQ = St George’s Respiratory Questionnaire.
Table 3. FEV1 network composition and transitivity assessment
a
Comparison Comparisons N Ageb % male %FEV1c Packs
d
LABA vs Placebo 13 8680 63.3 73.2 47.7 43.9
LAMA vs
Placebo
16 23,111 64.3 72.2 47.6 48.9
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Table 3. FEV1 network composition and transitivity assessment
a (Continued)
ICS vs Placebo 12 4574 63.6 71.9 46.2 45.2
LABA/ICS vs
Placebo
9 4978 63.9 73.5 41.6 44.4
LABA vs LAMA 2 2680 63.7 69.5 55.2 49.7
LABA vs ICS 5 2506 63.6 67.1 40.6 46.7
LABA vs LABA/
ICS
12 8005 63.7 68.8 39.9 45.8
LAMA vs ICS 0 - - - - -
LAMA vs
LABA/ICS
0 - - - - -
ICS vs LABA/
ICS
8 4560 63.6 71.7 39.0 45.5
aSummary population data are for all study comparisons excluding those made in the 23 studies that could not be included in either
the six-month or the 12-month FEV1 network; all doses are given in micrograms.
bAge = mean years.
c% FEV1 = mean percentage predicted FEV1.
dPacks = mean pack-years.
FEV1 = forced expiratory volume in one second.
ICS = inhaled corticosteroid.
LABA = long-acting beta2-agonist.
LABA/ICS = long-acting beta2-agonist/inhaled corticosteroid combination therapy.
LAMA = long-acting muscarinic antagonist.
Table 4. Distribution of studies by individual treatment node
Class Treatment node mcg Studies
LABA Formoterol 12 bid Calverley 2003a; Calverley 2003 [TRISTAN]; Calverley 2010;
Campbell 2005; Dahl 2010; Doherty 2012; Rennard 2009; Rossi 2002;
Sharafkhaneh 2012; Szafranski 2003; Tashkin 2008 [SHINE]; Tashkin 2012;
Vogelmeier 2008a
Formoterol 24 bid Rossi 2002
Indacaterol 300 qd Dahl 2010; Donohue 2010 [INHANCE]
Indacaterol 600 qd Dahl 2010
Indacaterol 150 qd Bateman 2013 [SHINE]; Donohue 2010 [INHANCE]
175Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 4. Distribution of studies by individual treatment node (Continued)
Salmeterol 50 bid Anzueto 2009; Brusasco 2003; Dal Negro 2003a ; Calverley 2007 [TORCH];
Ferguson 2008; Hanania 2003a ; Kardos 2007; Kornmann 2011; Mahler 2002a ;
Mahmud 2007a ; Ohar 2013a ; SCO100470; SCO40041a ; SLMF4010;
Vogelmeier 2011 [POET]a
LAMA Tiotropium 5 qd Abrahams 2013; Bateman 2010a; Bateman 2010b
Tiotropium 10 qd Bateman 2010b
Tiotropium 18 qd Bateman 2013 [SHINE]; Brusasco 2003; Casaburi 2002; Chan 2007;
Cooper 2010a ; Donohue 2010 [INHANCE]; Dusser 2006a ; Fang 2008a ;
GLOW22012;Mahmud 2007a ; Niewoehner 2005a ; Powrie 2007a ; SPARK2013;
Tashkin 2008a [UPLIFT]; Tonnel 2008 [TIPHON]; Trooster 2011a ;
Vogelmeier 2008a ; Vogelmeier 2011 [POET]a ; Wedzicha 2008 [INSPIRE]
Aclidinium bromide 200 qd ACCLAIM 2009; ACCLAIM II 2009
Aclidinium bromide 200 bid ATTAIN 2011; GLOW1 2011
Aclidinium bromide 400 bid ATTAIN 2011; Gelb 2012
Glycopyrronium bromide 50 qd Bateman 2013 [SHINE]; GLOW1 2011; GLOW2 2012; SPARK 2013
ICS Budesonide 320-400 bid Calverley 2003a; Laptseva 2002a ; Ozol 2005a ; Pauwels 1999a ;
Senderovitz 1999a ; Shaker 2009a ; Szafranski 2003; Tashkin 2008 [SHINE];
Zhong 2012
Budesonide 750-1000 bid Bourbeau 1998; Renkema 1996a ; Vestbo 1999
Fluticasone 250 bid FLTA3025; Hanania 2003
Fluticasone 500 bid Burge 2000 [ISOLDE]; Calverley 2003 [TRISTAN]; Calverley 2007 [TORCH];
FLTA3025; Lapperre 2009a ; Mahler 2002; Paggiaro 1998; Schermer 2009;
SCO30002a ; Verhoeven 2002a
Mometasone 400 bid or 800 qd Calverley 2003b; Calverley 2008; Doherty 2012; Tashkin 2012
LABA/ICS Formoterol/bud 12/160 bid Rennard 2009; Sharafkhaneh 2012; Tashkin 2008 [SHINE]; Zhong 2012
Formoterol/bud 12/320 bid Calverley 2003a; Calverley 2010; Rennard 2009; Sharafkhaneh 2012;
Szafranski 2003; Tashkin 2008 [SHINE]
Formoterol/mom 12/200 bid Doherty 2012; Tashkin 2012
Formoterol/mom 12/400 bid Doherty 2012; Tashkin 2012
Salmeterol/flut 50/250 bid Anzueto 2009; Dal Negro 2003; Fang 2008a ; Hanania 2003; Ohar 2013
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Table 4. Distribution of studies by individual treatment node (Continued)
Salmeterol/flut 50/500 bid Calverley 2003 [TRISTAN]; Calverley 2007 [TORCH];
Ferguson 2008; Lapperre 2009a ; Mahler 2002; SCO100470; SCO30002a ;
SCO40041a ; Wedzicha 2008 [INSPIRE]; Zheng 2006
PBO Placebo inhaler Abrahams 2013; ACCLAIM 2009; ACCLAIM II 2009; ATTAIN 2011;
Bateman 2010a; Bateman 2010b; Bateman 2013 [SHINE]; Bourbeau 1998;
Brusasco 2003; Burge 2000 [ISOLDE]; Calverley 2003a; Calverley 2003
[TRISTAN];
Calverley 2003b; Calverley 2007 [TORCH]; Calverley 2008; Calverley 2010;
Campbell 2005; Casaburi 2002; Chan 2007; Cooper 2010a ; Dahl 2010;
Dal Negro 2003; Doherty 2012; Donohue 2010 [INHANCE]; Dusser 2006a ;
FLTA3025;
GLOW1 2011; GLOW2 2012; Hanania 2003; Kornmann 2011; Lapperre 2009
a ;
Laptseva 2002a ; Mahler 2002; Niewoehner 2005a ; Ozol 2005; Paggiaro 1998;
Pauwels 1999a ; Powrie 2007; Renkema 1996a ; Rennard 2009; Rossi 2002;
Schermer 2009;
SCO30002; Senderovitz 1999; Shaker 2009; Sharafkhaneh 2012; SLMF4010;
SPARK2013; Szafranski 2003; Tashkin 2008 [SHINE]; Tashkin 2008a [UPLIFT];
Tashkin 2012; To 2011a ; Tonnel 2008 [TIPHON]; Trooster 2011; Verhoeven
2002a ;
Vestbo 1999; Vogelmeier 2008a ; Zheng 2006
aStudies not contributing data to either outcome.
bid = twice daily.
ICS = inhaled corticosteroid.
LABA = long-acting beta2-agonist.
LABA/ICS = long-acting beta2-agonist/inhaled corticosteroid combination therapy.
LAMA = long-acting muscarinic antagonist.
PBO = placebo inhaler.
qd = once daily.
Table 5. Sensitivity analysis-blinding
Study ID Arm removed Analyses affected
Bateman 2013 [SHINE] Tiotropium 18 mcg SGRQ6m, FEV6m
Donohue 2010 [INHANCE] Tiotropium 18 mcg SGRQ6m, FEV6m
GLOW2 2012 Tiotropium 18 mcg SGRQ6m, FEV6m, SGRQ12m, FEV12m
SPARK 2013 Whole study (2 arms) SGRQ6m, FEV6m, SGRQ12m, FEV12m
Vogelmeier 2008 Tiotropium 18 mcg Did not appear in analyses
FEV = forced expiratory volume in one second
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SGRQ = St George’s Respiratory Questionnaire
6m = six month analysis
12m = 12 month analysis
Table 6. SGRQ class effects versus placebo (six months)a
Effect vs placebo
Class NWMA
Effect vs placebo
Sensitivity analysis
Rank
Class Median 95% CrI Median 95% CrI Mean Median 95% CrI Pr (best)
LABA/ICS -3.89 (-4.70 to -2.
97)
-3.89 (-4.66 to -3.
05)
1.0 1 (1 to 2) 0.96
LAMA -2.63 (-3.53 to -1.
97)
-2.78 (-3.58 to -2.
13)
2.4 2 (1 to 4) 0.03
LABA -2.29 (-3.18 to -1.
53)
-2.09 (-2.93 to -1.
36)
3.1 3 (2 to 4) 0.01
ICS -2.00 (-3.06 to -0.
87)
-1.96 (-2.99 to -0.
91)
3.5 4 (2 to 4) 0.00
aFor effects versus placebo, smaller values indicate larger benefits of the active treatment; all doses are given in micrograms.
Crl = credible interval.
SGRQ = St George’s Respiratory Questionnaire.
ICS = inhaled corticosteroid.
LABA = long-acting beta2-agonist.
LABA/ICS = long-acting beta2-agonist/inhaled corticosteroid.
LAMA = long-acting antimuscarinic antagonist.
NWMA = network meta-analysis.
Pr = probability.
Table 7. SGRQ individual treatment effects versus placebo (six months)a
Rank (from class
NWMA)
Effect vs placebo
Class NWMA
Effect vs placebo
NWMA no class
Rank (from class NWMA)
Class Treatment
(num-
ber daily
doses)
Median 95% CrI Median 95% CrI Mean Median 95% CrI Pr (best)
LABA Form 12
(2)
-1.84 (-2.60 to -
0.94)
-1.20 (-2.10 to -
0.30)
14.9 15 (10 to 17) 0.00
Ind 300
(1)
-2.38 (-3.63 to -
1.44)
-3.10 (-4.86 to -
1.36)
11.3 12 (5 to 17) 0.00
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Table 7. SGRQ individual treatment effects versus placebo (six months)a (Continued)
Ind 150
(1)
-2.75 (-3.95 to -
1.85)
-3.67 (-4.76 to -
2.58)
8.7 8 (3 to 16) 0.01
Salm 50
(2)
-2.20 (-2.98 to -
1.43)
-2.27 (-3.27 to -
1.27)
12.9 13 (7 to 17) 0.00
LAMA Tio 5 (1) -2.50 (-3.16 to -
1.86)
-2.42 (-3.20 to -
1.63)
10.5 10 (6 to 16) 0.00
Tio 18 (1) -2.53 (-3.12 to -
1.97)
-2.66 (-3.33 to -
1.99)
10.3 10 (6 to 15) 0.00
Acl 200 (2) -2.66 (-4.04 to -
1.70)
-3.79 (-6.14 to -
1.45)
9.1 9 (2 to 16) 0.01
Acl 400 (2) -2.81 (-4.40 to -
1.90)
-4.59 (-6.94 to -
2.23)
7.9 7 (1 to 15) 0.03
Gly 50 (1) -2.63 (-3.42 to -
1.94)
-2.83 (-3.74 to -
1.91)
9.5 9 (5 to 15) 0.00
ICS Bud 400
(2)
-1.76 (-2.82 to -
0.55)
-0.97 (-2.32 to 0.
38)
14.9 16 (7 to 17) 0.00
Flut 500
(2)
-1.95 (-3.07 to -
0.74)
-1.71 (-3.40 to -
0.01)
13.9 15 (6 to 17) 0.00
Mom 400
(2)
-2.28 (-3.51 to -
1.19)
-2.77 (-4.47 to -
1.09)
11.9 13 (5 to 17) 0.00
LABA/ICS Form-bud
12/160 (2)
-4.04 (-4.91 to -
3.15)
-3.85 (-4.99 to -
2.70)
2.6 2 (1 to 6) 0.29
Form-bud
12/320 (2)
-3.80 (-4.63 to -
2.84)
-3.31 (-4.39 to -
2.22)
3.9 4 (1 to 9) 0.10
Form-
mom 12/
200 (2)
-3.85 (-4.82 to -
2.66)
-3.45 (-5.17 to -
1.74)
3.7 4 (1 to 10) 0.15
Form-
mom 12/
400 (2)
-3.75 (-4.72 to -
2.48)
-3.09 (-4.81 to -
1.37)
4.3 4 (1 to 11) 0.10
Salm-flut
50/500 (2)
-4.05 (-4.97 to -
3.18)
-4.36 (-5.60 to -
3.12)
2.6 2 (1 to 6) 0.31
aFor effects versus placebo, smaller values indicate larger benefits of the active treatment; all doses are given in micrograms.
Crl = credible interval.
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SGRQ = St George’s Respiratory Questionnaire.
ICS = inhaled corticosteroid.
LABA = long-acting beta2-agonist.
LABA/ICS = long-acting beta2-agonist/inhaled corticosteroid.
LAMA = long-acting antimuscarinic antagonist.
NWMA = network meta-analysis.
Pr = probability.
Table 8. FEV1 class effects versus placebo (six months)
a
Effect vs placebo
Class NWMA
Effect vs placebo
Sensitivity analysis
Rank
Class Median 95% CrI Median 95% CrI Mean Median 95% CrI Pr (best)
LABA/ICS 133.30 (100.60 to
164.00)
132.80 (98.93 to
165.60)
1.1 1 (1 to 2) 0.9
LAMA 103.50 (81.78,124.
90)
103.60 (79.01 to
126.60)
2.4 2 (1 to 3) 0.1
LABA 99.44 (71.98,127.
80)
99.86 (70.41 to
130.50)
2.6 3 (1 to 4) 0.0
ICS 65.36 (33.06,96.
91)
65.52 (31.23 to
97.16)
3.9 4 (3 to 4) 0.0
aFor effects versus placebo, smaller values indicate larger benefits of the active treatment; all doses are given in micrograms.
Crl = credible interval.
FEV1 = forced expiratory volume in one second.
ICS = inhaled corticosteroid.
LABA = long-acting beta2-agonist.
LABA/ICS = long-acting beta2-agonist/inhaled corticosteroid.
LAMA = long-acting antimuscarinic antagonist.
NWMA = network meta-analysis.
Pr = probability.
Table 9. FEV1 individual treatment effects versus placebo (six months)
a
Effect vs placebo
Class NWMA
Effect vs placebo
NWMA no class
Rank (from class NWMA)
Class Treatment
(num-
ber daily
doses)
Median 95% CrI Median 95% CrI Mean Median 95% CrI Pr (best)
LABA Form 12
(2)
94.88 (60.70 to
122.80)
53.92 (13.00 to
94.07)
12.0 13 (5 to 18) 0.00
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Table 9. FEV1 individual treatment effects versus placebo (six months)
a (Continued)
Ind 300
(1)
103.30 (71.95 to
150.10)
137.90 (63.69 to
209.90)
9.5 10 (2 to 16) 0.02
Ind 150
(1)
99.53 (72.32 to
127.20)
100.70 (65.74 to
133.80)
10.8 12 (4 to 16) 0.00
Salm 50
(2)
101.00 (73.39 to
130.70)
114.70 (75.96 to
149.30)
10.3 11 (4 to 16) 0.00
LAMA Tio 5 (1) 105.40 (81.87 to
131.80)
110.50 (73.82 to
145.40)
8.9 9 (3 to 15) 0.01
Tio 10 (1) 106.40 (79.80 to
142.00)
121.00 (62.88 to
175.20)
8.6 8 (2 to 15) 0.02
Tio 18 (1) 105.20 (85.54 to
125.50)
107.00 (82.93 to
129.50)
9.0 9 (4 to 15) 0.00
Acl 200 (1) 98.83 (59.06 to
123.20)
59.31 (9.47 to
107.90)
11.3 11 (5 to 18) 0.00
Acl 200 (2) 100.60 (65.20 to
127.10)
74.82 (11.81 to
134.20)
10.7 11 (4 to 17) 0.00
Acl 400 (2) 107.30 (80.93 to
143.50)
108.80 (45.06 to
168.30)
8.2 8 (2 to 15) 0.02
Gly 50 (1) 103.60 (79.83 to
127.50)
101.50 (67.86 to
133.40)
9.5 10 (3 to 15) 0.00
ICS Bud 400
(2)
61.89 (23.86 to
94.06)
14.59 (-29.22 to
58.25)
17.6 18 (14 to 19) 0.00
Bud 750+
(2)
63.10 (14.75 to
99.65)
-2.26 (-95.77 to
91.34)
17.3 18 (12 to 19) 0.00
Flut 250
(2)
66.78 (34.19 to
101.10)
76.18 (29.36 to
122.30)
16.9 17 (11 to 19) 0.00
Flut 500
(2)
72.16 (40.20 to
109.80)
97.04 (54.90 to
138.40)
15.9 16 (8 to 19) 0.00
LABA/ICS Form-bud
12/160 (2)
131.10 (91.65 to
164.00)
80.84 (26.99 to
132.70)
3.9 3 (1 to 13) 0.16
Form-bud
12/320 (2)
127.30 (85.14 to
159.50)
72.77 (28.75 to
116.70)
4.7 4 (1 to 14) 0.11
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Table 9. FEV1 individual treatment effects versus placebo (six months)
a (Continued)
Salm-flut
50/250 (2)
139.70 (106.20 to
182.90)
173.00 (116.20 to
226.40)
2.4 2 (1 to 8) 0.39
Salm-flut
50/500 (2)
137.10 (104.40 to
172.10)
152.40 (104.10 to
197.80)
2.8 2 (1 to 9) 0.26
aFor effects versus placebo, bigger values indicate larger benefits of the active treatment; all doses are given in micrograms.
Crl = credible interval.
FEV1 = forced expiratory volume in one second.
ICS = inhaled corticosteroid.
LABA = long-acting beta2-agonist.
LABA/ICS = long-acting beta2-agonist/inhaled corticosteroid.
LAMA = long-acting antimuscarinic antagonist.
NWMA = network meta-analysis.
Pr = probability.
A P P E N D I C E S
Appendix 1. The Cochrane Library search strategy
#1 MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] explode all trees
#2 MeSH descriptor: [Lung Diseases, Obstructive] this term only
#3 COPD:ti
#4 (obstruct*) near/3 (pulmonary or lung* or airway* or airflow* or bronch* or respirat*):ti
#5 #1 or #2 or #3 or #4
#6 indacaterol
#7 salmeterol
#8 *formoterol
#9 long* near (beta* near agonist*)
#10 budesonide
#11 fluticasone
#12 mometasone
#13 inhal* near (corticosteroid* or steroid*)
#14 tiotropium
#15 aclidinium
#16 Glycopyrronium
#17 long* near muscarinic*
#18 umeclidinium
#19 vilanterol
#20 (LABA or LAMA or ICS):ti,ab
#21 {or #6-#20}
#22 #5 and #21
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Appendix 2. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
CENTRAL (The Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
183Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
COPD search
1. Lung Diseases, Obstructive/
2. exp Pulmonary Disease, Chronic Obstructive/
3. emphysema$.mp.
4. (chronic$ adj3 bronchiti$).mp.
5. (obstruct$ adj3 (pulmonary or lung$ or airway$ or airflow$ or bronch$ or respirat$)).mp.
6. COPD.mp.
7. COAD.mp.
8. COBD.mp.
9. AECB.mp.
10. or/1-9
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and the RCT filter are adapted to identify trials in other electronic databases
Appendix 3. Search to retrieve relevant trials from the CAGR
#1 MeSH DESCRIPTOR Pulmonary Disease, Chronic Obstructive Explode All
#2 MeSH DESCRIPTOR Bronchitis, Chronic
#3 (obstruct*) near3 (pulmonary or lung* or airway* or airflow* or bronch* or respirat*)
#4 COPD:MISC1
#5 (COPD OR COAD OR COBD):TI,AB,KW
#6 #1 OR #2 OR #3 OR #4 OR #5
#7 indacaterol or QAB149
#8 salmeterol
#9 *formoterol
#10 long* near (beta* near agonist*)
#11 budesonide
#12 fluticasone
#13 mometasone
#14 inhal* near (corticosteroid* or steroid*)
#15 tiotropium
#16 aclidinium or LAS34273
#17 Glycopyrronium or NVA237
#18 long* near muscarinic*
#19 umeclidinium or GSK573719
#20 vilanterol or GW642444
#21 (LABA or LAMA or ICS):TI,AB
#22 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21
#23 #6 and #22
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[Note: in search line #4, MISC1 refers to the field in which the record has been coded for condition, in this case, COPD]
Appendix 4. SGRQ class effects versus placebo (12 months)a
Effect vs placebo
Class NWMA
Effect vs placebo
Sensitivity analysis
Rank
Class Median 95% CrI Median 95% CrI Mean Median 95% CrI Pr (best)
LABA/ICS -3.60 (-4.63 to -2.
34)
-3.53 (-4.69 to -2.
15)
1.2 1 (1 to 3) 0.86
LAMA -2.50 (-3.30 to -1.
68)
-2.56 (-3.49 to -1.
69)
2.9 3 (1 to 4) 0.04
LABA -2.55 (-3.68 to -1.
70)
-2.61 (-3.82 to -1.
68)
2.8 3 (1 to 4) 0.07
ICS -2.34 (-3.45 to -1.
27)
-2.34 (-3.58 to -1.
16)
3.2 3 (1 to 4) 0.03
aFor effects versus placebo, smaller values indicate larger benefits of the active treatment
Crl = credible interval.
SGRQ = St George’s Respiratory Questionnaire.
ICS = inhaled corticosteroid.
LABA = long-acting beta2-agonist.
LABA/ICS = long-acting beta2-agonist/inhaled corticosteroid.
LAMA = long-acting antimuscarinic antagonist.
NWMA = network meta-analysis.
Pr = probability.
Appendix 5. SGRQ individual treatment effects versus placebo (12 months)a
Effect vs placebo
Class NWMA
Rank
Class Treatment Median 95% CrI Mean Median 95% CrI Pr (best)
LABA Form 12 (2) -2.51 (-3.39 to -1.
73)
10.7 11 (4 to 17) 0.00
Form 24 (2) -2.71 (-4.43 to -1.
60)
8.8 8 (1 to 18) 0.05
185Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Ind 300 (1) -2.85 (-4.44 to -1.
77)
7.8 7 (1 to 17) 0.06
Ind 6000 (1) -2.81 (-4.38 to -1.
74)
8.1 7 (1 to 17) 0.05
Salm 50 (2) -1.81 (-2.62 to -0.
92)
16.0 17 (9 to 18) 0.00
LAMA Tio 5 (1) -2.77 (-3.50 to -2.
08)
8.1 8 (3 to 15) 0.00
Tio 10 (1) -2.83 (-4.04 to -1.
92)
7.6 7 (1 to 16) 0.03
Tio 18 (1) -2.15 (-2.88 to -1.
33)
13.6 14 (6 to 18) 0.00
Acl 200 (1) -2.33 (-3.28 to -1.
16)
12.0 12 (4 to 18) 0.00
Acl 200 (2) -2.52 (-3.94 to -1.
08)
10.3 10 (2 to 18) 0.02
Acl 400 (2) -2.49 (-3.89 to -1.
04)
10.5 11 (2 to 18) 0.02
Gly 50 (1) -2.42 (-3.31 to -1.
40)
11.2 11 (4 to 18) 0.00
ICS Bud 400 (2) -2.33 (-3.48 to -1.
21)
12.0 12 (4 to 18) 0.00
Flut 500 (2) -2.16 (-2.89 to -1.
41)
13.5 14 (6 to 18) 0.00
Mom 400 (2) -2.51 (-3.97 to -1.
31)
10.4 11 (2 to 18) 0.02
LABA/ICS Form-bud 12/
160 (2)
-3.45 (-4.75 to -1.
62)
4.9 3 (1 to 16) 0.19
Form-bud 12/
320 (2)
-3.74 (-4.80 to -2.
70)
2.6 2 (1 to 8) 0.35
Salm-flut 50/
500 (2)
-3.58 (-4.29 to -2.
85)
3.1 3 (1 to 8) 0.21
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aFor effects versus placebo, smaller values indicate larger benefits of the active treatment. All doses are in micrograms
Crl = credible interval.
SGRQ = St George’s Respiratory Questionnaire.
ICS = inhaled corticosteroid.
LABA = long-acting beta2-agonist.
LABA/ICS = long-acting beta2-agonist/inhaled corticosteroid.
LAMA = long-acting antimuscarinic antagonist.
NWMA = network meta-analysis.
Pr = probability.
Appendix 6. FEV1 class effects versus placebo (12 months)a
Effect vs placebo
Class NWMA
Effect vs placebo
Sensitivity analysis
Rank
Class Median 95% CrI Median 95% CrI Mean Median 95% CrI Pr (best)
LABA/ICS 100.80 (55.50 to
140.10)
100.00 (53.77 to
141.50)
1.7 1 (1 to 3) 0.5
LAMA 92.64 (56.23 to
129.60)
94.23 (56.08 to
134.30)
2.0 2 (1 to 3) 0.3
LABA 87.05 (47.28 to
130.50)
86.88 (46.12 to
132.00)
2.3 2 (1 to 3) 0.2
ICS 28.36 (-11.93 to
65.70)
28.00 (-13.34 to
66.90)
4.1 4 (4 to 5) 0.0
aFor effects versus placebo, smaller values indicate larger benefits of the active treatment
Crl = credible interval.
FEV1 = forced expiratory volume in one second.
ICS = inhaled corticosteroid.
LABA = long-acting beta2-agonist.
LABA/ICS = long-acting beta2-agonist/inhaled corticosteroid.
LAMA = long-acting antimuscarinic antagonist.
NWMA = network meta-analysis.
Pr = probability.
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Appendix 7. FEV1 individual treatment effects versus placebo (12 months)a
Effect vs placebo
Class NWMA
Rank
Class Treatment Median 95% CrI Mean Median 95% CrI Pr (best)
LABA Form 12 (2) 69.96 (33.27 to 105.
40)
12.2 13 (6 to 16) 0.00
Ind 300 (1) 102.20 (52.85 to 169.
30)
6.2 6 (1 to 14) 0.15
Ind 600 (1) 99.22 (51.43 to 162.
50)
6.7 6 (1 to 14) 0.10
Salm 50 (2) 78.73 (36.65 to 118.
20)
10.6 11 (4 to 15) 0.00
LAMA Tio 5 (1) 96.90 (59.78 to 136.
30)
7.0 7 (1 to 14) 0.04
Tio 10 (1) 103.00 (61.53 to 157.
10)
5.8 5 (1 to 13) 0.13
Tio 18 (1) 82.37 (50.63 to 114.
10)
9.9 10 (3 to 15) 0.01
Acl 200 (2) 87.55 (28.91 to 138.
30)
8.9 9 (1 to 16) 0.03
Acl 400 (2) 97.26 (48.15 to 159.
00)
6.8 6 (1 to 14) 0.10
Gly 50 (1) 91.43 (51.93 to 130.
90)
8.0 8 (1 to 14) 0.03
ICS Bud 400 (2) 25.02 (-23.30 to 66.
78)
16.7 17 (13 to 19) 0.00
Bud 750+ (2) 24.02 (-31.55 to 68.
90)
16.8 17 (13 to 19) 0.00
Flut 500 (2) 27.04 (-9.27 to 61.
93)
16.5 17 (14 to 19) 0.00
Mom 400 (2) 38.89 (-3.13 to 87.
00)
15.2 15 (9 to 18) 0.00
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LABA/ICS Form-bud 12/
160 (2)
99.60 (56.01 to 139.
80)
6.4 6 (1 to 14) 0.07
Form-bud 12/
320 (2)
105.00 (66.88 to 141.
80)
5.3 5 (1 to 12) 0.11
Salm-flut 50/
250 (2)
102.10 (35.97 to 158.
80)
6.3 5 (1 to 15) 0.14
Salm-flut 50/
500 (2)
100.50 (59.29 to 138.
70)
6.2 6 (1 to 13) 0.08
aFor effects versus placebo, smaller values indicate larger benefits of the active treatment. All doses are in micrograms
Crl = credible interval.
FEV1 = forced expiratory volume in one second.
ICS = inhaled corticosteroid.
LABA = long-acting beta2-agonist.
LABA/ICS = long-acting beta2-agonist/inhaled corticosteroid.
LAMA = long-acting antimuscarinic antagonist.
NWMA = network meta-analysis.
Pr = probability.
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